

FORM PTO-1390  
(REV 12-29-99)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

2534USOP

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

09/744226

INTERNATIONAL APPLICATION NO.  
PCT/JP99/03909INTERNATIONAL FILING DATE  
July 22, 1999PRIORITY DATE CLAIMED  
Jul. 23, 1998; Aug. 7, 1998 & Oct. 6, 1998

TITLE OF INVENTION

Novel G Protein Coupled Receptor Protein and Its DNA

APPLICANT(S) FOR DO/EO/US

Osamu OHARA et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)). \*
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. (two sets)
13. ☒ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
  - 1) Sequence Listing (Paper & Computer-readable copies)
  - 2) Sequence Listing Statement

\* This includes specification 136 total pages, including Claims 1-16(2 pgs), Abstract (1 pg), Sequence listing (26 pgs) and Drawings (25 pgs).

Express Mail EL783844580 VS

U.S. APPLICATION NO. (if known, see 37 CFR 1.55) <b>09/744226</b>		INTERNATIONAL APPLICATION NO PCT/JP99/03909		ATTORNEY'S DOCKET NUMBER 2534USOP	
17. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$970.00</b> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... <b>\$860.00</b> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$690.00</b> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$670.00</b> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$96.00</b>  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS PTO USE ONLY</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	23 - 20 =	3	X \$18.00	\$	54.00
Independent claims	1 - 3 =	0	X \$ 80.0	\$	0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$	260.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	1174.00
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
<b>SUBTOTAL =</b>				\$	1174.00
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$	1174.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property				\$	80.00
<b>TOTAL FEES ENCLOSED =</b>				\$	1254.00
				<b>Amount to be</b>	\$
				<b>refunded:</b>	
				<b>charged:</b>	\$

- a. ☐ A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 500799 in the amount of \$ 1254.00 to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 500799. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Customer No. 23,115

SIGNATURE:

Philippe Y. Riesen

NAME

35,657

REGISTRATION NUMBER

Date: January 12, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Osamu OHARA et al.  
Serial No. : Attn: Box PCT  
Filed on :  
Title : Novel G Protein Coupled Receptor Protein and Its DNA

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Preliminary to examination please amend the above-identified application as follows:

IN THE SPECIFICATION:

- Page 1, first sentence, insert "This application is the National Stage of International Application No. PCT/JP99/03909, filed on July 22, 1999."
- Page 2, line 1, delete "mean" and substitute therefor --means--; delete "medicals" and substitute therefor --medicines--  
line 3, before "regulation" delete "the"  
line 13, delete "mean" and substitute therefor --means--; delete "medicals" and substitute therefor --medicines--  
line 15, delete "medicals" and substitute therefor --medicines--  
line 17, delete "the"  
line 21, delete "in" and substitute therefor --of--
- Page 3, line 6, delete "property" and substitute therefor --properties--  
line 10, delete "property" and substitute therefor --properties--  
line 12, delete "studies" and substitute therefor --studied--  
line 21, delete "comprises" and substitute therefor --comprising--  
line 24, delete "comprises" and substitute therefor --comprising--
- Page 4, line 1, delete "comprising" and substitute therefor --comprises--
- Page 15, line 20, delete ")))"
- Page 16, line 18, delete "An" and substitute therefor --As an--  
line 20, delete "are" and substitute therefor --is--
- Page 17, line 1, before "a protein" insert --there is--  
line 10, delete "an" and substitute therefor --the--
- Page 18, line 8, delete "an" and substitute therefor --the--  
line 19, delete "in which a" and substitute therefor --and where the--  
line 19-20, delete "in the living body" and substitute therefor --in vivo--
- Page 20, line 15, before "N-terminal" delete "a" and substitute therefor --the--; delete

- "in the living body" and substitute therefor --in vivo--
- Page 21, line 1, delete "hydrocloric" and substitute therefor --hydrochloric--  
line 18, delete "the"  
line 23, delete "the"
- Page 25, line 13, delete "alcohols" and substitute therefor --alcohol--
- Page 27, line 2, delete "the"  
line 15, delete "the"
- Page 28, line 5, delete "the"
- Page 31, line 7, before "group" delete "the" and substitute therefor --a--  
line 14, delete "method" and substitute therefor --methods--
- Page 32, line 4, delete "the"
- Page 33, line 4, delete "These" and substitute therefor --The--
- Page 37, line 9, delete "airation" and substitute therefor --aeration--  
line 19, delete "airation" and substitute therefor --aeration--  
line 24, delete "airation" and substitute therefor --aeration--
- Page 38, line 7, delete "airation" and substitute therefor --aeration--
- Page 39, line 11, delete "acting" and substitute therefor --adding--
- Page 41, line 19, delete "serem" and substitute therefor --serum--
- Page 45, line 13, delete "the" and substitute therefor --a--
- Page 48, line 10, delete "at" and substitute therefor --in--  
line 11, delete "repturing" and substitute therefor --rupturing--
- Page 49, line 3, delete "at" and substitute therefor --in--
- Page 50, line 3, delete "dose" and substitute therefor --does--
- Page 54, line 16, delete "make" and substitute therefor --made--  
line 24, delete "agen" and substitute therefor --agent--  
line 25, delete "alamono" and substitute therefor --akamono--
- Page 55, line 5, delete "sesami" and substitute therefor --sesame--  
line 20, delete "ampul" and substitute therefor --ampule--
- Page 57, line 14, delete "alter" and substitute therefor --alters--  
line 22, delete "the"  
line 25, delete "the"
- Page 61, line 1, delete "at" and substitute therefor --in--
- Page 62, line 2, delete "at" and substitute therefor --in--
- Page 63, line 10, delete "dose" and substitute therefor --does--
- Page 67, line 8, delete "the"  
line 13, before "cell" delete "a"  
line 20, before "similar" delete "the" and substitute therefor --a--  
line 23, before "similar" delete "the" and substitute therefor --a--  
line 25, delete "the"
- Page 70, line 4, delete "in" and substitute therefor --from--
- Page 71, line 16, after "used" insert --in--
- Page 72, line 9, delete "presipitates resulted" and substitute therefor --precipitates

resulting--

line 12, delete "presipitates" and substitute therefor --precipitates--

line 16, delete "to" insert --in--

Page 73, line 8, delete "the"

Page 74, line 4, delete "at" and substitute therefor --in--

line 8, delete "ubiquous" and substitute therefor --ubiquitous--

line 13, delete "an embryo cell and a somatic cell" insert --the embryo cells  
and somatic cells--

line 16, delete "their all" and substitute therefor --all their--

line 17, after "such" delete "the"

Page 75, line 1, delete "expresses highly" and substitute therefor --highly expresses--

IN THE CLAIMS:

Claim 1, page 83, line 2, delete "comprises" and substitute therefor --comprising--

Claim 3, page 83, line 6, delete "comprises" and substitute therefor --comprising--

Claim 4, page 83, line 8, delete "comprising" and substitute therefor --comprises--

**REMARKS**

The above amendments correct typographical and clerical errors and do not constitute new matter. Entry of the above amendments prior to examination and early action on the merits are respectfully requested.

Date: January 12, 2001

Respectfully submitted,



Philippe Y. Riesen, Reg. No. 35,657  
Attorney for Applicants

Customer No. 23,115

25/PRB

09/744226

J002 Rec'd PCT/PTO 22 JAN 2001

## SPECIFICATION

### NOVEL G PROTEIN-COUPLED RECEPTOR PROTEIN AND ITS DNA

5

#### Technical Field

The present invention relates to a human brain-derived novel protein (G protein-coupled receptor protein) or a salt thereof and a DNA encoding it.

10 Background Technique

Many hormones and neurotransmitters regulate the functions of the living body via specific receptor proteins present in a cell membrane. Many of these receptor proteins perform intracellular signal transmittance through activation of conjugated guanine nucleotide-binding protein (hereinafter abbreviated as G protein in some cases) and, since they have the common structure having seven transmembrane regions, they are collectively called G protein-coupled receptor proteins or seven transmembranes receptor protein.

15

G protein-coupled receptor protein is present at various functional cell surfaces of cells or organs of the living body and carries an important role as a target for molecules which regulate the functions of cells or organs of the living body, for example, hormones, neurotransmitters and physiologically active substances.

20

Revelation of the relationship between substances which regulate the complex functions within cells and organs of the various living bodies and specific receptor proteins therefore, in particular, G protein-coupled receptors elucidates the functions of cells and organs of various living bodies and provides a very important

25

mean for development of medicals related to the functions.

For example, in central nervous system organs, regulation of the physiological functions of the brain is performed under the regulation by many hormones, neurotransmitters or physiologically active substances. In particular, neurotransmitters are present in various sites in the brain and perform the regulation of the physiological functions through each corresponding receptor protein. There are many unknown transmitters in the brain and it is thought that many of the structures of cDNA's encoding receptor proteins have not been reported yet. Further, whether a subtype of the known receptor protein is present or not has not been elucidated.

Revelation of the relationship between substances which regulate the complicated functions within cells and organs of the various living bodies and specific receptor proteins therefore is a very important mean for developing medicals related to the functions. In addition, in order to effectively screen agonists and antagonists for a receptor protein and develop medicals, it is necessary to elucidate the functions of genes for receptor proteins which are expressed in the brain and allow the genes to be expressed in the suitable expressing system.

Recently, as means for analyzing genes expressed in the living body, random analysis of the sequences of cDNA's have been actively studied and the sequences of fragments of cDNA's thus obtained are registered in database as Expressed Sequence Tag (EST) and published. However, many EST's are only information in the sequence and it is difficult to presume the functions.

#### Summary of the Invention

The present invention provides a human brain-derived novel protein (G

protein-coupled receptor protein), its partial peptide or a salt thereof, a DNA containing a DNA encoding the protein or its partial peptide, a recombinant vector containing the DNA, a transformant transformed with the recombinant vector, a process for producing the protein, an antibody to the protein, its partial peptide or the salt thereof, a method for determining a ligand for the protein (G protein-coupled receptor protein), a method of screening a compound for altering property of a ligand binding with the protein (G protein-coupled receptor protein) or a salt thereof, a kit for the screening, a compound for altering binding of a ligand obtainable by the screening method or the screening kit with the protein (G protein-coupled receptor protein) or a salt thereof, and a pharmaceutical containing a compound for altering property of a ligand binding with the protein (G protein-coupled receptor protein) or a salt thereof.

The present inventors studies intensively and, as a result, we successfully isolated a cDNA encoding a human brain-derived novel protein (G protein-coupled receptor protein) and analyzed the entire nucleotide sequence. And when this nucleotide sequence was translated into an amino acid sequence, the first to the seventh transmembrane regions were confirmed on a hydrophobic plot and a protein encoded by the cDNA was confirmed to be the seventh membrane type G protein-coupled receptor protein. The present inventors further continued to study based on these findings and, as a result, completed the present invention.

That is, the present invention provides:

- (1) A protein comprises the same or substantially the same amino acid sequence represented by SEQ ID No:1, SEQ ID No:3 or SEQ ID No:5, or a salt thereof,
- (2) A partial peptide of the protein according to the above item (1), or a salt thereof,
- (3) A DNA comprises a DNA having a nucleotide sequence encoding the protein according to the above item (1),



(4) The DNA according to the above item (3), which comprising a nucleotide sequence represented by SEQ ID No:2, SEQ ID No:4 or SEQ ID No:6,

(5) A recombinant vector comprising the DNA according to the above item (3).

(6) A transformant transformed with the recombinant vector according to the above item (5),

(7) A process for producing the protein or a salt thereof according to the above item (1), which comprises culturing the transformant according to the above item (6), and producing and accumulating the protein according to the above item (1),

(8) An antibody to the protein according to the above item (1), the partial peptide according to the above item (2) or a salt thereof,

(9) A method for determining a ligand for the protein according to the above item (1) or a salt thereof, which comprises using the protein according to the above item (1), the partial peptide according to the above item (2) or a salt thereof.

(10) A method for screening a compound or a salt thereof which alters property of a ligand binding with the protein according to the above item (1) or a salt thereof, which comprises using the protein to the above item (1), the partial peptide according to the above item (2) or a salt thereof,

(11) A kit for screening a compound or a salt thereof which alters property of a ligand binding with the protein according to the above item (1) or a salt thereof, which comprises the protein according to the above item (1), the partial peptide according to the above item (2) or a salt thereof,

(12) A compound or a salt thereof which alters property of a ligand binding with the protein according to the above item (1), or a salt thereof, which is obtainable by the method for screening according to the above item (10) or the kit for screening according to the above item (11).

(13) A pharmaceutical which comprises a compound or a salt thereof which alters property of a ligand binding with the protein according to the above item (1) or a salt thereof, which is obtainable by the method for screening according to the above item (10) or the kit for screening according to the above item (11),

5 (14) A DNA which hybridizes with the DNA according to the above item (3) under stringent conditions,

(15) A nucleotide containing a nucleotide sequence encoding the protein according to the above item (1), and

10 (16) A nucleotide containing a part of a nucleotide sequence which is complementary to a nucleotide sequence encoding the protein according to the above item (1).

More particularly, the present invention provides:

(17) The protein or a salt thereof according to the above item (1), wherein the protein is a protein containing:

15 ① an amino acid sequence in which 1 or 2 or more (preferably around 1 - 30, more preferably around 1-9, most preferably a few) amino acids in an amino acid sequence of SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.:5 are deleted, ② an amino acid sequence in which 1 or 2 or more (preferably around 1 - 30, more preferably around 1 - 10, most preferably a few) amino acids are added to an amino acid sequence of SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.:5, ③ an amino acid  
20 sequence in which 1 or 2 or more (preferably around 1 - 30, more preferably around 1-10, most preferably a few) amino acids in an amino acid sequence of SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.:5 are substituted with other amino acids, or ④ an amino acid sequence in combination thereof,

(18) A method for determining the ligand according to the above item (9), which  
25 comprises contacting the protein or a salt thereof according to the above item (1) or

the partial peptide or a salt thereof according to the above item (2) with a test compound,

(19) A method for determining the ligand according to the above item (9), wherein the ligand is angiotensin, bombesin, cannabinoid, cholecystokinin, glutamine, serotonin, melatonin, neuropeptide Y, opioid, purine, vasopressin, oxytocin, PACAP, secretin, glucagon, calcitonin, adrenomedulin, somatostatin, GHRH, CRF, ACTH, GRP, PTH, VIP (vasoactive intestinal and related polypeptide), somatostatin, dopamine, motilin, amylin, bradykinin, CGRP (calcitonin gene related peptide), leukotriene, pancreastatin, prostaglandin, thromboxane, adenosine, adrenaline,  $\alpha$  and  $\beta$ -chemokine (for example, IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2, ENA-78, PF4, IP10, GCP-2, MCP-1, HC14, MCP-3, I-309, MIP1 $\alpha$ , MIP-1 $\beta$ , RANTES and the like), endothelin, enterogastrin, histamine, neurotensin, TRH, pancreatic polypeptide, galanin,  $\alpha$ -latrotoxin, neurexophilin, subtype thereof, or analogue thereof,

(20) The method for determining a ligand according to the above item (9), wherein the ligand is  $\alpha$ -latrotoxin, neurexophilin, subtype thereof, or analogue thereof,

(21) The screening method according to the above item (10), wherein (i) the case where the protein or a salt thereof according to the above item (1) or the partial peptide or a salt thereof according to the above item (2) is contacted with a ligand, and (ii) the case where the protein or a salt thereof according to the above item (1) or the partial peptide or a salt thereof according to the above item (2) is contacted with a ligand and a test compound are compared,

(22) A method for screening a compound or a salt thereof which alters property of a ligand binding with the protein or a salt thereof according to the above item (1), which comprises measuring and comparing an amount of a labeled ligand binding to the protein or a salt thereof according to the above item (1) or the partial peptide or a salt

thereof according to the above item (2) in (i) the case where a labeled ligand is contacted with the protein or a salt thereof according to the above item (1) or the partial peptide or a salt thereof according to the above item (2) and the amount in (ii) the case where a labeled ligand and a test compound are contacted with the protein or a salt thereof according to the above item (1) or the partial peptide or a salt thereof according to the above item (3),

(23) A method for screening a compound or a salt thereof which alters property of a ligand binding with the protein or a salt thereof according to the above item (1), which comprises measuring and comparing an amount of a labeled ligand binding with a cell having the protein according to the above item (1) in (i) the case where a labeled ligand is contacted with the cell, and the amount in (ii) the case where a labeled ligand and a test compound are contacted with the cell,

(24) A method for screening a compound or a salt thereof which alters property of a ligand binding with the protein or a salt thereof according to the above item (1) which comprises measuring and comparing an amount of a labeled ligand binding with a membrane fraction of a cell having the protein according to the above item (1) in (i) the case where a labeled ligand is contacted with the cell, and the amount in (ii) the case where a labeled ligand and a test compound are contacted with the fraction,

(25) A method for screening a compound or a salt thereof which alters property of a ligand binding with the protein or a salt thereof according to the above item (1) which comprises measuring and comparing an amount of a labeled ligand binding with a protein expressed on a cell membrane of the transformant according to the above item (6) in (i) the case where a labeled ligand is contacted with the protein by culturing the transformant, and the amount in (ii) the case where a labeled ligand and a test compound are contacted with the protein by culturing the transformant,

09744226, 012201  
T022T0, 922446  
(26) A method for screening a compound or a salt thereof which alters property of a ligand binding with the protein or a salt thereof according to the above item (1), which comprises measuring and comparing the cell stimulating activity via a protein in (i) the case where a compound which activates the protein or a salt thereof according to the above item (1) is contacted with a cell containing the protein according to the above item (1), and the activity in (ii) the case where the protein or a salt thereof according to the above item (1) and a test compound are contacted with a cell containing the protein according to the above item (1),

(27) A method for screening a compound or a salt thereof which alters property of a ligand binding with the protein or a salt thereof according to the above item (1), which comprises measuring and comparing the cell stimulating activity via a protein expressed in the transformant according to the above item (6) in (i) the case where a compound or a salt thereof which activates the protein or a salt thereof according to the above item (1) is contacted with the protein by culturing the transformant according to the above item (6), and the activity in (ii) the case where a compound which activates the protein or a salt thereof according to the above item (1) and a test compound are contacted with the protein by culturing the transformant according to the above item (6),

(28) The screening method according to the above item (26) or (27), wherein the compound which activates the protein according to the above item (1) is angiotensin, bombesin, cannabinoid, cholecystokinin, glutamine, serotonin, melatonin, neuropeptide Y, opioid, purine, vasopressin, oxytocin, PACAP, secretin, glucagon, calcitonin, adrenomedulin, somatostatin, GHRH, CRF, ACTH, GRP, PTH, VIP (vasoactive intestinal and related polypeptide), somatostatin, dopamine, motilin, amylin, bradykinin, CGRP (calcitonin gene related peptide), leukotriene, pancreastatin,

prostaglandin, thromboxane, adenosine, adrenaline,  $\alpha$  and  $\beta$ -chemokine (for example, IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2, ENA-78, PF4, IP10, GCP-2, MCP-1, HC14, MCP-3, I-309, MIP1 $\alpha$ , MIP-1 $\beta$ , RANTES and the like), endothelin, enterogastrin, histamine, neurotensin, TRH, pancreatic polypeptide, galanin,  $\alpha$ -latrotoxin, neurexophilin, subtype thereof, or analogue thereof,

(29) The screening method according to the above item (26) or (27), wherein the compound which activates the protein according to the above item (1) is  $\alpha$ -latrotoxin, neurexophilin, a subtype thereof, or an analogue thereof,

(30) A compound which alters property of a ligand binding with the protein or a salt thereof, which is obtainable by the screening method according to the above item (21) to (28), or a salt thereof,

(31) A pharmaceutical which comprises a compound which alters property of a ligand binding with the protein or a salt thereof according to the above item (1), which is obtainable by the screening method according to the above item (21) to (28), or a salt thereof,

(32) A kit for the screening according to the above item (11), which comprises a cell containing the protein according to the above item (1),

(33) A kit for the screening according to the above item (11), which comprises a membrane fraction of a cell containing the protein according to the above item (1),

(34) A kit for the screening according to the above item (11), which comprises a protein expressed on a cell membrane of the transformant according to the above item (6) by culturing the transformant,

(35) A compound which alters property of a ligand binding with the protein or a salt thereof, which is obtainable by the kit for screening according to the above item (32) to (34), or a salt thereof,

(36) A pharmaceutical which comprises a compound which alters property of a ligand binding with the protein or a salt thereof according to the above item (1), which is obtainable by the kit for screening according to the above item (32) to (34), or a salt thereof,

5 (37) A method for quantitating the protein according to the above item (1), the partial peptide according to the above item (2) or a salt thereof, which comprises contacting the antibody according to the above item (8) with the protein according to the above item (1), the partial peptide according to the above item (2) or a salt thereof,

10 (38) A method for quantitating the protein according to the above item (1), the partial peptide according to the above item (2) or a salt thereof in a specimen solution, which comprises competitively reacting the antibody according to the above item (8) with the test solution and the labeled protein according to the above item (1), the partial peptide according to the above item (2) or a salt thereof, and determining a ratio of the protein according to the above item (1), the partial peptide according to the above item (2) or a salt thereof which is bound to the antibody,

15 (39) A method for quantitating the protein according to the above item (1), the partial peptide according to the above item (2) or a salt thereof in a specimen solution, which comprises reacting the specimen solution with the antibody according to the above item (8) and the labeled antibody according to the above item (8) which is  
20 unsolubilized on a carrier simultaneously or successively, and determining the activity of a labeling agent on the unsolubilized carrier.

#### Brief Description of the Drawings

Fig. 1 shows a nucleotide sequence encoding a human brain-derived protein  
25 of the present invention obtained in Example 1 and an amino acid sequence predicted

therefrom (continued to Fig. 2).

Fig. 2 shows a nucleotide sequence encoding a human brain-derived protein of the present invention obtained in Example 1 and an amino acid sequence predicted therefrom (continued from Fig. 1).

5 Fig. 3 shows a hydrophobic plot of a human brain-derived protein of the present invention, which was made based on the amino acid sequences shown in Fig. 1 and Fig. 2. Parts designated by 1 - 7 show a hydrophobic domain.

Fig. 4 shows an amino acid sequence predicted from a nucleotide sequence encoding a human brain-derived protein of the present invention obtained in Example 10 1 (a sequence represented by HK05006 in the figure) and an amino acid sequence predicted from a nucleotide sequence encoding a human brain-derived protein of the present invention obtained in Example 2 (a sequence represented by HK05490 in the figure)(continued to Fig. 5).

Fig. 5 shows an amino acid sequence predicted from a nucleotide sequence encoding a human brain-derived protein of the present invention obtained in Example 15 1 (a sequence represented by HK05006 in the figure) and an amino acid sequence predicted from a nucleotide sequence encoding a human brain-derived protein of the present invention obtained in Example 2 (a sequence represented by HK05490 in the figure)(continued from Fig. 4).

20 Fig. 6 shows a hydrophobic plot of a human brain-derived protein of the present invention, which was made based on the amino acid sequence predicted based on a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2. Part designated by 1 - 7 show a hydrophobic domain.

25 Fig. 7 shows a nucleotide sequence of a DNA encoding a human brain-



derived protein of the present invention obtained in Example 2, and an amino acid sequence predicted therefrom (continued to Fig. 8).

Fig. 8 shows a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2, and an amino acid sequence predicted therefrom (continued from Fig. 7 and continued to Fig. 9).

Fig. 9 shows a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2, and an amino acid sequence predicted therefrom (continued from Fig. 8 and continued to Fig. 10).

Fig. 10 shows a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2, and an amino acid sequence predicted therefrom (continued from Fig. 9 and continued to Fig. 11).

Fig. 11 shows a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2, and an amino acid sequence predicted therefrom (continued from Fig. 10 and continued to Fig. 12).

Fig. 12 shows a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2, and an amino acid sequence predicted therefrom (continued from Fig. 11 and continued to Fig. 13).

Fig. 13 shows a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2, and an amino acid sequence predicted therefrom (continued from Fig. 12 and continued to Fig. 14).

Fig. 14 shows a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2, and an amino acid sequence predicted therefrom (continued from Fig. 13 and continued to Fig. 15).

Fig. 15 shows a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2, and an amino acid

sequence predicted therefrom (continued from Fig. 14).

Fig. 16 shows an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 1 (a sequence represented by HK05006 in the figure), an amino acid  
5 sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2 (a sequence represented by HK05490 in the figure) and an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 3 (a sequence represented by HH02631 in  
10 figure)(continued to Fig.17).

Fig. 17 shows an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 1 (a sequence represented by HK05006 in the figure), an amino acid  
15 sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2 (a sequence represented by HK05490 in the figure) and an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 3 (a sequence represented by HH02631 in the  
figure)(continued to Fig.18).

Fig. 18 shows an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 1 (a sequence represented by HK05006 in the figure), an amino acid  
20 sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2 (a sequence represented by HK05490 in the figure) and an amino acid sequence predicted from a  
25

nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 3 (a sequence represented by HH02631 in the figure)(continued to Fig.19).

Fig. 19 shows an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 1 (a sequence represented by HK05006 in the figure), an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2 (a sequence represented by HK05490 in the figure) and an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 3 (a sequence represented by HH02631 in the figure)(continued to Fig.20).

Fig. 20 shows an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 1 (a sequence represented by HK05006 in the figure), an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 2 (a sequence represented by HK05490 in the figure) and an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 3 (a sequence represented by HH02631 in the figure)(continued from Fig.19).

Fig. 21 shows a nucleotide sequence contained in the plasmid pHH02631 obtained in Example 3 (continued to Fig. 22).

Fig. 22 shows a nucleotide sequence contained in the plasmid pHH02631 obtained in Example 3 (continued to Fig. 23).

Fig. 23 shows a nucleotide sequence contained in the plasmid pHH02631 obtained in Example 3 (continued to Fig. 24).

Fig. 24 shows a nucleotide sequence contained in the plasmid pHH02631 obtained in Example 3 (continued from Fig. 23).

5 Fig. 25 shows a hydrophobic plot of a human brain-derived protein of the present invention, which was made based on an amino acid sequence predicted from a nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention obtained in Example 3. Parts designated by 1 - 7 show a hydrophobic domain.

#### 10 Best Mode for Carrying Out the Invention

A protein of the present invention (G protein-coupled receptor protein) is a receptor protein containing the same or substantially the same amino acid sequence as amino acid sequence represented by SEQ ID No.:1 [amino acid sequence of Fig. 1 and  
15 Fig. 2], an amino acid sequence represented by SEQ ID No.:3 [amino acid sequence represented by HK05490 in Fig.4 and Fig. 5; an amino acid sequence in Fig.7 to Fig. 15] or an amino acid sequence represented by SEQ ID No.:5 [amino acid sequence represented by HH02631 Fig.16 to Fig.20] (hereinafter a protein of the present invention (G protein-coupled receptor protein) or a salt thereof is abbreviated as  
20 present protein in some cases))).

Present protein (G protein conjugated type protein) may be derived from, for example, in cases of human being and mammal (for example, guinea pig, rat, mouse, rabbit, pig, sheep, cow, monkey and the like), any cell (for example, spleen cell, nerve cell, glia cell, pancreatic  $\beta$  cell, marrow cell, mesangial cell, Langerhans's cell,  
25 epidermic cell, epithelial cell, endothelial cell, fibroblast, fibrocyte, myocyte, fat cell,

immunocyte (for example, macrophage, T cell, B cell, natural killer cell, mast cell, neutrophil, basophil, eosinophil, monocyte), megakaryocyte, synovial cell, chondrocyte, bone cell, osteoblast, osteoclast, mammary cell, hepatic cell or interstitial cell, or precursor cell, stem cell or cancer cell thereof) and blood cell (for example, MEL, M1, CTLL-2, HT-2, WEHI-3, HL-60, JOSK-1, K562, ML-1, MOLT-3, MOLT-4, MOLT-10, CCRF-CEM, TALL-1, Jurkat, CCRT-HSB-2, KE-37, SKW-3, HUT-78, HUT-102, H9, U937, THP-1, HEL, JK-1, CMK, KO-812, MEG-01 and the like), or any tissue in which the above cells are present, for example, brain, each site of brain (bulb olfactorius, tonsil nucleus, cerebral basal bulb, hippocampus, thalamus, hypothalamus, subthalamic nucleus, cerebral cortex, meddula oblongata, cerebellum, occipital lobe, frontal lobe, temporal lobe, putamen, caudatum, corpus callosum, nigra), spinal cord, pituitary gland, stomach, pancreas, kidney, liver, gonad, thyroid gland, cholecystis, bone marrow, drenal gland, skin, muscle, lung, alimentary tract (for example, large intestine, small intestine), blood vessel, cardiac thymus, spleen, submadibular gland, peripheral blood, peripheral blood cell, prostate, testis, testicle, ovary, placenta, uterus, bone, joint, skeletal muscle (in particular, brain and respective sites of brain), or a synthetic protein.

An amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.: 5, there are an amino acid sequence having about 50% or more, preferably about 70% or more, more preferably about 80% or more, further preferably about 90% or more, most preferably about 95% or more homology with an amino acid sequence represented by SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.: 5.

As a protein having an amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID No.:1, SEQ

ID No.:3 or SEQ ID No.: 5, a protein having the substantially same amino acid sequence as an amino acid sequence represented by SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.: 5 and having substantially the same nature of activity as that of an amino acid sequence represented by SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.: 5.

5 As the activity of substantially the same nature, for example, there is a ligand binding property, signal information transmitting action and the like. "Substantially the same" denotes that their activities are the same in nature. Therefore, it is preferable that the activities such as ligand binding activity and signal information transmitting action are equivalent (for example, about 0.5-2-fold) but quantitative  
10 elements such as an extent of these activities and a molecular weight of a protein may be different.

Measurement of the activities such as ligand binding and signal transmitting action can be performed according to the method known per se but, for example, measurement can be performed according to a method for determining a ligand or a  
15 method for screening described below.

In addition, as present protein, proteins having ① an amino acid sequence in which 1 or 2 or more (preferably around 1 - 30, more preferably around 1 - 10, further preferably a few (1 or 2)) amino acids in an amino acid sequence represented by SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.: 5 are deleted, ② an amino acid sequence in  
20 which 1 or 2 or more (preferably around 1 - 30, more preferably around 1 - 10, further preferably a few (1 or 2)) amino acids are added to an amino acid sequence represented by SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.: 5, ③ an amino acid sequence in which 1 or 2 or more (preferably around 1 - 30, more preferably around 1 - 10, further preferably a few (1 or 2)) amino acids in an amino acid sequence  
25 represented by SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.: 5 are substituted with an

another amino acid, or ④ amino acid sequence in combination thereof may be used.

In present protein, a left end is a N-terminal (amino terminal) and a right end is a C-terminal (carboxyl terminal) according to the usual convention. In present protein including a protein having an amino acid sequence represented by SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.:5, a C-terminal is usually a carboxyl group (-COOH) or carboxylate (-COO<sup>-</sup>) but a C-terminal may be amide (-CONH<sub>2</sub>) or ester (-COOR).

As R in an ester, C<sub>1-6</sub> alkyl group such as methyl, ethyl, n-propyl, isopropyl and n-butyl, C<sub>3-8</sub> cycloalkyl group such as cyclopentyl and cyclohexyl, C<sub>6-12</sub> aryl group such as phenyl and  $\alpha$ -naphthyl, phenyl-C<sub>1-2</sub> alkyl group such as benzyl and phenethyl, or C<sub>7-14</sub> aralkyl group such as  $\alpha$ -naphthyl-C<sub>1-2</sub> alkyl group such as  $\alpha$ -naphthylmethyl as well as pivaloyloxymethyl group which is used for an oral ester may be used.

When present protein has a carboxyl group (carboxylate) at a site other than a terminal, a protein in which a carboxyl group is amidated or esterified is contained in present protein. As an ester of this case, for example, the aforementioned C-terminal ester and the like are used.

Further, the aforementioned protein in which an amino group of a methionine residue at a N-terminal is protected with a protecting group (for example, C<sub>1-6</sub> acyl group such as formyl group, acetyl group), in which a N-terminal side is cut in the living body and the produced glutamyl group is pyroglutamine-oxidized, or in which a substituent (for example, -OH, -COOH, amino group, imidazole group, indole group, guanidino group) on a side chain of an intramolecular amino acid is protected with a suitable protecting group (for example, C<sub>1-6</sub> acyl group such as formyl group, acetyl group), and a glucoprotein in which a sugar chain is bound are included in present protein.

As an embodiment of present protein, for example, a human-derived (more preferably human brain-derived) protein having an amino acid sequence represented by SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.:5 and the like are used.

As a partial peptide of present protein (hereinafter referred to as partial peptide in some cases), any partial peptide may be used as long as it is a partial peptide of the aforementioned present protein, for example, a site which is protruding outside a cell membrane and has a receptor activity within present protein is used.

More particularly, as a partial peptide of a protein having an amino acid sequence represented by SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.:5, it is a peptide containing a part which is analyzed to be an extracellular region (hydrophilic site) in hydrophobic plot analysis shown by [Fig.3], [Fig.6] or [Fig. 25]. In addition, a peptide containing a hydrophobic region in its part may be also used. A peptide containing separately an individual domain may be used, a peptide of a part containing a plurality of domains at the same time may be used.

Regarding the number of amino acids of a partial peptide of the present invention, a peptide having at least 20 or more, preferably 50 or more, more preferably 100 or more amino acid sequences among component amino acid sequences of the aforementioned present protein is preferable.

“Substantially the same amino acid sequence” denotes an amino acid sequence having about 50% or more, preferably about 70% or more, more preferably about 80% or more, further preferably about 90% or more, most preferably about 95% or more homology with these amino acid sequences.

Here, “substantially the same nature of activity” is as defined above. Measurement of “substantially the same nature of activity” can be performed as described above.



In addition, in a partial peptide of the present invention, 1 or 2 or more (preferably around 1 - 10, more preferably a few (1 or 2) amino acids may be deleted from the aforementioned amino acid sequence, 1 or 2 or more (preferably around 1 - 20, more preferably around 1 - 10, further preferably a few (1 or 2) amino acids may be added to the aforementioned amino acid sequence, or 1 or 2 or more (preferably around 1 - 10, more preferably around 1 - 5, further preferably a few (1 or 2) amino acids in the aforementioned amino acid sequence may be substituted with an another amino acid.

In addition, in a partial peptide of the present invention, a C-terminal is usually a carboxyl group (-COOH) or carboxylate (-COO<sup>-</sup>) but, as in the aforementioned present protein, a C-terminal may be amide (-CONH<sub>2</sub>) or ester (-COOR).

Further, as in the aforementioned present protein, a partial peptide in which an amino group of a methionine residue of a N-terminal is protected with a protecting group, a partial peptide in which a N-terminal side is cut in the living body and the produced Gln is pyroglutamine-oxidized, a partial peptide in which a substituent on a side chain of an intramolecular amino acid is protected with a suitable protecting group, and a composite peptide such as a glucopeptide in which a sugar chain is bound thereto are included in a partial peptide of the present invention.

In addition, in a partial peptide of the present invention, a C-terminal is usually a carboxyl group (-COOH) or carboxylate (-COO<sup>-</sup>) but, as in the aforementioned present protein, a C-terminal may be amide (-CONH<sub>2</sub>) or ester (-COOR).

As salts of present protein or a partial peptide thereof, inter alia, physiologically acceptable acid addition salts are preferable. As such the salt, for

example, salts with inorganic acids (such as hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid), salts with organic acids (such as acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid) and the like are used.

Present protein or a salt thereof can be prepared from the aforementioned cells or tissues derived from human or a mammal by the method of purifying a protein which is known per se, or may be prepared by culturing a transformant containing a DNA encoding present protein described below. Alternatively, the protein may be prepared by a method for synthesizing a protein described below or a similar method.

When prepared from tissues or cells of human being or a mammal, tissues or cells of human being or a mammal are homogenized and, thereafter, extraction is performed with an acid or the like, and the extract may be purified and isolated by combining chromatography such as reverse phase chromatography, ion-exchange chromatography and the like.

In order to synthesize present protein, or a partial peptide thereof or a salt thereof or an amide thereof, a commercially available resin for synthesizing a protein may be usually used. As such the resin, for example, there are chloromethyl resin, hydroxymethyl resin, benzhydrylamine resin, aminomethyl resin, 4-benzyloxybenzylalcohol resin, 4-methylbenzhydrylamine resin, PAM resin, 4-hydroxymethylmethylphenylacetamidemethyl resin, polyacrylamide resin, 4-(2',4'-dimethoxyphenyl-hydroxymethyl)phenoxy resin, 4-(2',4'-dimethoxyphenyl-Fmoc aminoethyl)phenoxy resin and the like. By using such the resin,  $\alpha$ -amino acid and an amino acid having a side functional group suitably protected are condensed on a resin as a sequence of a protein of interest according to various condensing methods which

are known per se. At the end of a reaction, a protein is cut from a resin and at the same time various protecting groups are removed and, further, an intramolecular disulfide linkage forming reaction is performed and a protein of interest or an amide thereof is obtained.

5 As the aforementioned condensation of a protected amino acid, although various activating reagents which can be used for synthesizing a protein may be used, in particular, carbodiimides are better. As carbodiimides, DCC, N',N'-diisopropylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide and the like are used. For activation by them, a protected amino acid is directly added to a  
10 resin together with a racemization inhibiting agent (for example, HOBt, HOObt), or after a protected amino acid is activated in advance as a symmetrical anhydride or HOBt ester or HOObt ester, it may be added to a resin.

A solvent used for activating a protected amino acid or condensing with a resin may be appropriately selected from solvents which are known to be used for a  
15 protein synthesizing reaction. For example, acid amides such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone and the like, halogenated hydrocarbons such as methyl chloride, chloroform and the like, alcohols such as trifluoroethanol and the like, sulfoxides such as dimethyl sulfoxide and the like, ethers such as pyridine, dioxane, tetrahydrofuran and the like, nitriles such as  
20 acetonitrile, propionitrile and the like, esters such as methyl acetate, ethyl acetate and the like or an appropriate mixture thereof may be used. A reaction temperature is appropriately selected from a range which is known to be used for a protein binding forming reaction and is usually selected from a range of about -20°C to 50°C. An activated amino acid derivative is usually used at 1.5-4 fold excess amount. When  
25 condensation is insufficient as a result of a test using a ninhydrin reaction, sufficient

condensation can be performed by repeating a condensation reaction without leaving a protecting group. When sufficient condensation is not obtained even by repeating a reaction, an unreacted amino acid may be acetylated using acetic anhydride or acetylimidazole.

5 As a protecting group for a raw material amino acid, for example, Z, Boc, tertiary pentylcarbonyl, isobornylloxycarbonyl, 4-methoxybenzyloxycarbonyl, Cl-Z, Br-Z, adamantylloxycarbonyl, trifluoroacetyl, phthaloyl, formyl, 2-nitrophenylsulfonyl, diphenylphosphinothiyl, Fmoc and the like are used.

A carboxyl group can be protected by, for example, alkylesterification  
10 (straight, branched or cyclic alkylesterification such as methyl, ethyl, propyl, butyl, tertiary-butyl, cyclopentyl, cyclohexyl, cyclopentyl, cyclooctyl, 2-adamantyl and the like), aralkylesterification (for example, benzylester, 4-nitrobenzylester, 4-methoxybenzylester, 4-chlorobenzylester, benzhydrylesterification), phenacylesterification, benzyloxycarbonylhydrazidation, tertiary-  
15 butoxycarbonylhydrazidation, tritylhydrazidation and the like.

A hydroxy group of serine can be protected by, for example, esterification or etherification. As a group suitable for this esterification, for example, lower alkanoyl group such as acetyl group, aroyl group such as benzoyl group, a group derived from carbonic acid such as benzyloxycarbonyl group, ethoxycarbonyl group  
20 and the like are used. In addition, a group suitable for etherification, for example, there are benzyl group, tetrahydropyranyl group, t-butyl group and the like.

As a protecting group for a phenolic hydroxy group of tyrosine, for example, Bzl, Cl<sub>2</sub>-Bzl, 2-nitobenzyl, Br-Z, tertiary-butyl and the like are used.

As a protecting group for imidazole of histidine, for example, Tos, 4-  
25 methoxy-2,3,6-trimethylbenzenesulfonyl, DNP, benzyloxymethyl, Bum, Boc, Trt,

Fmoc and the like are used.

As activated carboxyl group of a raw material, for example, corresponding anhydride, azide, active ester [ester with alcohol (for example, pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol, cyanomethylalcohol, para-nitrophenol, HONB, N-hydroxysuccinimide, N-hydroxyphthalimide, HOBt)] and the like are used.

As an activated amino group of a raw material, for example, corresponding phosphoric amide is used.

As a method of removing (eliminating) a protecting group, for example, catalytic reduction in a hydrogen stream in the presence of a catalyst such as Pd-black or Pd-carbon, treatment with an acid such as anhydrous hydrofluoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid or a mixture thereof, treatment with a base such as diisopropylethylamine, triethylamine, piperidine and the like, and reduction with sodium in liquid ammonia are used. In the acid treatment, for example, the addition of a cation capturing agent such as anisole, phenol, thioanisole, methacresol, paracresol, dimethyl sulfide, 1,4-butanediol, 1,2-ethanedithiol and the like is effective. In addition, 2,4-dinitrophenyl group used as a protecting group for imidazole of histidine is removed by treatment with thiophenol, and formyl group used as a protecting group for indole of tryptophan is also removed by alkali treatment with an aqueous dilute solution of sodium hydroxide, dilute ammonia and the like, in addition to deprotection by the aforementioned acid treatment in the presence of 1,2-ethanedithiol, 1,4-butanedithiol and the like.

Protection of functional groups which should not be involved in a reaction of a raw material and protecting group, elimination of the protecting groups, and activation of functional groups which should be involved in a reaction can be appropriately selected from the known groups and the known means.

As an another method for obtaining an amide of a protein, for example, an  $\alpha$ -carboxyl group of a carboxyl terminal amino acid is first amidated for protection and, thereafter, a peptide (protein) chain is extended to a desired chain length on an amino group side, a protein in which only a protecting group for a N-terminal  $\alpha$ -amino acid of the peptide chain is removed and a protein in which only a protecting group for a C-terminal carboxyl group is removed are prepared, and both proteins are condensed in the aforementioned mixed solvent. The details of a condensing reaction are as defined above. After a protected protein obtained by condensation is purified, all the protecting groups can be removed by the aforementioned method to obtain a crude desired protein. The crude protein can be purified by the known various purifying means and main fractions can be lyophilized to obtain an amide of a desired protein.

In order to obtain an ester, for example, after a  $\alpha$ -carboxyl group of a carboxy terminal amino acid is condensed with a desired alcohols to make an amino acid ester, an ester of a desired protein can be obtained as in an amide of a protein.

Present protein and a salt thereof can be prepared according to the method of synthesizing a peptide which is known per se, or by cutting present protein with a suitable peptidase. A method of synthesizing a peptide may be by a solid phase synthesizing method or a solution phase synthesizing method. That is, a partial peptide or amino acids which can constitute present protein can be condensed with the remaining part and, when a product has a protecting group, a protecting group can be eliminated to prepare a peptide of interest. As the known condensing method and elimination of a protecting group, for example, there are methods described in the following ①-⑤.

① M. Bondanszky and M.A. Ondetti, Peptide Synthesis, Interscience Publishers, New York (1966),

② Schroeder and Luebke, The Peptide, Academic Press, New York (1965),

③ Nobuo Izumiya and others, Fundament and Experiment of Peptide  
Synthesis, Maruzen (K.K.)(1975)

④ Haruaki Yajima and Shunpei Sakakibara, Biochemistry Experiment 1,  
5 Chemistry for Proteins IV, 205, (1977),

⑤ Supervised by Haruaki Yajima, Development of Drugs, Second Series,  
vol.14, Peptide Synthesis, Hirokawa Shoten.

In addition, after a reaction, a partial peptide of the present invention can be  
purified and isolated by combining, for example, solvent extraction, distillation,  
10 column chromatography, liquid chromatography, recrystallization and the like.

When a partial peptide obtained by the aforementioned method is a free compound, it  
can be converted into a suitable salt by the known method and, conversely, when it is  
obtained as a salt, it can be converted into a free compound by the known method.

As a DNA encoding present protein, it may be any DNA as long as it contains  
15 a nucleotide sequence encoding the aforementioned present protein. In addition, it  
may be any of a genomic DNA, a genomic DNA library, a cDNA derived from the  
aforementioned cells or tissues, a cDNA library derived from the aforementioned cells  
or tissues, and a synthetic DNA. A vector used in a library may be any of  
bacteriophage, plasmid, cosmid, phagemide and the like. In addition, a total RNA or  
20 a mRNA fraction is prepared from the aforementioned cells or tissues, which may be  
used to directly amplify by Reverse Transcriptase Polymerase Chain Reaction  
(hereinafter, abbreviated as RT-PCR method).

More particularly, a DNA encoding present protein may be, for example, a  
DNA having a nucleotide sequence which hybridizes with a nucleotide sequence  
25 represented by SEQ ID No.:2, SEQ ID No.:4 or SEQ ID No.:6, or any DNA having a

nucleotide sequence which hybridizes with a nucleotide sequence represented by SEQ ID No.:2, SEQ ID No.:4 or SEQ ID No.:6 under the stringent conditions and encoding a protein having substantially the same nature of activity (for example, ligand binding activity, signal information transmitting action and the like) as that of present protein.

5 As a DNA which can hybridize with a nucleotide sequence represented by SEQ ID No.:2, SEQ ID No.:4 or SEQ ID No.:6, a DNA having a nucleotide sequence having about 70% or more, preferably about 80% or more, more preferably about 90% or more, most preferably about 95% or more homology with a nucleotide sequence represented by SEQ ID No.:2, SEQ ID No.:4 or SEQ ID No.:6 is used.

10 Hybridization can be performed according to the method known per se or a similar method, for example, a method described in Molecular Cloning, 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). In addition, when a commercially available library is used, hybridization can be performed by a method described in the attached specification. More preferably, hybridization can be  
15 performed according to the high stringent conditions.

High stringent conditions show the conditions in which the sodium concentration is about 19-40 mM, preferably about 19-20 mM, and a temperature is about 50-70°C, preferably about 60-65°C. In particular, the case where the sodium concentration is about 19 mM and a temperature is about 65°C is the most preferable.

20 More particularly, as a DNA encoding a protein having an amino acid sequence represented by SEQ ID No.:1, SEQ ID No.:3 or SEQ ID No.:5, a DNA having a nucleotide sequence represented by SEQ ID No.:2, SEQ ID No.:4 or SEQ ID No.:6 is used.

A nucleotide (oligonucleotide) a nucleotide sequence having a nucleotide  
25 sequence encoding present protein, or having a part of a nucleotide sequence



complementary to the aforementioned nucleotide sequence is meant to include not only a DNA but also a RNA encoding present protein or a partial peptide thereof.

According to the present invention, an antisense • (oligo)nucleotide (nucleic acid) can be designed and synthesized based on a nucleotide sequence information of a nucleotide sequence encoding a cloned or sequenced protein. Such the (oligo)nucleotide (nucleic acid) can hybridize with a RNA of a G protein coupled receptor protein gene. Synthesis or function of the RNA can be inhibited, or expression of a G protein coupled receptor protein gene can be regulated and controlled via interaction with a G protein coupled receptor protein related RNA. An (oligo)nucleotide complementary to a selected sequence of a G protein coupled receptor protein related RNA, and an (oligo)nucleotide which can specifically hybridize with a G protein coupled receptor protein related RNA are useful for regulating and controlling expression of a G protein coupled receptor protein gene in or outside the living body and also useful for treating or diagnosing diseases.

Term “corresponding” means to have homology with or complementary to a particular sequence of a nucleotide, a nucleotide sequence or a nucleic acid including a gene. “Corresponding” between a nucleotide, a nucleotide sequence or a nucleic acid and a peptide (protein) denotes an amino acid of a peptide (protein) under direction derived from a nucleotide (nucleic acid) sequence or a complementary sequence thereof. Although 5' terminal hairpin loop, 5' terminal 6 base pair repeat, 5' terminal untranslated region, polypeptide translation initiation codon, protein coding region, ORF translation initiation codon, 3'terminal untranslated region, 3'terminal palindrome region, and 3'terminal hairpin loop can be selected as a preferable target region, any region within a G protein conjugated type protein gene can be selected as a target.

Relationship between a nucleic acid of interest and an (oligo)nucleotide which is complementary to at least a part of a target region, and relationship between a subject and an (oligo)nucleotide which can hybridize with the subject can be said to be "antisense". As an antisense (oligo)nucleotide, there are a polydeoxynucleotide containing 2-deoxy-D-ribose, a polydeoxynucleotide containing D-ribose, an another type of polynucleotide which is N-glycoside of pyrine or pyrimidine base, or an another polymer having a non-nucleotide skeleton (for example, a commercially available protein nucleic acid and a synthetic sequence-specific nucleic acid polymer) or an another polymer containing a special linkage (provided that the polymer contains a nucleotide having arrangement permitting a phase pairing or base attachment found in a DNA or a RNA). They can be a double-stranded DNA, a single-stranded DNA, a double-stranded RNA, a single-stranded RNA, or a DNA:RNA hybrid, further may be an unmodified polynucleotide or an unmodified oligonucleotide, or further may have the known modification added, for example, may have a label which is known in the art, may have a cap added, may be methylated, may have 1 or more natural nucleotides substituted with an analogue, may have an intramolecular nucleotide modified, for example, may have non-charged linkage (for example, methylphosphonate, phosphotriester, phosphoramidate, carbamate and the like), may have a linkage having a charge or a sulfur-containing linkage (for example, phosphorothioate, phosphorodithioate and the like), for example, may have a side group such as a protein (nuclease, nuclease inhibitor, toxin, antibody, signal peptide, poly-L-lysine and the like) or a sugar (for example, monosaccharide and the like), may have an interchalant compound (for example, acridine, psoralen and the like), may have a chelating compound (for example, a metal, a metal having radioactivity, boron, an oxidative metal and the like), may have an alkylating agent, may have a modified

linkage (for example,  $\alpha$  anomer type nucleic acid). Here, "nucleoside", "nucleotide" and "nucleic acid" may not only contain a pyrine and a pyrimidine base but also an another heterocyclic base. Such the modification may contain a methylated purine and pyrimidine, an acylated purine and pyrimidine, or an another heterocycle. In a modified nucleoside and a modified nucleotide, a sugar part may be modified and, for example, 1 or more hydroxy groups may be substituted with a halogen or an aliphatic group, or may be converted into a functional group such as ether and amine.

An antisense nucleic acid of the present invention is a RNA, a DNA, or a modified nucleic acid. Embodiments of a modified nucleic acid are not limited to but include a sulfur derivative or a thiophosphate derivative of a nucleic acid, and a nucleic acid having resistance to degradation of polynucleosideamide or oligonucleosideamide. An antisense nucleic acid of the present invention can be preferably designed according to the following guideline. That is, an antisense nucleic acid is made stable in a cell, cell permeability of an antisense nucleic acid is enhanced, affinity for a target sense chain is made greater and, if it has toxicity, toxicity is made smaller.

A number of such the modifications are known in the art and are disclosed in J. Kawakami et al., Pharm Tech Japan, Vol. 8, pp.247 1992; Vol. 8, pp.395, 1992; S.T. Crooke et al. ed., Antisense Research and Applications, CRC Press, 1993.

An antisense nucleic acid of the present invention may be altered or may have a modified sugar, base or linkage, and can be supplied as a special form such as a microsphere, or may be applied to gene therapy, or may be given as an added form. As an antisense nucleic acid which is used as such an added form, there are a polycation such as polylysine which exerts so as to neutralize a charge of a phosphate skeleton, and a hydrophobic lipid (for example, phospholipid, cholesterol and the like)

which increases uptake of a nucleic acid. As a preferable lipid to be added, there are cholesterol and its derivatives (for example, cholesteryl chloroformate, cholic acid and the like). They can be attached to a 3'terminal or a 5'terminal of a nucleic acid, can be attached via a base, a sugar or an intramolecular nucleoside linkage. As the  
5 other group, there is a group for capping which is specifically arranged at a 3'terminal or a 5'terminal of a nucleic acid and is for inhibiting degradation by nuclease such as exonuclease, RNase and the like. Examples of such the group for capping are not limited to but include protecting groups known in the art including glycols such as polyethylene glycol, tetraethylene glycol and the like.

10 The inhibitory activity of an antisense nucleic acid of the present invention can be examined using a transformant of the present invention, gene expressing system in and outside the living body of the present invention, or translation system for a protein in and outside the living body. The nucleic acid can be applied to cells by various method known per se.

15 A DNA encoding a partial peptide of the present invention may be any one as long as it has a nucleotide sequence encoding a partial peptide of the present invention. Further, the DNA may be any of a genomic DNA, a genomic DNA library, a cDNA derived from the aforementioned cells or tissues, a cDNA library derived from the aforementioned cells or tissues, or a synthetic DNA. A vector used for a library may  
20 be any of bacteriophage, plasmid, cosmid, and phagemide. In addition, a mRNA fraction is prepared from the aforementioned cells or tissues, which may be used to directly amplify by Reverse Transcriptase Polymerase Chain Reaction (hereinafter, abbreviated as RT-PCR method).

More particularly, as a DNA encoding a partial peptide of the present  
25 invention may be, for example, a DNA having a partial nucleotide sequence of a DNA

which has a nucleotide sequence represented by SEQ ID No.:2, SEQ ID No.:4 or SEQ ID No.:6, or any DNA having a nucleotide sequence which hybridizes with a nucleotide sequence represented by SEQ ID No.:2, SEQ ID No.:4 or SEQ ID No.:6 under the high stringent conditions and having a partial nucleotide sequence of a DNA encoding a protein having substantially the same nature of activity (for example, ligand binding activity, signal information transmitting action and the like) as that of a protein peptide of the present invention is used.

As a DNA which can hybridize with a nucleotide sequence represented by SEQ ID No.:2, SEQ ID No.:4 or SEQ ID No.:6, a DNA having a nucleotide sequence having about 70% or more, preferably about 80% or more, more preferably about 90% or more, most preferably about 95% or more homology with a nucleotide sequence represented by SEQ ID No.:2, SEQ ID No.:4 or SEQ ID No.:6 is used.

For cloning a DNA fully encoding present protein or a partial peptide thereof (hereinafter, abbreviated as present protein), the DNA can be amplified by a PCR method using a synthetic DNA primer having a partial nucleotide sequence of present protein, or can be selected by hybridization of a DNA incorporated into a suitable vector with a labeled DNA fragment or synthetic DNA encoding a part of or an entire region of present protein. A hybridization method may be performed by a method described in, for example, Molecular Cloning 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). In addition, when a commercially available library is used, it can be performed according to a method described in the attached specification.

Conversion of a nucleotide sequence of a DNA can be performed by the method known per se such as a Gapped duplex method or a Kunkel method or a similar method using Mutant<sup>TM</sup>-G (Takara shuzo Co., Ltd.), Mutant<sup>TM</sup>-K (Takara shuzo Co., Ltd.) or the like.

0974426-01201  
T02210-92244260

A DNA encoding a cloned protein can be used as it is, or used optionally by digesting with a restriction enzyme, or adding a linker, depending upon the purposes. The DNA may have ATG as a translation initiation codon at its 5'terminal, or TAA, TGA or TAG as a translation termination codon at its 3'terminal. These termination  
5 initiation codon and translation termination codon can be added using a suitable synthetic DNA adapter.

An expression vector for present protein can be prepared by, for example, (a) excising a DNA fragment of interest from a DNA encoding present protein, (b) ligating the DNA fragment to downstream of a promoter in a suitable expression  
10 vector.

As a vector, a plasmid derived from Escherichia coli (for example, pBR322, pBR325, pUC12, pUC13), a plasmid derived from Bacillus subtilis (for example, pUB110, pTP5, pC194), a plasmid derived from yeast (for example, pSH19, pSH15), bacteriophage such as  $\gamma$  phase, animal virus such as retrovirus, vaccinia virus,  
15 baculovirus, as well as pA1-11, pXT1, pRc/CMV, pRc/RSV, pcDNAI/Neo and the like are used.

As a promoter used in the present invention, any promoter which is suitable for a host used for expressing a gene may be used. For example, when an animal cell is used as a host, there are SR $\alpha$  promoter, SV40 promoter, LTR promoter, CMV  
20 promoter, HSV-TK promoter and the like.

Among them, the use of CMV promoter and SR $\alpha$  promoter is preferable. When a host is a bacterium belonging to genus Escherichia, trp promoter, lac promoter, recA promoter,  $\lambda$ PL promoter, lpp promoter and the like are preferable and, when a host is a bacterium belonging to genus Bacillus, SPO1 promoter, SPO2  
25 promoter, penP promoter are preferable and, when a host is yeast, PHO5 promoter,

PGK promoter, GAP promoter, ADH promoter and the like are preferable. When a host is an insect cell, polyhedron, P10 promoter and the like are preferable.

As an expression vector, a vector optionally containing enhancer, splicing signal, polyA addition signal, selectable marker, SV40 replication origin (hereinafter abbreviated as SV40ori in some cases) or the like may be used. As a selectable marker, for example, there are dihydrofolate reductase (hereinafter, abbreviated as dhfr in some cases) gene [methotrexate (MTX) resistant], ampicillim resistant gene (hereinafter, abbreviated as Amp<sup>r</sup> in some cases), neomycin resistant gene (hereinafter, abbreviated as Neo in some cases, G418 resistant) and the like. In particular, when dhfr gene is used as a selectable marker using CHO (dhfr<sup>-</sup>) cell, a gene of interest can be selected also on a medium containing no thymidine.

In addition, as necessary, a signal sequence compatible for a host is added to a N-terminal of present protein. When a host is a bacterium belonging to genus Escherichia, PhoA·signal sequence, Omp A·signal sequence and the like can be utilized and, when a host is a bacterium belonging to genus Bacillus, α-amylase·signal sequence, subtilisin·signal sequence and the like can be utilized and, when a host is yeast, MFα·signal sequence, SUC2·signal sequence and the like can be utilized and, when a host is an animal cell, insulin·signal sequence, α-interferon·signal sequence, antibody·signal sequence and the like can be utilized.

A vector containing a DNA encoding present protein thus constructed can be used to produce a transformant.

As a host, for example, a bacterium belonging to genus Escherichia, a bacterium belonging to genus Bacillus, yeast, insect cell, insect, animal cell and the like are used.

As an example of a bacterium belonging to genus Escherichia, Escherichia

coli K12·DH1 [Proc. Natl. Acad. Sci. USA), vol.60, 160 (1968), JM103 [Nucleic  
Acids Research), Vol.9, 309(1981), JA211 [Journal of Molecular Biology], vol.120,  
517 (1978), HB101[Journal of Molecular Biology, vol.41, 459(1969)], C600  
[Genetics, vol.39, 440(1954)] and the like are used.

5 As an example of a bacterium belonging to genus *Bacillus*, for example,  
*Bacillus subtilis* MI114 [Gene, vol.24, 255 (1983)], 207-21 [Journal of Biochemistry,  
vol.95, 87(1984)] and the like are used.

As yeast, for example, *Saccharomyces cerevisiae*) AH22, AH22R<sup>-</sup>, NA87-11A,  
DKD-5D, 20B-12, *Schizosaccharomyces pombe*) NCYC1913, NCYC2036, *Pichia*  
10 *pastoris* and the like are used.

As an insect cell, established cell derived from *Barathra* larva (*Spodoptera*  
*frugiperda* cell; Sf cell), MG1 cell derived from midgut of *Trichoplusia ni*, High  
Five<sup>TM</sup> cell derived from egg of *Trichoplusia ni*, cell derived from *Mamestra brassicae*,  
cell derived from *Estigmena acrea* and the like are used. When a virus is BmNPV,  
15 established cell derived from silkworm (*Bombyx mori* N; BmN cell) and the like are  
used. As the Sf cell, for example, Sf9 cell (ATCC CRL1711), Sf21 cell (Vaughn, J.L.  
et al., *In Vivo*, 13, 213-217 (1977)) and the like are used.

As an insect, for example, silkworm larva and the like are used [Maeda et al.,  
*Nature*, vol.315, 592(1985)].

20 As an animal cell, for example, monkey COS-7, V ero, Chinese hamster cell  
CHO (hereinafter, abbreviated as CHO cell), dhfr gene-deficient Chinese hamster cell  
CHO (hereinafter, abbreviated as CHO (dhfr<sup>-</sup>) cell), mouse L cell, mouse AtT-20,  
mouse myeloma cell, rat GH3, human FL cell and the like are used.

In order to transform a bacterium belonging to genus *Escherichia*, for  
25 example, transformation can be performed according to a method described in Proc.



Natl. Acad. Sci. USA, vol.69, 2110(1972) and Gene, vol.17, 107(1982). In order to transform a bacterium belonging to genus Bacillus, for example, transformation can be performed according to a method described in Molecular & General Genetics, vol.168, 111(1979).

5 In order to transform yeast, transformation can be performed according to a method described, for example, in Methods in Enzymology, vol.194, 182-187 (1991), Proc. Natl. Acad. Sci. USA, vol.75, 1929(1978) and the like.

In order to transform an insect cell or an insect, transformation can be performed according to a method described in Bio/Technology, 6, 47-55(1988) and  
10 the like.

In order to transform an animal cell, transformation can be performed according to a method described, for example, in Cell Technology, separate column 8, New Cell Technology Experiment Protocol, 263-267 (1995) (published by Shujunsha), Virology, vol.52, 456(1973) and the like.

15 Like this, a transformant transformed with an expression vector containing a DNA encoding a G protein conjugated protein can be obtained.

When a transformant, a host of which is a bacterium belonging to genus Escherichia or a bacterium belonging to genus Bacillus, is cultured, as a medium used for culturing, a liquid medium is suitable and carbon source, nitrogen source,

20 inorganic substances and other necessary for growth of the transformant are contained therein. As carbon source, for example, there are glucose, dextrin, soluble starch, sucrose and the like. As nitrogen source, for example, there are inorganic and organic substances such as ammonium salts, nitrate salts, corn steep liquor, peptone, casein, broth extract, soy bean bran, potato extract solution and the like. As an

25 inorganic substance, for example, there are calcium chloride, sodium dihydrogen

phosphate, magnesium chloride and the like. In addition, yeast, vitamins, growth promoting factor and the like may be added. pH of a medium is desirably about 5-8.

As a medium when a bacterium belonging to *Escherichia* is cultured, for example, the M9 medium containing glucose and casamino acid [Miller, Journal of Experiments in Molecular Genetics, 431-433, Cold Spring Harbor Laboratory, New York, 1972] is preferable. In order to allow a promoter to exert effectively as necessary, for example, a chemical such as 3 $\beta$ -indolyl acrylic acid can be added. When a host is a bacterium belonging to genus *Escherichia*, culturing is usually performed at about 15-43°C for about 3-24 hours and, if needed, aeration and stirring may be added.

When a host is a bacterium belonging to genus *Bacillus*, culturing is usually carried out at about 30-40°C for about 6-24 hours and aeration and stirring may be added as necessary.

When a transformant, a host of which is yeast, is cultured, as a medium, there are Burkholder minimum medium [Bostian, K.L. et al. (Proc. Natl. Acad. Sci. USA, vol.77, 4505(1980))] and the SD medium containing 0.5% casamino acid [Bitter, G.A. et al. (Proc. Natl. Acad. Sci. USA), vol.81, 5330(1984)]. pH of a medium is preferably adjusted to about 5-8. Culturing is usually performed at about 20-35°C for about 24-72 hours and aeration and stirring are added as necessary.

When a transformant, a host of which is an insect cell or an insect, is cultured, as a medium, Grace's Insect Medium (Grace T.C.C., Nature, 195, 788 (1962)) to which an additive such as immobilized 10% bovine serum is appropriately added and the like are used. pH of a medium is preferably adjusted to about 6.2-6.4. Culturing is usually performed at about 27°C for 3-5 days and aeration and stirring are added as necessary.

When a transformant, a host of which is an animal cell, is cultured, as a medium, MEM medium containing about 5-20% fetal bovine serum [Science, vol.122, 501 (1952)], DMEM medium [Virology, vol.8, 396(1959)], RPMI 1640 medium [The Journal of the American Medical Association, vol.199, 519(1967)], 199 medium  
5 [Proceedings of the Society for the Biological Medicine, vol.73, 1(1950)] and the like are used. pH is preferably about 6-8. Culturing is performed at about 30-40°C for 15-60 hours and aeration and stirring are added as necessary.

Like this, a G protein coupled receptor protein of the present invention can be produced in a cell membrane of a transformant.

10 In order to purify and isolate present protein from the aforementioned culture, for example, purification and isolation can be performed according to the following method.

Upon extraction of present protein from cultured bacterium or cells, a method of collecting the bacterium or cell by the known method after culturing, suspending  
15 this in a suitable buffer, disrupting the bacterium or cell by lysozyme and/or freeze-melting, and obtaining a crude extract of a protein by centrifugation or filtration or the like is appropriately used. A protein denaturing agent such as urea and guanidine hydrochloride, or a surfactant such as TritonX-100<sup>TM</sup> may be contained in the buffer. When a protein is secreted in the culturing solution, after culturing is complete, the  
20 bacterium or cell and the supernatant are separated by the method known per se and the supernatant is collected.

Purification of the culturing supernatant thus obtained or a protein contained in the extract may be performed by combining the separating and purifying methods known per se. As the known separating and purifying methods, a method utilizing  
25 the solubility such as salting out and a solvent precipitation method, a method

utilizing mainly a difference in a molecular weight such as dialysis, ultrafiltration, gel filtration and SDS-polyacrylamide electrophoresis, a method utilizing a difference in charge such as ion-exchange chromatography, a method utilizing the specific affinity such as affinity chromatography, a method utilizing a difference in hydrophobicity such as reverse phase high performance liquid chromatography, a method utilizing a difference in isoelectric point such as electrofocusing and the like are used.

When the protein thus obtained is obtained as a free material, it can be converted into a salt by the method known per se or a similar method and, conversely, when the protein is obtained as a salt, it can be converted into a free material or other salt by the method known per se or a similar method.

By acting a suitable protein modifying enzyme before or after purification, a protein produced by a transformant may be modified or a polypeptide may be partially removed therefrom. As a protein modifying enzyme, for example, trypsin, chymotrypsin, aluginineendopeptidase, proteinkinase, glucosidase and the like are used.

The activity of present protein or a salt thereof thus obtained can be measured by an experiment for binding with a labeled ligand, enzyme immunoassay and the like.

An antibody to present protein, a partial peptide thereof or a salt thereof may be any of polyclonal antibody and monoclonal antibody as long as it is an antibody which can recognize present protein, a partial peptide thereof or a salt thereof.

An antibody to present protein, a partial peptide thereof or a salt thereof (hereinafter, abbreviated as present protein or the like) can be prepared using the present protein or the like as an antigen according to the method for preparing an antibody or antiserum known per se.

[Preparation of a monoclonal antibody]

(a) Preparation of a monoclonal antibody producing cell

The present protein or the like is administered to a site of a mammal being capable of producing an antibody as it is or together with a carrier or a diluent. In order to enhance the antibody producing ability upon administration, Freund's complete adjuvant or Freund's incomplete adjuvant may be administered. Administration is usually conducted once per 2-6 weeks at a total of around 2-10 times. As a mammal to be used, although there are, for example, monkey, rabbit, dog, guinea pig, mouse, rat, sheep and goat, mouse and rat are preferably used.

Upon preparation of a monoclonal antibody producing cell, a monoclonal producing hybridoma can be prepared by selecting a warm blood animal immunized with an antigen, for example, an individual having recognized titer from mice, taking spleen or lymph node 2-5 days after final immunization, and fusing an antibody producing cell contained therein with a myeloma cell. Measurement of the antibody titer in antiserum can be performed, for example, by measuring the activity of a labeling agent bound to an antibody after the labeled present protein or the like described below is reacted with antiserum. The fusing operation can be performed, for example, by a method of Khler and Milstein [Nature, vol.256, pp.495 (1975)]. As a fusion promoting agent, for example, although there are polyethylene glycol (PEG), Sendai virus and the like, PEG is preferably used.

As a myeloma cell, although there are, for example, NS-1, P3U1, SP2/0 and the like, P3U1 is preferably used. A preferable ratio of the number of antibody producing cells (spleen cells) used and that of myeloma cells used is around 1:1-20:1. PEG (preferably PEG 1000-PEG 6000) is added at the concentration of around 10-80%. Cell fusion can be performed effectively by incubation at about 20-40°C,

preferably about 30-37°C for about 1-10 minutes.

For screening a monoclonal antibody producing hybridoma, a variety of methods can be used. For example, there are a method of adding the hybridoma culturing supernatant to a solid phase on which the present protein or the like is adsorbed directly or together with a carrier (for example, microplate) and, then, adding an anti-immunoglobulin antibody (when a cell used in cell fusion is mouse, an anti-mouse immunoglobulin antibody is used) labeled with a radioisotope or an enzyme or protein A to detect a monoclonal antibody bound to a solid phase, a method of adding the hybridoma culturing supernatant to a solid phase on which anti-immunoglobulin antibody or a protein A is adsorbed and adding the present protein or the like labeled with a radioisotope or an enzyme to detect a monoclonal antibody bound to a solid phase and the like.

Although selection of a monoclonal antibody can be performed according to the method known per se or a similar method, it can be usually performed with a medium for an animal cell to which HAT (hypoxanthine, aminopterin, thymidine) is added. As a medium for selection and growth, any medium may be used as long as a hybridoma can be grown therein. For example, RPMI 1640 medium containing 1-20%, preferably 10-20% fetal bovine serum, GIT medium containing 1-10% fetal bovine serum (Wako Pure Chemical Industries, Ltd.) or serum-free medium for growing a hybridoma (SFM-101, Nissui Pharmaceutical Co., Ltd.) and the like can be used. A culturing temperature is usually 20-40°C, preferably about 37°C. A culturing time is usually 5 days to 3 weeks, preferably 1 to 2 weeks. Culturing can be usually performed under 5% carbonic acid gas. The antibody titer of the hybridoma culturing supernatant can be measured as in the measurement of the antibody titer of antiserum described above.

(b) Purification of a monoclonal antibody

Separation and purification of a monoclonal antibody can be usually performed according to a separation and purification method of an immunoglobulin [for example, salting out method, alcohol precipitation method, isoelectric focusing method, electrophoresis method, adsorption and desorption method by ion exchanging material (for example, DEAE), ultracentrifugation method, gel filtration method, a specific purifying method of taking only antibody with an active adsorbing agent such as antigen binding solid phase, protein A or protein G].

[Preparation of a polyclonal antibody]

The polyclonal antibody of the present invention can be prepared according to the method known per se or a similar method. For example, it can be prepared by making a complex of an immunological antigen (receptor protein and the like antigen) and a carrier protein, which is used to immunize a mammal as in the case of the aforementioned preparation of a monoclonal antibody, and taking a material containing an antibody to the present protein or the like from the immunized mammal to perform separation and purification of an antibody.

As a complex of an immunoantigen and a carrier protein which is used for immunizing a mammal, any of a kind of a carrier protein and a mixturing ratio of a carrier and a hapten may be used for cross-linking as long as an antibody can be effective to a hapten immunized by cross-linking with a carrier. For example, a method for coupling bovine serum alubmin, bovine thyroglobulin, keyhole limpet hemocyanin and the like with a hapten at a rate by weight of about 0.1-20, preferably about 1-5 relative to 1 of hapten is used.

In addition, for coupling hapten with a carrier, a variety of condensing agents can be used, and glutaraldehyde and carbodiimide, maleimide-active ester, active ester reagent containing a thiol group or a dithiobenzidyl group can be used.

A condensation product can be administered to a site of a mammal which can produce an antibody as it is or together with a carrier or a diluent. In order to enhance the antibody producing ability upon administration, Freund's complete adjuvant or Freund's incomplete adjuvant can be administered. Administration can be usually performed once per about 2-6 weeks, at a total about 3-10 times.

A polyclonal antibody can be taken from blood, ascites and the like, preferably blood of a mammal immunized according to the above method.

The polyclonal titer in antiserum can be measured as in the aforementioned measurement of the antibody titer in serum. Separation and purification of a polyclonal antibody can be carried out according to separation and purification of immunoglobulin as in the aforementioned separation and purification of a monoclonal antibody.

Present protein, a partial peptide thereof or a salt thereof can be used as (1) a method of determining a ligand for present protein, (2) obtaining of an antibody and antiserum, (3) construction of an expression system for a recombinant protein, (4) development of a receptor binding assay using the same expression system, and screening of medicine candidates, (5) implementation of drug design based on comparison with a ligand receptor having the structural similarity, (6) a reagent for making a probe and a PCR primer in gene therapy, (7) production of a transgenic animal, or (8) a drug for gene prophylaxis and therapy.

In particular, a compound which alters property of a ligand binding with a G protein-coupled receptor specific for human being or a mammal (for example, agonist,



antagonist and the like) can be screened by using a receptor binding assay system using an expression system for a recombinant protein of the present invention, and the agonist and the antagonist can be used as an agent for preventing or treating various diseases.

5           The use of present protein, a partial peptide or a salt thereof (hereinafter, abbreviated as present protein or the like in some cases), a DNA encoding present protein or a partial peptide thereof (hereinafter, abbreviated as present DNA in some cases) and an antibody to the present invention or the like (hereinafter, abbreviated as present antibody in some cases) is explained more particularly.

10           (1) A method of determining a ligand (agonist) for present protein

          Present protein or a salt thereof or a partial peptide of the present invention or a salt thereof are useful as a reagent for searching or determining a ligand (agonist) for present protein or a salt.

15           That is, the present invention provides a method for determining a ligand for present protein, which comprises contacting a test compound with present protein or a salt thereof or a partial peptide of the present invention or a salt thereof.

          As a test compound, there are the known ligand (for example, angiotensin, bombesin, cannabinoid, cholecystokinin, glutamine, serotonin, melatonin, neuropeptide  
20   Y, opioid, purine, vasopressin, oxytocin, PACAP, secretin, glucagon, calcitonin, adrenomedulin, somatostatin, GHRH, CRF, ACTH, GRP, PTH, VIP (vasoactive intestinal and related polypeptide), somatostatin, dopamine, motilin, amylin, bradykinin, CGRP (calcitonin gene related peptide), leukotriene, pancreastatin, prostaglandin, thromboxane, adenosine, adrenaline,  $\alpha$  and  $\beta$ -chemokine (for example,  
25   IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2, ENA-78, PF4, IP10, GCP-2, MCP-1, HC14,

09744266-01201  
MCP-3, I-309, MIP1 $\alpha$ , MIP-1 $\beta$ , RANTES and the like), endothelin, enterogastrin, histamine, neurotensin, TRH, pancreatic polypeptide, galanin), subtype thereof or analogue thereof, known  $\alpha$ -latrotoxin, neurexophilin, subtype thereof, or analogue thereof, and for example, tissues extract, and cell culture supernatant of human being  
5 or a mammal (for example, mouse, rat, pig, cow, sheep, monkey and the like) are used. For example, the tissue extract, cell culture supernatant or the like is added to present protein, fractionated while measuring the cell stimulating activity and, finally, a single ligand can be obtained. Inter alia,  $\alpha$ -latrotoxicin, neurophilin, subtype thereof or an analogue thereof are a preferable ligand.

10 More particularly, a method for determining a ligand of the present invention is a method for determining a compound (for example, peptide, protein, non-peptide compound, synthetic compound, fermented product and the like) or a salt thereof having the cell stimulating activity (for example, activity of promoting or inhibiting arachidonic acid release, acetylcholine release, intracellular Ca<sup>2+</sup> release, intracellular  
15 cAMP production, intracellular cGMP production, inositol phosphate production, intracellular potential variation, phosphorylation of an intracellular protein, c-fos activation, decrease in pH and the like) by binding to present protein using present protein, a partial peptide thereof or a salt thereof, or using the receptor binding assay system using a constructed expression system for a recombinant protein.

20 A method for determining a ligand of the present invention is characterized in that an amount of a test compound bound to present protein or a partial peptide thereof when a test compound is contacted with the protein or the partial peptide.

More particularly, the present invention provides:

(1) a method for determining the ligand for present protein or a salt thereof,  
25 which comprises measuring an amount of a labeled test compound bound to present

protein or a salt thereof or a partial peptide of the present invention or a salt thereof when a labeled compound is contacted with the protein or the salt or the partial peptide or the salt,

(2) a method for determining a ligand for present protein or a salt thereof,  
5 which comprises measuring an amount of a labeled test compound bound to a cell containing present protein or a membrane fraction of a cell when a labeled test compound is contacted with the cell or the membrane fraction,

(3) a method for determining a ligand for present protein, which comprises measuring an amount of a labeled test compound bound to a protein expressed on a  
10 cell membrane by culturing a transformant containing a DNA encoding present protein when a labeled test compound is contacted with the protein or a salt thereof,

(4) a method for determining a ligand for present protein or a salt thereof, which comprises measuring the cell stimulation activity (for example, the activity of promoting or inhibiting arachidonic acid release, acetylcholine release, intracellular  
15  $\text{Ca}^{2+}$  release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential variation, phosphorylation of intracellular protein, activation of c-fos, decrease in pH and the like) via a protein when a test compound is contacted with a cell containing present protein,

(5) a method for determining a ligand for present protein or a salt thereof,  
20 which comprises measuring the cell stimulation activity (for example, the activity of promoting or inhibiting arachidonic acid release, acetylcholine release, intracellular  $\text{Ca}^{2+}$  release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential variation, phosphorylation of intracellular protein, activation of c-fos, decrease in pH and the like) via a protein  
25 when a test compound is contacted with a protein expressed on a cell membrane by

culturing a transformant containing a DNA encoding present protein.

In particular, it is preferable that, after the aforementioned tests (1)-(3) are conducted and the binding of a test compound with present protein is confirmed, the aforementioned (4)-(5) are conducted.

5 First, although a protein used for a method for determining a ligand may be any protein as long as it contains the aforementioned protein of the present invention or the partial peptide of the present invention, a protein which is expressed using an animal cell is suitable.

10 In order to prepare present protein, the aforementioned expression method is used and it is preferable that preparation is conducted by expressing a DNA encoding the protein in a mammal cell or an insect cell. As a DNA fragment encoding a protein part of interest, a complementary DNA is usually used and the fragment is not necessarily limited to it. For example, a gene fragment and a synthetic DNA may be used. In order to introduce a DNA fragment encoding present protein into a host  
15 animal cell and express it effectively, it is preferable that the DNA fragment is incorporated downstream of polyhedron promoter of nuclear polyhedrosis virus (NPV) belonging to genus baculovirus, promoter derived from SV40, promoter of retrovirus, metallothionein promoter, human heat shock promoter, cytomegalovirus promoter, SR $\alpha$  promoter and the like. Examination of an amount and quality of  
20 expressed receptor can be conducted by the method known per se. For example, examination can be conducted according to a method described in the literature [Nambi, P. et al., The Journal of Biological Chemistry, J. Biol. Chem., vol.267, 19555-19559, 1992).

25 Therefore, as one containing present protein, a partial peptide thereof or a salt thereof, it may be a protein purified according to the method known per se, a partial

peptide thereof or a salt thereof, or a cell containing the protein or its cell membrane fraction may be used.

In a method for determining a ligand, when a cell containing present protein is used, the cell may be fixed by glutaraldehyde, formalin or the like. A fixing  
5 method can be conducted according to the method known per se.

A cell containing present protein refers to a host cell which expressed present protein. As the host cell, *Escherichia coli*, *Bacillus subtilis*, yeast, insect cell, animal cell and the like are used.

A cell membrane fraction refers to a fraction in which a cell membrane  
10 obtained by the method known per se after a cell is ruptured is contained at a large amount. As a method for rupturing a cell, there are a method of squeezing a cell with a Potter-Elvehjem type homogenizer, rupture with Waring blender or Polytron (manufactured by Kinematica), rupture by ultrasound, rupture by ejecting a cell through a thin nozzle while pressing with a French press and the like. For  
15 fractionating a cell membrane, a fractionating method by centrifugation such as a fractionation centrifugation method and a density gradient centrifugation method are mainly used. For example, a ruptured cell solution is centrifuged at a low speed (500 rpm-3000 rpm) for a shorter period of time (usually, about 1 minute to 10 minutes), a supernatant is further centrifuged at a higher speed (15000 rpm-30000 rpm) usually  
20 for 30 minutes to 2 hours and the resulting precipitates are used as a membrane fraction. An expressed protein and a membrane component such as phospholipid and membrane protein derived from a cell are contained in the membrane fraction at a large amount.

An amount of a cell containing the protein or a protein in the membrane  
25 fraction is preferably  $10^3$ - $10^8$  molecules per 1 cell, suitably  $10^5$ - $10^7$  molecules. As

an expression amount grows larger, the ligand binding activity (specific activity) is increased and, thereby, not only construction of high sensitive screening system becomes possible but also a large amount of samples can be measured at the same lot.

In order to perform the aforementioned methods (1)-(3) for determining a ligand for present protein or a salt thereof, a suitable protein fraction and a labeled test compound are necessary.

As a protein fraction, a natural receptor protein fraction or a recombinant receptor fraction having the equivalent activity thereto are desirable. Here, equivalent activity denotes equivalent ligand binding activity, signal information transmitting action and the like.

As a labeled test compound, angiotensin, bombesin, cannabinoid, cholecystokinin, glutamine, serotonin, melatonin, neuropeptide Y, opioid, purine, vasopressin, oxytocin, PACAP, secretin, glucagon, calcitonin, adrenomedulin, somatostatin, GHRH, CRF, ACTH, GRP, PTH, VIP (vasoactive intestinal and related polypeptide), somatostatin, dopamine, motilin, amylin, bradykinin, CGRP (calcitonin gene related peptide), leukotriene, pancreastatin, prostaglandin, thromboxane, adenosine, adrenaline,  $\alpha$  and  $\beta$ -chemokine (for example, IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2, ENA-78, PF4, IP10, GCP-2, MCP-1, HC14, MCP-3, I-309, MIP1 $\alpha$ , MIP-1 $\beta$ , RANTES and the like), endothelin, enterogastrin, histamine, neurotensin, TRH, pancreatic polypeptide, galanin,  $\alpha$ -latrotoxin, neurexophilin, subtype thereof, or analogue thereof labeled with [ $^3\text{H}$ ], [ $^{125}\text{I}$ ], [ $^{14}\text{C}$ ], [ $^{35}\text{S}$ ] or the like are suitable. Among them,  $\alpha$ -latrotoxin, neurexophilin, subtype thereof or an analogue thereof are preferably used.

More particularly, in order to perform a method for determining a ligand for present protein or a salt thereof, an authentic receptor is first prepared by suspending a

cell containing present protein or a membrane fraction of the cell in a buffer suitable for determination. As a buffer, any buffer such as phosphate buffer having pH 4-10 (desirably, pH6-8) and Tris-HCl buffer may be used as long as it does not inhibit binding of a ligand with present protein. In addition, in order to reduce the non-specific binding, surfactants such as CHAPS, Tween-80<sup>TM</sup> (Kao-Atlas), digitonin and deoxycholate, and proteins such as serum albumin and gelatin may be added to a buffer. Further, in order to suppress degradation of lipase or a ligand by protease, protease inhibiting agents such as PMSF, leupeptin, E-64 (manufactured by Peptide Laboratory) and pepstatin may be added thereto. A test compound labeled with [<sup>3</sup>H], [<sup>125</sup>I], [<sup>14</sup>C], [<sup>35</sup>S] or the like at a constant amount (5000 cpm-500000 cpm) is present in 0.01 ml-10 ml of a solution of the receptor. In order to know an amount of non-specific binding (NBS), a reaction tube to which a large excess unlabeled test compound is added is prepared. A reaction is performed at 0°C to 50°C, desirably at about 4°C to 37°C for about 20 minutes to 24 hours, desirably for about 30 minutes to 3 hours. After reaction, the reaction is filtered with a glass fiber filter or the like, washed with a suitable amount of a buffer, and the radioactivity remaining on a glass fiber filter is measured with a liquid scintillation counter or a  $\gamma$ -counter. A compound having the count (non-specific binding amount (NSB)) is subtracted from whole binding amount (B)) (B-NSB) over 0 cpm can be a ligand (an agonist) for present protein or a salt thereof.

In order to perform the aforementioned methods (4)-(5) for determining a ligand for present protein or a salt thereof, the cell stimulating activity (for example, activity of promoting or inhibiting arachidonic acid release, acetylcholine release, intracellular Ca<sup>2+</sup> release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, intracellular potential variation,

phosphorylation of an intracellular protein, c-fos activation, decrease in pH and the like) via the protein can be measured using the known protein or a commercially available measuring kit. More particularly, first, a cell containing present protein is cultured on a multiwell-plate or the like. Upon implementation of ligand

5 determination, a test compound and the like are added, incubated for a certain time, the cell is extracted or the supernatant is recovered to quantitate the resulting products according to respective methods. When the production of a substance [for example, arachidonic acid and the like] which is an index for the cell stimulating activity is difficult to be detected due to degradation of a degrading enzyme contained in the cell,

10 an inhibiting agent for the degrading enzyme may be added to perform an assay. In addition, regarding the activity of cAMP production suppression, it can be detected as production inhibiting action for a cell for which fundamental producing amount has been increased with forskolin.

A kit for determining a ligand for present protein or a salt thereof contains

15 present protein or a salt thereof, a partial peptide of the present invention or a salt thereof, a cell containing present protein, or a membrane fraction of a cell containing present protein.

As an example of a kit for determining a ligand of the present invention, there are the following ones:

20

1. A reagent for determining a ligand

(1) A buffer for measurement and a buffer for washing

0.05% bovine serum albumin (manufactured by Sigma) is added to Hank's Balanced Salt Solution (manufactured by Gibco)

25 Filter-sterilized with a filter having a pore size 0.45  $\mu\text{m}$ , which may be stored



at 4°C or prepared upon use.

(2) An authentic G protein-coupled receptor protein

CHO cell in which present protein is expressed is subcultured on a 12-well plate at  $5 \times 10^5$  cells/well, and cultured at 37°C, in 5% CO<sub>2</sub> and 95% air.

5 (3) A labeled test compound

A compound labeled with commercially available [<sup>3</sup>H], [<sup>125</sup>I], [<sup>14</sup>C], [<sup>35</sup>S] or the like, or labeled by a suitable method.

An aqueous solution is stored at 4°C or -20°C and diluted with a measuring buffer upon use. A test compound which shows the poor water-solubility is  
10 dissolved in dimethylformamide, DMSO, methanol or the like.

(4) Non-labeled test compound

Prepared to 100-1000 fold higher concentration as in a labeled compound.

2. A detecting method

15 (1) CHO cell, expressing present protein, which was cultured on a 12-well plate for tissue culturing is washed twice with a 1 ml of a measuring buffer, and a 490 µl of a measuring buffer is added to each well.

(2) 5 µl of a labeled test compound is added, which is reacted at room temperature for 1 hour. In order to know an amount of non-specific binding, 5 µl of  
20 a non-labeled test compound is added.

(3) The reaction solution is removed and washed with 1 ml of a washing buffer three times. A labeled test compound bound to a cell is dissolved with 0.2N NaOH-1% SDS, and mixed with 4 ml of liquid scintillator A (manufactured by Wako Pure Chemical Industries, Ltd.).

25 (4) The radioactivity is measured using a liquid scintillation counter

(manufactured by Beckmann).

As a ligand which can bind to present protein or a salt thereof, there are substances which are specifically present, for example, in brain, pituitary gland, pancreas or the like. More particularly, angiotensin, bombesin, cannabinoid, cholecystokinin, glutamine, serotonin, melatonin, neuropeptide Y, opioid, purine, vasopressin, oxytocin, PACAP, secretin, glucagon, calcitonin, adrenomedulin, somatostatin, GHRH, CRF, ACTH, GRP, PTH, VIP (vasoactive intestinal and related polypeptide), somatostatin, dopamine, motilin, amylin, bradykinin, CGRP (calcitonin gene related peptide), leukotriene, pancreastatin, prostaglandin, thromboxane, adenosine, adrenaline,  $\alpha$  and  $\beta$ -chemokine (for example, IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2, ENA-78, PF4, IP10, GCP-2, MCP-1, HC14, MCP-3, I-309, MIP1 $\alpha$ , MIP-1 $\beta$ , RANTES and the like), endothelin, enterogastrin, histamine, neurotensin, TRH, pancreatic polypeptide, galanin,  $\alpha$ -latrotoxin, neurexophilin, subtype thereof, or analogue thereof are used. Inter alia,  $\alpha$ -latrotoxin, neurexophilin, subtype thereof, or analogue thereof are preferably used.

(2) An agent for preventing or treating present protein deficient-disease

In the aforementioned method (1), if a ligand for present protein is revealed, the present protein or a DNA encoding the present protein can be used as a medicine such as an agent for preventing or treating present protein deficient-disease.

For example, regarding a patient in which physiological action of a ligand is not expected due to decrease in present protein in the living body, an amount of a protein in the living body of a patient can be increased and an action of a ligand can be sufficiently exerted by (1) administering present protein to a patient to supplement an amount of the protein, or (2) (a) administering a DNA encoding present protein to the

patient to express it, or (b) inserting a DNA encoding present protein to express it, which is transplanted into the patient. Therefore, a DNA encoding present protein is useful as a safe and low-toxic medicine for preventing or treating present protein deficient-disease.

5 When a DNA encoding present protein (hereinafter, abbreviated as present DNA in some cases) is used as the aforementioned preventing or treating agent, present DNA can be used according to the conventional method as it is or by inserting into a suitable vector such as retrovirus vector, adenovirus vector, adenovirus associated virus vector or the like. Present DNA can be administrated as it is or  
10 together with an adjuvant for promoting uptake by a gene gun or a catheter such as a hydrocatheter.

For example, present DNA can be orally administrated as a tablet optionally coated with a sugar coating, capsule, elixir or microcapsule and the like, or parenterally administrated in the form of a sterile solution with water or other  
15 pharmaceutically acceptable solution or an injectable such as suspension. For example, pharmaceutical preparations can be made by mixing present DNA with a carrier, a flavor, an excipient, a vehicle, a preservative, a stabilizer or a binding agent into an unit dosage form required for art-recognized preparations. An amount of an ingredient in these preparations is adjusted such that a suitable dose can be obtained in  
20 a designated range.

As an additive which can be mixed into a tablet, a capsule or the like, for example, a binding agent such as gelatin, corn starch, tragacanth and gum arabic, an excipient such as crystalline cellulose, a swelling agent such as corn starch, gelatin and alginic acid, a lubricating agent such as magnesium stearate, a sweetening agent  
25 such as sucrose, lactose and saccharin, a flavor such as peppermint, an essential oil

and cherry are used. When a preparation unit form is a capsule, a liquid carrier such as a lipid can be contained in the aforementioned type material. A sterile composition for injection can be formulated according to the conventional pharmacy by such as dissolving or suspending an active substance in a vehicle such as water for injection, a natural vegetable oil such as a sesame oil and a palm oil. As an aqueous solution for injection, for example, an isotonic (for example, D-sorbitol, D-mannitol, sodium chloride or the like) containing, for example, a physiological saline, glucose or other adjuvant and the like are used, and may be used together with a suitable solubilizer, for example, an alcohol (for example, ethanol), a polyalcohol (for example, propylene glycol, polyethylene glycol), nonionic surfactant (for example, polysorbate 80 (TM), HCO-50) or the like. As an oily solution, for example, a sesame oil and a soybean oil are used, and may be used together with benzyl benzoate, benzylalcohol or the like.

In addition, the aforementioned preventing or treating agent may be incorporated with, for example, a buffer (for example, a phosphate buffer, a sodium acetate buffer), a soothing agent (for example, benzalkonium chloride, procaine hydrochloride and the like), a stabilizing agent (for example, human serum albumin, polyethylene glycol and the like), a preservative (for example, benzylalcohol, phenol and the like), and an antioxidant. A prepared injectable is usually filled into a suitable ampul.

Since pharmaceutical preparations thus obtained are safe and low toxic, and can be administered to, for example, human being or a mammal (for example, rat, rabbit, sheep, pig, cow, cat, dog, monkey).

A dose of present protein or DNA is different depending upon an administration subject, a subject organ, symptom and an administration method and,

in the case of oral administration, the dose is generally about 0.1 mg-100 mg, preferably about 1.0-50 mg, more preferably about 1.0-20 mg per day, in an adult (60 kg). When parentally administrated, one time dose is different depending upon an administration subject, a subject organ, symptom and an administration method and, in the form of injectable, it is usually advantageous to administer about 0.01-30 mg, preferably about 0.1-20 mg, more preferably about 0.1-10 mg by intravenous injection per day, in an adult (60 kg). In other animals, an amount calculated per 60 kg can be administrated.

### (3) An agent for diagnosing a gene

Since abnormality (gene abnormality) of a DNA or a mRNA encoding present protein in human being or a mammal (for example, rat, rabbit, sheep, pig, cow, cat, dog, monkey and the like) can be detected by using present DNA as a probe, for example, the present DNA is useful as an agent for diagnosing a gene such as damage of the DNA or the mRNA, mutation or decrease in expression, increase in excess expression of the DNA or the mRNA.

The aforementioned gene diagnosis using present DNA can be conducted by, for example, northern hybridization and a PCR-SSCP method which are known per se (Genomics, vol. 5, 874-879 (1989), Proceedings of the National Academy of Sciences of the United States of America, vol.86, pp.2766-2770 (1989)).

### (4) A method for quantitating a ligand for present protein

Since present protein or the like has the binding property to a ligand, the concentration of a ligand in the living body can be quantitated with high sensitivity.

A quantitating method of the present invention can be used by combining

with, for example, a competition method. That is, the concentration of a ligand in a specimen by contacting a specimen with present protein or the like. More particularly, for example, it can be used according to a method described in the following (i) or (ii) or a similar method.

(i) "Radioimmuno assay" edited by Hiroshi Irie (Kodansha, published in 1973)

(ii) "A Sequel to the Radioimmuno assay" edited by Hiroshi Irie (Kodansha, published in 1978)

(5) A method for screening a compound which alters property of ligand binding with present protein

By using the receptor binding assay by using present protein or the like, or by constructing an expression system for a recombinant protein and using the expression system, a compound which alter property of a ligand binding with present protein or the like (for example, peptide, protein, non-peptide compound, synthetic compound, fermented product and the like) or a salt thereof can be effectively screened.

(a) a compound having the cell stimulating activity (for example, activity of promoting or suppressing arachidonic acid release, acetylcholin release, intracellular  $\text{Ca}^{2+}$  release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential variation, phosphorylation of intracellular protein, activation of c-fos and decrease in pH) via a G protein-coupled receptor (so called agonist to present protein), (b) a compound having no such the cell stimulating activity (so called antagonist to present protein), (c) a compound which enhances binding force of a ligand with present protein, and (d) a compound which decreases binding force of a ligand with present protein are contained in such the

compound (it is preferred that the above (a) compound is screened by the  
aforementioned method for determining a ligand).

That is, the present invention provides a method for screening a compound  
which alters property of a ligand with present protein, a partial peptide thereof or a  
5 salt thereof, which comprises comparing (i) the case where present protein, a partial  
peptide thereof or a salt thereof and a ligand are contacted, and (ii) the case where  
present protein, a partial peptide thereof or a salt thereof and a ligand and a test  
compound are contacted.

In a method for screening of the present invention is characterized in that, for  
10 example, an amount of a ligand to bind with the protein or the like and cell stimulating  
activity in the cases (i) and (ii) are measured and compared.

More particularly, the present invention provides:

(1) a method for screening a compound which alters property of a ligand  
binding with present protein or the like or a salt thereof, which comprises measuring  
15 and comparing an amount of a labeled ligand to bind to present protein or the like in  
the case where a labeled ligand is contacted with present protein or the like, and the  
case where a labeled ligand and a test compound are contacted with present protein or  
the like,

(2) a method for screening a compound which alters property of a ligand  
20 binding with present protein or the like or a salt thereof, which comprises measuring  
and comparing an amount of a labeled ligand to bind to a cell containing present  
protein or the like or a membrane fraction of the cell in the case where a labeled ligand  
is contacted with the cell or the membrane fraction, and the case where a labeled  
ligand and a test compound are contacted with the cell or the membrane fraction,

25 (3) a method for screening a compound which alters property of a ligand

binding with present protein or the like or a salt thereof, which comprises measuring and comparing an amount of a labeled ligand to bind to protein or the like expressed on a cell membrane by culturing a transformant containing present DNA in the case where a labeled ligand is contacted with the protein or the like, and the case where a  
5 labeled ligand and a test compound are contacted with the protein or the like,

(4) a method for screening a compound which alters property of a ligand binding with present protein or the like, which comprises measuring and comparing cell stimulating activity (for example, activity of promoting or suppressing arachidonic acid release, acetylcholin release, intracellular  $\text{Ca}^{2+}$  release, intracellular  
10 cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential variation, phosphorylation of intracellular protein, activation of c-fos and decrease in pH) via a receptor in the case where a compound which activates present protein or the like (for example, ligand for present protein or the like) is contacted with a cell containing present protein or the like, and the case where a  
15 compound which activates present protein or the like and a test compound are contacted with a cell containing present protein or the like, and

(5) a method for screening a compound which alters property of a ligand binding with present protein or the like, which comprises measuring and comparing cell stimulating activity (for example, activity of promoting or suppressing  
20 arachidonic acid release, acetylcholin release, intracellular  $\text{Ca}^{2+}$  release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential variation, phosphorylation of intracellular protein, activation of c-fos and decrease in pH) via a receptor in the case where a compound which activates present protein or the like (for example, ligand for present protein or the like) is  
25 contacted with present protein or the like expressed on a cell membrane by culturing a



transformant containing present DNA, and the case where a compound which activates present protein or the like and a test compound are contacted with present protein or the like expressed on a cell membrane by culturing a transformant containing present DNA.

5           Before present protein or the like is obtained, when a G protein-coupled receptor agonist or antagonist is screened, a test was necessary in which a cell, a tissue or its cell membrane fraction which contains a G protein-coupled receptor agonist or antagonist is first used to obtain candidate compounds (first screening) and, thereafter, whether candidate compounds actually inhibit binding of a human G protein-coupled  
10 receptor protein and a ligand is confirmed (secondary screening). When a cell, a tissue or a cell membrane fraction is used as it is, it was difficult to actually screen an agonist or an antagonist for a receptor protein of interest due to the presence of other receptors.

          However, for example, the use of a human-derived protein of the present  
15 invention excludes the necessity of first screening and a compound which inhibits binding of a ligand and a G protein-coupled receptor protein can be effectively screened. Further, whether a screened compound is an agonist or an antagonist can be simply evaluated.

          A method for screening of the present invention is explained more  
20 particularly.

          First, as present protein or the like used in a method for screening of the present invention, any protein can be used as long as it contains the aforementioned present protein or the like, although a cell membrane fraction of an organ of a mammal containing present protein or the like is suitable. However, since a human-  
25 derived organ is obtained with very difficulty, a human-derived receptor protein or the

like which was expressed at a large amount using a recombinant is suitable for use in screening.

For preparing present protein or the like, the aforementioned method is used, although it is preferred that present DNA is expressed in a mammal cell or an insect cell. As a DNA fragment coding a protein portion of interest, a complementary DNA is used, being not limiting. For example, a gene fragment and a synthetic DNA may be used. In order to introduce a DNA fragment encoding present protein and express it effectively, the DNA fragment is preferably incorporated downstream of polyhedron promoter of nuclear polyhedrosis virus (NPV) belonging to genus Baculovirus, a host of which is an insect, SV40-derived promoter, promoter of retrovirus, metallothionein promoter, human heat shock promoter, cytomegalovirus promoter and SR $\alpha$  promoter. Examination of an amount and quality of expressed receptor can be performed by the method known per se. For example, it can be performed according to a method described in the literature [Nambi, P. et al., The Journal of Biological Chemistry, J. Biol. Chem., vol.267, pp.19555-19559, 1992].

Therefore, in a method for screening of the present invention, as one containing present protein or the like, protein or the like which was purified by the method known per se may be used, or a cell containing the protein or the like may be used, or a membrane fraction of a cell containing the protein or the like may be used.

In a method for screening of the present invention, when a cell containing present protein or the like is used, the cell may be fixed with glutaraldehyde, formalin or the like. Fixation can be carried out according to the method known per se.

A cell containing present protein or the like refers to a host cell which expressed the protein or the like and, as a host cell, *Escherichia coli*, *Bacillus subtilis*, yeast, insect cell and animal cell are preferable.

102270 9224460

A cell membrane fraction refers to a fraction containing a cell membrane obtained according to a method known per se at a large amount after a cell is ruptured. As a method for rupturing a cell, there are a method of squeezing a cell with a Potter-Elvehjem type homogenizer, rupture with Waring blender or Polytron (manufactured by Kinematica), rupture by ultrasound, rupture by ejecting a cell through a thin nozzle while pressing with a French press and the like. For fractionating a cell membrane, a fractionating method by centrifugation such as a fractionation centrifugation method and a density gradient centrifugation method are mainly used. For example, a ruptured cell solution is centrifuged at a low speed (500 rpm-3000 rpm) for a shorter period of time (usually, about 1 minute to 10 minutes), a supernatant is further centrifuged at a higher speed (15000 rpm-30000 rpm) usually for 30 minutes to 2 hours and the resulting precipitates are used as a membrane fraction. An expressed protein and a membrane component such as phospholipid and membrane protein derived from a cell are contained in the membrane fraction at a large amount.

15 An amount of a cell containing the protein or the protein in the membrane fraction is preferably  $10^3$ - $10^8$  molecules per 1 cell, suitably  $10^5$ - $10^7$  molecules. As an expression amount grows larger, the ligand binding activity (specific activity) is increased and, thereby, not only construction of high sensitive screening system becomes possible but also a large amount of samples can be measured at the same lot.

20 In order to perform the aforementioned methods (1)-(3) for screening a compound which alters property of a ligand binding with present protein or the like, for example, a suitable protein fraction and a labeled test compound are necessary.

As a protein fraction, a natural receptor protein fraction or a recombinant receptor fraction having the equivalent activity thereto are desirable. Here, equivalent activity denotes equivalent ligand binding activity, signal information

25

transmitting action and the like.

As a labeled test compound, a labeled ligand and a labeled ligand analogue compound are used. For example, a ligand labeled with [ $^3\text{H}$ ], [ $^{125}\text{I}$ ], [ $^{14}\text{C}$ ] or [ $^{35}\text{S}$ ] is used.

5 More particularly, in order to perform a method for screening a compound which alters property of a ligand binding with present protein or the like, an authentic protein is first prepared by suspending a cell containing present protein or the like or a membrane fraction of the cell in a buffer suitable for screening. As a buffer, any buffer such as phosphate buffer having pH 4-10 (desirably, pH 6-8) and Tris-HCl  
10 buffer may be used as long as it dose not inhibit binding of a ligand with a protein. In addition, in order to reduce the non-specific binding, surfactants such as CHAPS, Tween-80<sup>TM</sup> (Kao-Atlas), digitonin and deoxycholate may be added to a buffer. Further, in order to suppress degradation of a receptor or a ligand by protease, protease inhibiting agents such as PMSF, leupeptin, E-64 (manufactured by Peptide  
15 Laboratory) and pepstatin may be added thereto. A labeled ligand is added to 0.01 ml-10 ml of a solution of the receptor at a certain amount (5000 cpm-500000 cpm) and, at the same time, a test compound is present at  $10^{-4}\text{M}$ - $10^{-10}\text{M}$ . In order to know an amount of non-specific binding (NBS), a reaction tube to which a large excess unlabeled ligand is added is prepared. A reaction is performed at  $0^{\circ}\text{C}$  to  $50^{\circ}\text{C}$ ,  
20 desirably at about  $4^{\circ}\text{C}$  to  $37^{\circ}\text{C}$  for about 20 minutes to 24 hours, desirably for about 30 minutes to 3 hours. After reaction, the reaction is filtered with a glass fiber filter or the like, washed with a suitable amount of a buffer, and the radioactivity remaining on a glass fiber filter is measured with a liquid scintillation counter or a  $\gamma$ -counter. A test compound having non-specific binding amount (B-NSB) (wherein a count (B0-  
25 NSB) obtained by subtracting non-specific binding amount (NSB) from a count (B0)

of no competing substance) can be selected as a candidate compound having the competition inhibiting ability.

In order to perform the aforementioned methods (4)-(5) for screening a compound which alters property of a ligand binding with present protein or the like, for example, the cell stimulating activity (for example, activity of promoting or inhibiting arachidonic acid release, acetylcholine release, intracellular Ca release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, intracellular potential variation, phosphorylation of an intracellular protein, c-fos activation, decrease in pH and the like) via a protein can be measured using the known method or a commercially available measuring kit.

More particularly, first, a cell containing present protein or the like is cultured on a multiwell-plate or the like. Upon implementation of screening medium is freshly prepared or buffer is changed to the proper one which does not denote toxicity for cell beforehand, a test compound and the like are added, incubated for a certain time, the cell is extracted or the supernatant is recovered to quantitate the resulting products according to respective methods. When the production of a substance (for example, arachidonic acid and the like) which is an index for the cell stimulating activity is difficult to be detected due to a degrading enzyme contained in the cell, an inhibiting agent for the degrading enzyme may be added to perform an assay. In addition, regarding the activity of cAMP production suppression, it can be detected as production inhibiting action for a cell for which fundamental producing amount has been increased with forskolin.

In order to perform screening by measuring the cell stimulating activity, a cell which expressed a suitable protein is necessary. As a cell which expressed present protein or the like, a cell strain containing natural type present protein or the like, and

a cell strain which expressed the aforementioned recombinant protein or the like are desirable.

As a test compound, for example, a peptide, a protein, a non-peptide compound, a synthetic compound, a fermented product, a cell extract solution, a plant extract solution, and an animal tissue extract solution are used, and these compounds may be a novel compound or the known compound.

A kit for screening a compound which alters property of a ligand binding with present protein or the like contains present protein or the like, a cell containing present protein or the like, or a membrane fraction of a cell containing present protein or the like.

As an example of a kit for screening of the present invention, there are the following ones:

1. A reagent for screening

(1) A buffer for measurement and a buffer for washing

0.05% bovine serum albumin (manufactured by Sigma) is added to Hanks' Balanced Salt Solution (manufactured by Gibco).

Filter-sterilized with a filter having a pore size of 0.45  $\mu\text{m}$ , which may be stored at 4°C or prepared upon use.

(2) An authentic G protein-coupled receptor

CHO cell in which a protein of the present invention is expressed is subcultured on a 12-well plate at  $5 \times 10^5$  cells/well, and cultured at 37°C, in 5% CO<sub>2</sub> and 95% air for two days.

(3) A labeled ligand

A ligand labeled with commercially available [<sup>3</sup>H], [<sup>125</sup>I], [<sup>14</sup>C], [<sup>35</sup>S] or the

like. An aqueous solution is stored at 4°C or -20°C and diluted with a measuring buffer upon use.

(4) A standard solution of ligand

A ligand is dissolved to be 1 Mm with PBS which obtained 0.1 % bovine serum albumin (manufactured by Sigma) and stored at -20°C

2. A measuring method

(1) CHO cell, expressing present protein, which was cultured on a 12-well plate for tissue culturing is washed twice with a 1 ml of a measuring buffer, and a 490 µl of a measuring buffer is added to each well.

(2) After 5 µl of a  $10^{-3}$ - $10^{-10}$ M test compound is added, 5 µl of a labeled ligand is added, which is reacted at room temperature for 1 hour. In order to know an amount of non-specific binding, 5 µl of a  $10^{-3}$ M ligand is added instead of a test compound.

(3) The reaction solution is removed and washed with 1 ml of a washing buffer three times. A labeled ligand bound to a cell is dissolved with 0.2N NaOH-1% SDS, and mixed with 4 ml of liquid scintillator A (manufactured by Wakojunyaku).

(4) The radioactivity is measured using a liquid scintillation counter (manufactured by Beckmann) and Percent Maximum Binding (PMB) is obtained according to the following equation [Mathematic 1]

[Mathematic 1]

$$\text{PMB} = \frac{(B - \text{NSB})}{(B_0 - \text{NSB})} \times 100$$

PMB: Percent Maximum Binding

B: value when a specimen is added

NSB: Non-specific Binding (non-specific binding amount)

B0: Maximum binding amount

5           A compound obtained by using a method for screening or a kit for screening  
of the present invention or a salt thereof is a compound which alters property of a  
ligand binding with present protein or the like. More particularly, there are (a) a  
compound having the cell stimulating activity (for example, activity of promoting or  
suppressing arachidonic acid release, acetylcholin release, intracellular  $\text{Ca}^{2+}$  release,  
10 intracellular cAMP production, intracellular cGMP production, inositol phosphate  
production, cell membrane potential variation, phosphorylation of intracellular protein,  
activation of c-fos and decrease in pH) via a G protein-coupled receptor (so called  
agonist to present protein), (b) a compound having no such a cell stimulating activity  
(so called antagonist to present protein), (c) a compound which enhances binding  
15 force of a ligand with present G protein-coupled receptor, and (d) a compound which  
decreases binding force of a ligand with present G protein conjugated type protein.

As the compound, there are a peptide, a protein, a non-peptide compound, a  
synthetic compound and a fermented product, and these compounds may be a novel  
compound or the known compound.

20           Since an agonist to present protein or the like has the similar physiological  
activity to that of a ligand for present protein or the like, it is useful as a safe and low-  
toxic drug depending upon the ligand activity.

Since an antagonist to present protein or the like has the similar physiological  
activity to that of a ligand for present protein or the like, it is useful as a safe and low-  
25 toxic drug which inhibits the ligand activity.



A compound which enhances the binding force of a ligand binding with present protein is useful as a safe and low-toxic drug for enhancing the physiological activity harbored by a ligand for present protein or the like.

A compound which decreases the binding force of a ligand binding with present protein is useful as a safe and low-toxic drug for decreasing the physiological activity harbored by a ligand for present protein or the like.

A compound obtained by a screening method or a kit for screening of the present invention or a salt thereof can be used as the aforementioned pharmaceutical composition according to the conventional method. For example, it can be formulated into a tablet, a capsule, an elixir, a microcapsule, a sterile solution or a suspension solution as in the aforementioned drug containing present DNA.

Since pharmaceutical preparations thus obtained are safe and low toxic, they can be administered to, for example, human being or a mammal (for example, rat, rabbit, sheep, pig, cow, cat, dog, monkey).

A dose of the compound or a salt thereof is different depending upon an administration subject, a subject organ, symptom and an administration method and, in the case of oral administration, the dose is generally about 0.1 mg-100 mg, preferably about 1.0-50 mg, more preferably about 1.0-20 mg per day, in an adult (60 kg). When parentally administrated, one time dose is different depending upon an administration subject, a subject organ, symptom and an administration method and, in the form of injectable, it is usually advantageous to administer about 0.01-30 mg, preferably about 0.1-20 mg, more preferably about 0.1-10 mg by intravenous injection per day, in an adult (60 kg). In other animals, an amount calculated per 60 kg can be administrated.

(6) Quantitation of present protein , or a partial peptide thereof or a salt thereof

Since an antibody of the present invention can specifically recognize present protein or the like, it can be used for quantitation of present protein or the like in a specimen solution, in particular, quantitation by a sandwich immunodetection method.

5 That is, the present invention provides, for example, (i) a method for quantitating present protein or the like in a specimen solution, which comprises reacting competitively an antibody of the present invention with a specimen solution and a labeled protein or the like, and measuring a ratio of a labeled protein or the like bound to the antibody, (ii) a method for quantitating present protein or the like in a specimen  
10 solution, which comprises reacting a specimen solution with an antibody of the present invention which is insolubilized on a carrier and a labeled antibody of the present invention simultaneously or successively, and measuring the activity of a labeling agent on an insolubilized carrier.

In the above (ii), it is preferred that one antibody is an antibody which  
15 recognizes a N-terminal of present protein or the like and an another antibody is an antibody which reacts with a C-terminal of present protein or the like.

By using a monoclonal antibody to present protein or the like (hereinafter, referred to as present monoclonal antibody in some cases), detection by tissue staining or the like can be conducted in addition to measurement of present protein or the like.  
20 For these purposes, an antibody molecule may be used or F(ab')<sub>2</sub>, Fab' or Fab fraction of an antibody may be used. A method for measurement using an antibody to present protein or the like is not particularly limited, but any measuring method may be used as long as it is a method for chemically or physically detecting an amount of an antibody, an antigen or an antibody-antigen complex corresponding to an amount of  
25 antigen in a specimen solution (for example, an amount of a protein), and calculating

1022270" 92244260  
this from a standard curve made using a standard solution containing the known  
amounts of an antigen. For example, nephrometry, competitive method,  
immunometric method and sandwich method are suitably used, although the use of a  
sandwich method described below is particularly preferable in a viewpoint of  
5 sensitivity and specificity.

As a labeling agent used in a measuring method using a labeling substance,  
for example, a radioisotope, an enzyme, a fluorescent substance and emitting  
substance are used. As a radioisotope, for example, [ $^{125}\text{I}$ ], [ $^{131}\text{I}$ ], [ $^3\text{H}$ ] and [ $^{14}\text{C}$ ] are  
used. As the above enzyme, enzymes which are safe and have the great specific  
10 activity are preferable. For example,  $\beta$ -galactosidase,  $\beta$ -glycosidase, alkaline  
phosphatase, peroxidase and malate dehydrogenase are used. As a fluorescent  
substance, for example, fluorescamine and fluorescein isothiocyanate are used. As  
an emitting substance, for example, luminol, luminol derivative, luciferin and  
lucigenin are used. Further, biotin-avidin system may be used for binding an  
15 antibody or an antigen and a labeling agent.

Upon insolubilization of an antigen or an antibody, physical adsorption may be  
used and, a method using chemical binding usually used for insolubilizing or  
immobilizing a protein or an enzyme may be used. As a carrier, for example,  
insoluble polysaccharides such as agarose, dextran and cellulose, synthetic resins such  
20 as polystyrene, polyacrylamide, silicone and the like, or glasses are used.

In a sandwich method, a specimen solution is reacted with an insolubilized  
monoclonal antibody of the present invention (primary reaction) and a labeled  
monoclonal antibody of the present invention is further reacted therewith (secondary  
reaction) and, thereafter, the activity of a labeling agent on an insolubilized carrier can  
25 be measured to quantitate an amount of present protein in a specimen solution. The

primary reaction and the secondary reaction may be performed in the reverse order, or simultaneously, or at a different time. A labeling agent and an insolubilizing method can be according to the aforementioned methods.

In addition, in an immunological detecting method by a sandwich method, an antibody used for a solid phase antibody or a labeling antibody is not necessarily one kind and a mixture of two or more kinds of antibodies may be used for improving the measuring sensitivity.

In a method for measuring present protein or the like, as monoclonal antibodies of the present invention used in the primary reaction and the secondary reaction, antibodies having a different site to which present protein or the like is bound are preferably used. That is, regarding antibodies used in the primary reaction and the secondary reaction, an antibody used in the primary reaction is preferably an antibody which recognizes a site other than a C-terminal, for example, a N-terminal when an antibody used in the secondary reaction recognizes a C-terminal of present protein.

A monoclonal antibody of the present invention can be used a measuring system other than a sandwich method, for example, competitive method, immunometric method or nephrometry. In a competitive method, after an antigen in a specimen solution and a labeled antigen are reacted competitively with an antibody, an unreacted labeled antigen (F) and a labeled antigen (B) bound to an antibody are separated (B/F separation), and a labeled amount of either of B or F is measured to quantitate an amount of an antigen in a specimen solution. In the present reaction, there are used a solution method in which a soluble antibody is used as an antibody, B/F separation is performed using polyethylene glycol and the second antibody to the aforementioned antibody, and a solid phase method in which a soluble antibody is

used as the first antibody and a solid phased antibody is used as the second antibody.

In an immunometric method, after an antigen in a specimen solution and a solid phased antigen are reacted competitively with a constant amount of labeled antibody, the solid phase and the solution phase are separated, or after an antigen in a specimen solution and an excessive amount of labeled antibody are reacted and, then, a solid phased antigen is added to bind unreacted labeled antibody to a solid phase, the solid phase and the solution phase are separated. Next, a labeled amount of either phase is measured to quantitate an amount of an antigen in a specimen solution.

In addition, in nephrometry, an amount of insoluble presipitates resulted from an antigen-antibody reaction in a gel or a solution is measured. Also when an amount of an antigen in a specimen solution is small and a small amount of presipitates are obtained, laser nephrometry using laser scattering is used.

Upon application of individual immunological measuring methods to the present measuring method, setting of special conditions and operations are not required. A system for measuring present protein or a salt thereof may be constructed by addition of technical consideration by those skilled in the art to the conventional conditions and operation procedures in respective methods. For details of these general technical means, a reference can be made to reviews and books [for example, see "Radioimmunoassay" edited by Hiroshi Irie (Kodansha, published in 1974), "Radioimmunoassay, Second Series" edited by Hiroshi Irie (Kodansha, published in 1979), "Enzyme Immunoassay" edited by Eiji Ishikawa et al. (Igakushoin, published in 1978), "Enzyme Immunoassay" edited by Eiji Ishikawa et al. (2nd edition) (Igakushoin, published in 1982), "Enzyme Immunoassay" edited by Eiji Ishikawa et al. (3rd edition) (Igakushoin, published in 1987), "Methods in ENZYMOLOGY" Vol. 70 (Immunochemical Techniques (Part A)), Ibid. Vol. 73

09744233-012301  
T022T0 92244/60

(Immunochemical Techniques (Part B)), Ibid. Vol. 74 (Immunochemical Techniques (Part C)), Ibid. Vol. 84 (Immunochemical Techniques (Part D: Selected Immunoassay)), Ibid. Vol. 92 (Immunochemical Techniques (Part E: Monoclonal Antibodies and General Immunoassay Methods)), Ibid. Vol. 121 (Immunochemical Techniques (Part I: Hybridoma Technology and Monoclonal Antibodies)) (All published by Academic Press).

As described above, by using an antibody of the present invention, present protein or a salt thereof can be quantitated with the high sensitivity. Further, various diseases can be diagnosed by quantitating present protein or a salt thereof using an antibody of the present invention.

In addition, an antibody of the present invention can be used to detect present protein or the like present in a specimen such as a body liquid or a tissue. In addition, it can be used for manufacturing an antibody column used for purifying present protein or the like, detecting present protein or the like in each fraction upon purification, and analyzing the behavior of present protein or the like in a specimen cell.

(7) Preparation of non-human animal having a DNA encoding a G protein conjugated type protein of the present invention

A transgenic non-human animal expressing present protein or the like can be made using a DNA of the present invention. As a non-human animal, there is a mammal (for example, rat, mouse, rabbit, sheep, pig, cow, cat, dog, monkey and the like) (hereinafter, abbreviated as animal), although mouse and rabbit are particularly suitable.

Upon transference of a DNA of the present invention to a subject animal, it is

generally advantageous to use as a gene construct bound downstream of promoter which can express the DNA in an animal. For example, when a DNA of the present invention derived from a rabbit is transferred, a DNA-transferred animal which produces present protein or the like at a large amount can be produced by introducing a gene construct in which a DNA of the present invention, derived from an animal, having high homology with the above DNA is bound downstream of various promoters which can express a DNA of the present invention in an animal cell, into rabbit fertilized ovum by microinjection. As this promoter, for example, ubiquitous expression promoters such as virus-derived promoter, metallothionein promoter and the like may be also used, although NGF gene promoter and enolase gene promoter which are specifically expressed in brain are preferably used.

Transference of a DNA of the present invention at fertilized ovum cell stage is maintained such that the DNA is present in all of an embryo cell and a somatic cell of a subject animal. The presence of present protein or the like in an embryo cell in a produced animal after DNA transference means that all progenies of produced animal have present protein or the like in their all embryo cells and somatic cells. A progeny of such the animal which inherited a gene has present protein or the like in all its embryo cells and somatic cells.

A DNA transferred animal of the present invention can be passage-bred as an animal harboring the DNA under the normal breeding circumstances by assuring that a gene is stably retained by mating. Further, a homozygote animal having an introduced gene in both of homologous chromosomes can be obtained by mating male and female animals retaining a DNA of interest and breeding passage may be performed such that all progenies have the DNA, by mating the male and female.

Since an animal, in which a DNA of the present invention is introduced,

expresses highly present protein or the like, it is useful as an animal for screening an agonist or an antagonist for present protein or the like.

A DNA-transferred animal of the present invention may be used as a cell source for tissue culturing. For example, present protein or the like can be analyzed by analyzing directly a DNA or a RNA in a tissue of a DNA-transferred mouse of the present invention, or by analyzing a tissue in which a protein of the present invention expressed by a gene is present. A cell of a tissue having present protein or the like is cultured by standard tissue culturing technique, which can be used to study the function of a cell from a tissue which is generally difficult to culture, such as derived from brain or peripheral tissue. In addition, by using the cell, for example, a drug which enhances the function of various tissues can be selected. In addition, when there is a high expressing cell strain, present protein or the like can be also isolated and purified therefrom.

When a nucleotide, an amino acid and the like are expressed as an abbreviation in the present invention and drawings, the abbreviation is based on abbreviation by IUPAC-IUB Commission on Biochemical Nomenclature or the conventional abbreviation in the art. Examples thereof are shown below. When there are optical isomers regarding an amino acid, L amino acid is shown unless indicated.

DNA: deoxyribonucleic acid

cDNA: complementary deoxyribonucleic acid

A: adenine

T: thymine

G: guanine

C: cytosine



RNA: ribonucleic acid

mRNA: messenger ribonucleic acid

dATP: deoxyadenosine triphosphate

dTTP: deoxythymidine triphosphate

5 dGTP: deoxyguanosine triphosphate

dCTP: deoxycytidine triphosphate

ATP: adenosine triphosphate

EDTA: ethylenediamine tetraacetic acid

SDS: sodium dodecylsulfate

10 Gly: glycine

Ala: alanine

Val: valine

Leu: leucine

Ile: isoleucine

15 Ser: serine

Thr: threonine

Cys: cysteine

Met: methionine

Glu: glutamic acid

20 Asp: aspartic acid

Lys: lysine

Arg: arginine

His: histidine

Phe: phenylalanine

25 Tyr: tyrosine

Trp: tryptophan

Pro: proline

Asn: asparagine

Gln: glutamine

5 pGlu: pyroglutamic acid

Me: methyl group

Et: ethyl group

Bu: butyl group

Ph: phenyl group

10 TC: thiazolidine-4(R)-carboxamide group

In addition, substituents, protecting groups and reagents which are frequently used are expressed by the following symbols:

Tos: p-toluenesulfonyl

CHO: formyl

15 Bzl: benzyl

Cl<sub>2</sub>Bzl: 2,6-dichlorobenzyl

Bom: benzyloxymethyl

Z: benzyloxycarbonyl

Cl-Z: 2-chlorobenzyloxycarbonyl

20 Br-Z: 2-bromobenzyloxycarbonyl

Boc: t-butoxycarbonyl

DNP: dinitrophenol

Trt: trityl

Bom: t-butoxymethyl

25 Fmoc: N-9-fluorenylmethoxycarbonyl

HOBt: 1-hydroxybenztriazole

HOObt: 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine

HONB: 1-hydroxy-5-norbornene-2,3-dicarboximide

DCC: N,N'-dicyclohexylcarbodiimide

5           Sequence numbers of SEQ ID Tables in the present specification show the following sequences.

[SEQ ID No:1]

          An amino acid sequence of a human brain-derived protein of the present invention is shown.

10   [SEQ ID No:2]

          A nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention having an amino acid represented by SEQ ID No:1.

[SEQ ID No:3]

          An amino acid sequence of a human brain-derived protein of the present invention is shown.

15   [SEQ ID No:4]

          A nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention having an amino acid represented by SEQ ID No:3.

[SEQ ID No:5]

20           An amino acid sequence of a human brain-derived protein of the present invention is shown.

[SEQ ID No:6]

          A nucleotide sequence of a DNA encoding a human brain-derived protein of the present invention having an amino acid represented by SEQ ID No:5.

25           Transformant Escherichia coli JM109/pHK05006 obtained in Example 1

below has been deposited at Trade and Commerce Ministry Industrial Technology Institute Life Technology Industrial Technology Laboratory (NIBH) under accession number of FERM BP-6433 since July 21, 1998 and at Foundation Fermentation Laboratory under accession number of IFO 16189 since July 8, 1998.

5 Transformant *Escherichia coli* JM109/pHK05490 obtained in Example 2 below has been deposited at Trade and Commerce Ministry Industrial Technology Institute Life Technology Industrial Technology Laboratory (NIBH) under accession number of FERM BP-6456 since August 7, 1998.

10 Transformant *Escherichia coli* JM109/pHH02631 obtained in Example 3 below has been deposited at Trade and Commerce Ministry Industrial Technology Institute Life Technology Industrial Technology Laboratory (NIBH) under accession number of FERM BP-6540 since October 6, 1998.

#### Examples

15 The following Examples illustrate the present invention but do not limit the scope thereof. Gene manipulations using *Escherichia coli* were according to a method described in Molecular cloning.

#### Example 1

20 Search of a human brain-derived G protein-coupled receptor protein and determination of a nucleotide sequence (1)

Homology search was made to amino acid sequences encoded by cDNAs obtained by a method described in DNA RESEARCH, vol.4, pp.53-59 (1997) or a similar method using sequences of the known receptors; in particular, sequences of  
25 human ORF receptors as a template, and an amino acid sequence represented by SEQ

ID No:1 (amino acid sequence in Fig. 1 and Fig. 2) showed homology.

Then, cDNA corresponding to amino acid sequence in SEQ ID No:1 (amino acid sequence in Fig. 1 and Fig. 2) was sequence-analyzed and SEQ ID No:2 (nucleotide sequence in Fig. 1 and Fig. 2) was obtained. Hydrophobicity plot shown in Fig. 3 was obtained and it was found that seven times transmembrane type (G protein conjugated type) receptor is encoded.

Further, plasmid pHK05006 harboring a DNA represented by SEQ ID No:2 was introduced into E. coli JM109 to obtain E. coli JM109/pHK05006.

## Example 2

Search of a human brain-derived G protein-coupled receptor protein and determination of a nucleotide sequence (2)

Homology search was made to amino acid sequences encoded by cDNAs [SEQ ID No:4 (DNA sequence in Fig.7-Fig. 15)] obtained by a method described in DNA RESEARCH, vol.4, pp.53-59 (1997) or a similar method using sequences of the known receptors; in particular, sequences of human ORF receptors as a template, and an amino acid sequence represented by SEQ ID No:3 (amino acid sequence represented by HKO05490 in Fig. 4 and Fig. 5; amino acid sequence in Fig. 7-Fig.15) showed homology.

Then, hydrophobicity plot was analyzed and this is shown in Fig. 6, and it was found that seven times transmembrane type (G protein conjugated type) receptor is encoded. In addition, it was confirmed that a protein represented by an amino acid sequence represented by SEQ ID No:3 shows high homology with a protein represented by an amino acid sequence represented by SEQ ID No:1 described in

Example 1 (Fig.4).

Further, plasmid pHK05490 harboring a DNA represented by SEQ ID No:4 was introduced into E. coli JM109 to obtain E. coli JM109/pHK05490.

### Example 3

Search of a human brain-derived G protein-coupled receptor protein and determination of a nucleotide sequence (1)

Homology search was made to amino acid sequences encoded by cDNAs obtained by a method described in DNA RESEARCH, vol.4, pp.53-59 (1997) or a similar method using sequences of the known receptors; in particular, sequences of human ORF receptors as a template, and an amino acid sequence represented by SEQ ID No:5 showed homology.

Then, cDNA corresponding to amino acid sequence in SEQ ID No:5 was sequence-analyzed and SEQ ID No:6 was obtained. Hydrophobicity plot shown in Fig. 25 was obtained and it was found that seven times transmembrane type (G protein conjugated type) receptor is encoded.

Further, plasmid pHH02631 harboring a DNA represented by SEQ ID No:6 was introduced into E. coli JM109 to obtain E. coli JM109/pHH02631.

### Industrial Applicability

A protein of the present invention, a partial peptide thereof or a salt thereof, and a DNA encoding it can be used in or as (1) determination of a ligand (agonist), (2) obtaining of an antibody and antiserum, (3) construction of the expression system for a recombinant protein, (4) development of the receptor binding assay using the same expression system and screening of drug candidates, (5) implementation of drug design based on comparison with a ligand receptor having the structural similarity, (6)

reagents for preparing a probe or a PCR primer in gene therapy, (7) production of a transgenic animal, or (8) a drug for gene prophylaxis or therapy.

What is claimed is:

1. A protein comprises the same or substantially the same amino acid sequence represented by SEQ ID No:1, SEQ ID No:3 or SEQ ID No:5, or a salt thereof.

2. A partial peptide of the protein according to claim 1, or a salt thereof.

3. A DNA comprises a DNA having a nucleotide sequence encoding the protein according to claim 1.

4. The DNA according to claim 3, which comprising a nucleotide sequence represented by SEQ ID No:2, SEQ ID No:4 or SEQ ID No:6.

5. A recombinant vector comprising the DNA according to claim 3.

6. A transformant transformed with the recombinant vector according to claim 5.

7. A process for producing the protein or a salt thereof according to claim 1, which comprises culturing the transformant according to claim 6, and producing and accumulating the protein according to claim 1.

8. An antibody to the protein according to claim 1, the partial peptide according to claim 2 or a salt thereof.

9. A method for determining a ligand for the protein according to claim 1 or a salt thereof, which comprises using the protein according to claim 1, the partial peptide according to claim 2 or a salt thereof.

10. A method for screening a compound or a salt thereof which alters property of a ligand binding with the protein according to claim 1 or a salt thereof, which comprises using the protein according to claim 1, the partial peptide according to claim 2 or a salt thereof.

11. A kit for screening a compound or a salt thereof which alters property of





# SEQUENCE LISTING

<110> Takeda Chemical Industries, Ltd.

<120> Novel G Protein Coupled Receptor Protein and Its Use

<130> A99137

5 <150> JP 10-207579

<151> 1998-07-23

<150> JP 10-225060

<151> 1998-08-07

<150> JP 10-284328

10 <151> 1998-10-06

<160> 6

<210> 1

<211> 872

<212> PRT

15 <213> Human

<400> 1

Ala Glu Gln Thr Arg Asn His Leu Asn Ala Gly Asp Ile Thr Tyr Ser

1 5 10 15

Val Arg Ala Met Asp Gln Leu Val Gly Leu Leu Asp Val Gln Leu Arg

20 25 30

Asn Leu Thr Pro Gly Gly Lys Asp Ser Ala Ala Arg Ser Leu Asn Lys

35

40

45

Ala Met Val Glu Thr Val Asn Asn Leu Leu Gln Pro Gln Ala Leu Asn

50

55

60

5 Ala Trp Arg Asp Leu Thr Thr Ser Asp Gln Leu Arg Ala Ala Thr Met

65

70

75

80

Leu Leu His Thr Val Glu Glu Ser Ala Phe Val Leu Ala Asp Asn Leu

85

90

95

Leu Lys Thr Asp Ile Val Arg Glu Asn Thr Asp Asn Ile Lys Leu Glu

10

100

105

110

Val Ala Arg Leu Ser Thr Glu Gly Asn Leu Glu Asp Leu Lys Phe Pro

115

120

125

Glu Asn Met Gly His Gly Ser Thr Ile Gln Leu Ser Ala Asn Thr Leu

130

135

140

15 Lys Gln Asn Gly Arg Asn Gly Glu Ile Arg Val Ala Phe Val Leu Tyr

145

150

155

160

Asn Asn Leu Gly Pro Tyr Leu Ser Thr Glu Asn Ala Ser Met Lys Leu

165

170

175

Gly Thr Glu Ala Leu Ser Thr Asn His Ser Val Ile Val Asn Ser Pro

20

180

185

190

Val Ile Thr Ala Ala Ile Asn Lys Glu Phe Ser Asn Lys Val Tyr Leu

195

200

205

Ala Asp Pro Val Val Phe Thr Val Lys His Ile Lys Gln Ser Glu Glu

210

215

220

25 Asn Phe Asn Pro Asn Cys Ser Phe Trp Ser Tyr Ser Lys Arg Thr Met

09744226.012301

225 230 235 240

Thr Gly Tyr Trp Ser Thr Gln Gly Cys Arg Leu Leu Thr Thr Asn Lys

245 250 255

Thr His Thr Thr Cys Ser Cys Asn His Leu Thr Asn Phe Ala Val Leu

5 260 265 270

Met Ala His Val Glu Val Lys His Ser Asp Ala Val His Asp Leu Leu

275 280 285

Leu Asp Val Ile Thr Trp Val Gly Ile Leu Leu Ser Leu Val Cys Leu

290 295 300

10 Leu Ile Cys Ile Phe Thr Phe Cys Phe Phe Arg Gly Leu Gln Ser Asp

305 310 315 320

Arg Asn Thr Ile His Lys Asn Leu Cys Ile Ser Leu Phe Val Ala Glu

325 330 335

Leu Leu Phe Leu Ile Gly Ile Asn Arg Thr Asp Gln Pro Ile Ala Cys

15 340 345 350

Ala Val Phe Ala Ala Leu Leu His Phe Phe Phe Leu Ala Ala Phe Thr

355 360 365

Trp Met Phe Leu Glu Gly Val Gln Leu Tyr Ile Met Leu Val Glu Val

370 375 380

20 Phe Glu Ser Glu His Ser Arg Arg Lys Tyr Phe Tyr Leu Val Gly Tyr

385 390 395 400

Gly Met Pro Ala Leu Ile Val Ala Val Ser Ala Ala Val Asp Tyr Arg

405 410 415

Ser Tyr Gly Thr Asp Lys Val Cys Trp Leu Arg Leu Asp Thr Tyr Phe

25 420 425 430



	625	630	635	640
	Ser Asn Cys Val Gln Ile Ile Asp Arg Gly Tyr Asn His Asn Glu Thr			
	645	650	655	
	Ala Leu Glu Lys Lys Ile Leu Lys Glu Leu Thr Ser Asn Tyr Ile Pro			
5	660	665	670	
	Ser Tyr Leu Asn Asn His Glu Arg Ser Ser Glu Gln Asn Arg Asn Leu			
	675	680	685	
	Met Asn Lys Leu Val Asn Asn Leu Gly Ser Gly Arg Glu Asp Asp Ala			
	690	695	700	
10	Ile Val Leu Asp Asp Ala Thr Ser Phe Asn His Glu Glu Ser Leu Gly			
	705	710	715	720
	Leu Glu Leu Ile His Glu Glu Ser Asp Ala Pro Leu Leu Pro Pro Arg			
	725	730	735	
	Val Tyr Ser Thr Glu Asn His Gln Pro His His Tyr Thr Arg Arg Arg			
15	740	745	750	
	Ile Pro Gln Asp His Ser Glu Ser Phe Phe Pro Leu Leu Thr Asn Glu			
	755	760	765	
	His Thr Glu Asp Leu Gln Ser Pro His Arg Asp Ser Leu Tyr Thr Ser			
	770	775	780	
20	Met Pro Thr Leu Ala Gly Val Ala Ala Thr Glu Ser Val Thr Thr Ser			
	785	790	795	800
	Thr Gln Thr Glu Pro Pro Pro Ala Lys Cys Gly Asp Ala Glu Asp Val			
	805	810	815	
	Tyr Tyr Lys Ser Met Pro Asn Leu Gly Ser Arg Asn His Val His Gln			
25	820	825	830	

Leu His Thr Tyr Tyr Gln Leu Gly Arg Gly Ser Ser Asp Gly Phe Ile

835

840

845

Val Pro Pro Asn Lys Asp Gly Thr Pro Pro Glu Gly Ser Ser Lys Gly

850

855

860

5 Pro Ala His Leu Val Thr Ser Leu

865

870

<210> 2

<211> 2616

<212> DNA

10 <213> Human

<400> 2

GCTGAACAGA CAAGAAATCA CTTGAATGCT GGGGACATCA CCTACTCTGT CCGGGCCATG 60

GACCAGCTGG TAGGCCTCCT AGATGTACAG CTCGGAAGT TGACCCAGG TGGAAAAGAT 120

AGTGCTGCCC GGAGTTTGAA CAAGGCAATG GTCGAGACAG TTAACAACCT CCTTCAGCCA 180

15 CAAGCTTTGA ATGCATGGAG AGACCTGACT ACGAGTGATC AGCTGCGTGC GGCCACCATG 240

TTGCTTCATA CTGTGGAGGA AAGTGCTTTT GTGCTGGCTG ATAACCTTTT GAAGACTGAC 300

ATTGTCAGGG AGAATACAGA CAATATTAAA TTGGAAGTTG CAAGACTGAG CACAGAAGGA 360

AACTTAGAAG ACCTAAAATT TCCAGAAAAC ATGGGCCATG GAAGCACTAT CCAGCTGTCT 420

GCAAATACCT TAAAGCAAAA TGGCCGAAAT GGAGAGATCA GAGTGGCCTT TGTCTGTAT 480

20 AACAACTTGG GTCCTTATTT ATCCACGGAG AATGCCAGTA TGAAGTTGGG AACGGAAGCT 540

TTGTCCACAA ATCATTCTGT TATTGTCAAT TCCCCTGTTA TTACGGCAGC AATAAACAAA 600

GAGTTCAGTA ACAAGGTTTA TTTGGCTGAT CCTGTGGTAT TTAGTGTTAA ACATATCAAG 660

CAGTCAGAGG AAAATTTCAA CCCTAACTGT TCATTTTGGA GCTACTCCAA GCGTACAATG 720

ACAGGTTATT GGTCACACA AGGCTGTCGG CTCCTGACAA CAAATAAGAC ACATACTACA 780

25 TGCTCTTGTA ACCACCTAAC AAATTTTGCA GTACTGATGG CACATGTGGA AGTTAAGCAC 840

	AGTGATGCGG TCCATGACCT CCTTCTGGAT GTGATCACGT GGGTTGGAAT TTTGCTGTCC	900
	CTTGTITGTC TCCTGATTG CATCTTCACA TTTTGCTTTT TCCGCGGGCT CCAGAGTGAC	960
	CGTAACACCA TCCACAAGAA CCTCTGCATC AGTCTCTTTG TAGCAGAGCT GCTCTTCCTG	1020
	ATTGGGATCA ACCGAACTGA CCAACCAATT GCCTGTGCTG TTTTCGCTGC CCTGTTTTCT	1080
5	TCTTCTTGGC TGCCTTCACC TGGATGTTC TGGAGGGGGT GCAGCTTTAT ATACATCATG	1140
	CTGGTGGAGG TTTTGAGAG TGAACATTCA CGTAGGAAAT ACTTTTATCT GGTCCGCTAT	1200
	GGGATGCCTG CACTCATTGT GGCTGTGTCA GCTGCAGTAG ACTACAGGAG TTATGGAACA	1260
	GATAAAGTAT GTTGGCTCCG ACTTGACACC TACTTCATTT GGAGTTTTAT AGGACCAGCA	1320
	ACTTTGATAA TTATGCTTAA TGTAATCTTC CTTGGGATTG CTTTATATAA AATGTTTCAT	1380
10	CATACTGCTA TACTGAAACC TGAATCAGGC TGTCTTGATA ACATCAAGTC ATGGGTTATA	1440
	GGTGCAATAG CTCTTCTCTG CCTATTAGGA TTGACCTGGG CCTTTGGACT CATGTATATT	1500
	AATGAAAGCA CAGTCATCAT GGCCTATCTC TTCACCATTT TCAATTCTCT ACAGGGAATG	1560
	TTTATATTTA TTTTCCATTG TGTCTACAG AAGAAGGTAC GAAAAGAGTA TGGGAAATGC	1620
	CTGCGAACAC ATTGCTGTAG TGGCAAAAGT ACAGAGAGTT CCATTGGTTC AGGGAAAACA	1680
15	TCTGGTTCTC GAACTCCTGG ACGCTACTCC ACAGGCTCAC AGAGCCGAAT CCGTAGAATG	1740
	TGGAATGACA CGGTTGCAAA GCAGTCAGAG TCTTCCTTTA TTACTGGAGA CATAAACAGT	1800
	TCAGCGTCAC TCAACAGAGA GGGGCTTCTG AACAATGCCA GGGATACAAG TGTCATGGAT	1860
	ACTCTACCAC TGAATGGTAA CCATGGCAAT AGTTACAGCA TTGCCAGCGG CGAATACCTG	1920
	AGCAACTGTG TGCAATCAT AGACCGTGGC TATAACCATA ACGAGACCGC CCTAGAGAAA	1980
20	AAGATTCTGA AGGAACTCAC TTCCAATAT ATCCCTTCTT ACCTGAACAA CCATGAGCGC	2040
	TCCAGTGAAC AGAACAGGAA TCTGATGAAC AAGCTGGTGA ATAACTTGG CAGTGGAAGG	2100
	GAAGATGATG CCATTGTCCT GGATGATGCC ACCTCGTTTA ACCACGAGGA GAGTTTGGGC	2160
	CTGGAATCA TTCATGAGGA ATCTGATGCT CCTTTGCTGC CCCAAGAGT ATACTCCACC	2220
	GAGAACCACC AGCCACACCA TTATACCAGA AGGCGGATCC CCCAAGACCA CAGTGAGAGC	2280
25	TTTTTCCCTT TGCTAACCAA CGAGCACACA GAAGATCTCC AGTCACCCCA TAGAGACTCT	2340



CTCTATACCA GCATGCCGAC ACTGGCTGGT GTGGCCGCCA CAGAGAGTGT TACCACCAGC 2400  
 ACCCAGACCG AACCCCCACC GGCCAAATGT GGTGATGCCG AAGATGTTTA CTACAAAAGC 2460  
 ATGCCAAACC TAGGCTCCAG AAACCACGTC CATCAGCTGC ATACTTACTA CCAGCTAGGT 2520  
 CGCGGCAGCA GTGATGGATT TATAGTTCCT CCAAACAAAG ATGGGACCCC TCCCGAGGGA 2580  
 5 AGTTCAAAAG GACCGGCTCA TTTGGTCACT AGTCTA 2616

<210> 3

<211> 1021

<212> PRT

<213> Human

10 <400> 3

Glu Gly Ser Lys Gly Thr Lys Pro Pro Pro Ala Val Ser Thr Thr Lys

1 5 10 15

Ile Pro Pro Ile Thr Asn Ile Phe Pro Leu Pro Glu Arg Phe Cys Glu

20 25 30

15 Ala Leu Asp Ser Lys Gly Ile Lys Trp Pro Gln Thr Gln Arg Gly Met

35 40 45

Met Val Glu Arg Pro Cys Pro Lys Gly Thr Arg Gly Thr Ala Ser Tyr

50 55 60

Leu Cys Met Ile Ser Thr Gly Thr Trp Asn Pro Lys Gly Pro Asp Leu

20 65 70 75 80

Ser Asn Cys Thr Ser His Trp Val Asn Gln Leu Ala Gln Lys Ile Arg

85 90 95

Ser Gly Glu Asn Ala Ala Ser Leu Ala Asn Glu Leu Ala Lys His Thr

100 105 110

25 Lys Gly Pro Val Phe Ala Gly Asp Val Ser Ser Ser Val Arg Leu Met

	115	120	125	
	Glu Gln Leu Val Asp Ile Leu Asp Ala Gln Leu Gln Glu Leu Lys Pro			
	130	135	140	
	Ser Glu Lys Asp Ser Ala Gly Arg Ser Tyr Asn Lys Leu Gln Lys Arg			
5	145	150	155	160
	Glu Lys Thr Cys Arg Ala Tyr Leu Lys Ala Ile Val Asp Thr Val Asp			
	165	170	175	
	Asn Leu Leu Arg Pro Glu Ala Leu Glu Ser Trp Lys His Met Asn Ser			
	180	185	190	
10	Ser Glu Gln Ala His Thr Ala Thr Met Leu Leu Asp Thr Leu Glu Glu			
	195	200	205	
	Gly Ala Phe Val Leu Ala Asp Asn Leu Leu Glu Pro Thr Arg Val Ser			
	210	215	220	
	Met Pro Thr Glu Asn Ile Val Leu Glu Val Ala Val Leu Ser Thr Glu			
15	225	230	235	240
	Gly Gln Ile Gln Asp Phe Lys Phe Pro Leu Gly Ile Lys Gly Ala Gly			
	245	250	255	
	Ser Ser Ile Gln Leu Ser Ala Asn Thr Val Lys Gln Asn Ser Arg Asn			
	260	265	270	
20	Gly Leu Ala Lys Leu Val Phe Ile Ile Tyr Arg Ser Leu Gly Gln Phe			
	275	280	285	
	Leu Ser Thr Glu Asn Ala Thr Ile Lys Leu Gly Ala Asp Phe Ile Gly			
	290	295	300	
	Arg Asn Ser Thr Ile Ala Val Asn Ser His Val Ile Ser Val Ser Ile			
25	305	310	315	320

	Asn Lys Glu Ser Ser Arg Val Tyr Leu Thr Asp Pro Val Leu Phe Thr		
	325	330	335
	Leu Pro His Ile Asp Pro Asp Asn Tyr Phe Asn Ala Asn Cys Ser Phe		
	340	345	350
5	Trp Asn Tyr Ser Glu Arg Thr Met Met Gly Tyr Trp Ser Thr Gln Gly		
	355	360	365
	Cys Lys Leu Val Asp Thr Asn Lys Thr Arg Thr Thr Cys Ala Cys Ser		
	370	375	380
	His Leu Thr Asn Phe Ala Ile Leu Met Ala His Arg Glu Ile Ala Tyr		
10	385	390	395
	Lys Asp Gly Val His Glu Leu Leu Leu Thr Val Ile Thr Trp Val Gly		
	405	410	415
	Ile Val Ile Ser Leu Val Cys Leu Ala Ile Cys Ile Phe Thr Phe Cys		
	420	425	430
15	Phe Phe Arg Gly Leu Gln Ser Asp Arg Asn Thr Ile His Lys Asn Leu		
	435	440	445
	Cys Ile Asn Leu Phe Ile Ala Glu Phe Ile Phe Leu Ile Gly Ile Asp		
	450	455	460
	Lys Thr Lys Tyr Ala Ile Ala Cys Pro Ile Phe Ala Gly Leu Leu His		
20	465	470	475
	Phe Phe Phe Leu Ala Ala Phe Ala Trp Met Cys Leu Glu Gly Val Gln		
	485	490	495
	Leu Tyr Leu Met Leu Val Glu Val Phe Glu Ser Glu Tyr Ser Arg Lys		
	500	505	510
25	Lys Tyr Tyr Tyr Val Ala Gly Tyr Leu Phe Pro Ala Thr Val Val Gly		

	515	520	525	
	Val Ser Ala Ala Ile Asp Tyr Lys Ser Tyr Gly Thr Glu Lys Ala Cys			
	530	535	540	
	Trp Leu His Val Asp Asn Tyr Phe Ile Trp Ser Phe Ile Gly Pro Val			
5	545	550	555	560
	Thr Phe Ile Ile Leu Leu Asn Ile Ile Phe Leu Val Ile Thr Leu Cys			
	565	570	575	
	Lys Met Val Lys His Ser Asn Thr Leu Lys Pro Asp Ser Ser Arg Leu			
	580	585	590	
10	Glu Asn Ile Lys Ser Trp Val Leu Gly Ala Phe Ala Leu Leu Cys Leu			
	595	600	605	
	Leu Gly Leu Thr Trp Ser Phe Gly Leu Leu Phe Ile Asn Glu Glu Thr			
	610	615	620	
	Ile Val Met Ala Tyr Leu Phe Thr Ile Phe Asn Ala Phe Gln Gly Val			
15	625	630	635	640
	Phe Ile Phe Ile Phe His Cys Ala Leu Gln Lys Lys Val Arg Lys Glu			
	645	650	655	
	Tyr Gly Lys Cys Phe Arg His Ser Tyr Cys Cys Gly Gly Leu Pro Thr			
	660	665	670	
20	Glu Ser Pro His Ser Ser Val Lys Ala Ser Thr Thr Arg Thr Ser Ala			
	675	680	685	
	Arg Tyr Ser Ser Gly Thr Gln Ser Arg Ile Arg Arg Met Trp Asn Asp			
	690	695	700	
	Thr Val Arg Lys Gln Ser Glu Ser Ser Phe Ile Ser Gly Asp Ile Asn			
25	705	710	715	720

09744266 012204  
FOETD "G22H260

	Ser Thr Ser Thr Leu Asn Gln Gly Met Thr Gly Asn Tyr Leu Leu Thr			
	725	730	735	
	Asn Pro Leu Leu Arg Pro His Gly Thr Asn Asn Pro Tyr Asn Thr Leu			
	740	745	750	
5	Leu Ala Glu Thr Val Val Cys Asn Ala Pro Ser Ala Pro Val Phe Asn			
	755	760	765	
	Ser Pro Gly His Ser Leu Asn Asn Ala Arg Asp Thr Ser Ala Met Asp			
	770	775	780	
	Thr Leu Pro Leu Asn Gly Asn Phe Asn Asn Ser Tyr Ser Leu His Lys			
10	785	790	795	800
	Gly Asp Tyr Asn Asp Ser Val Gln Val Val Asp Cys Gly Leu Ser Leu			
	805	810	815	
	Asn Asp Thr Ala Phe Glu Lys Met Ile Ile Ser Glu Leu Val His Asn			
	820	825	830	
15	Asn Leu Arg Gly Ser Ser Lys Thr His Asn Leu Glu Leu Thr Leu Pro			
	835	840	845	
	Val Lys Pro Val Ile Gly Gly Ser Ser Ser Glu Asp Asp Ala Ile Val			
	850	855	860	
	Ala Asp Ala Ser Ser Leu Met His Ser Asp Asn Pro Gly Leu Glu Leu			
20	865	870	875	880
	His His Lys Glu Leu Glu Ala Pro Leu Ile Pro Gln Arg Thr His Ser			
	885	890	895	
	Leu Leu Tyr Gln Pro Gln Lys Lys Val Lys Ser Glu Gly Thr Asp Ser			
	900	905	910	
25	Tyr Val Ser Gln Leu Thr Ala Glu Ala Glu Asp His Leu Gln Ser Pro			

	915	920	925
	Asn Arg Asp Ser Leu Tyr Thr Ser Met Pro Asn Leu Arg Asp Ser Pro		
	930	935	940
	Tyr Pro Glu Ser Ser Pro Asp Met Glu Glu Asp Leu Ser Pro Ser Arg		
5	945	950	955 960
	Arg Ser Glu Asn Glu Asp Ile Tyr Tyr Lys Ser Met Pro Asn Leu Gly		
	965	970	975
	Ala Gly His Gln Leu Gln Met Cys Tyr Gln Ile Ser Arg Gly Asn Ser		
	980	985	990
10	Asp Gly Tyr Ile Ile Pro Ile Asn Lys Glu Gly Cys Ile Pro Glu Gly		
	995	1000	1005
	Asp Val Arg Glu Gly Gln Met Gln Leu Val Thr Ser Leu		
	1010	1015	1020
	<210> 4		
15	<211> 3063		
	<212> DNA		
	<213> Human		
	<400> 4		
	GAAGGAAGCA AAGGGACAAA ACCACCTCCA GCAGTTTCTA CAACCAAAAT TCCACCTATA	60	
20	ACAAATATTT TTCCCTGCC AGAGAGATTC TGTGAAGCAT TAGACTCCAA GGGGATAAAG	120	
	TGGCCTCAGA CACAAAGGGG AATGATGGTT GAACGACCAT GCCCTAAGGG AACAAGAGGA	180	
	ACTGCCTCAT ATCTCTGCAT GATTTCCTACT GGAACATGGA ACCCTAAGGG CCCCATCTT	240	
	AGCAACTGTA CCTCACACTG GGTGAATCAG CTGGCTCAGA AGATCAGAAG CGGAGAAAAT	300	
	GCTGCTAGTC TTGCAATGA ACTGGCTAAA CATACCAAAG GGCCAGTGTT TGCTGGGGAT	360	
25	GTAAGTTCTT CAGTGAGATT GATGGAGCAG TTGGTGGACA TCCTTGATGC ACAGCTGCAG	420	

GAACTGAAAC CTAGTGAAAA AGATTCAGCT GGACGGAGTT ATAACAAGCT CCAAAAACGA 480  
 GAGAAGACAT GCAGGGCTTA CCTTAAGGCA ATTGTTGACA CAGTGGACAA CCTTCTGAGA 540  
 CCTGAAGCTT TGAATCATG GAAACATATG AATTCTTCTG AACAAGCACA TACTGCAACA 600  
 ATGTTACTCG ATACATTGGA AGAAGGAGCT TTTGTCCTAG CTGACAATCT TTTAGAACCA 660  
 5 ACAAGGGTCT CAATGCCCAC AGAAAATATT GTCCTGGAAG TTGCCGTACT CAGTACAGAA 720  
 GGACAGATCC AAGACTTTAA ATTTCTCTG GGCATCAAAG GAGCAGGCAG CTCAATCCAA 780  
 CTGTCCGCAA ATACCGTCAA ACAGAACAGC AGGAATGGGC TTGCAAAGTT GGTGTTTCATC 840  
 ATTTACCGGA GCCTGGGACA GTTCCTTAGT ACAGAAAATG CAACCATTAA ACTGGGTGCT 900  
 GATTTTATTG GTCGTAATAG CACCATTGCA GTGAACTCTC ACGTCATTTT AGTTTCAATC 960  
 10 AATAAAGAGT CCAGCCGAGT ATACCTGACT GATCCTGTGC TTTTACCCT GCCACACATT 1020  
 GATCCTGACA ATTATTTCAA TGCAAACTGC TCCTTCTGGA ACTACTCAGA GAGAACTATG 1080  
 ATGGGATATT GGTCTACCCA GGGCTGCAAG CTGGTTGACA CTAATAAAAC TCGAACAACG 1140  
 TGTGCATGCA GCCACCTAAC CAATTTTGCA ATTCTCATGG CCCACAGGGA AATTGCATAT 1200  
 AAAGATGGCG TTCATGAATT ACTTCTTACA GTCATCACCT GGGTGGGAAT TGTCATTTCC 1260  
 15 CTTGTTTGCC TGGCTATCTG CATCTTACC TTCTGCTTTT TCCGTGGCCT ACAGAGTGAC 1320  
 CGAAATACTA TTCACAAGAA CCTTTGTATC AACCTTTTCA TTGCTGAATT TATTTTCCTA 1380  
 ATAGGCATTG ATAAGACAAA ATATGCGATT GCATGCCCAA TATTTGCAGG ACTTCTACAC 1440  
 TTTTCTTTT TGGCAGCTTT TGCTTGATG TGCCTAGAAG GTGTGCAGCT CTACCTAATG 1500  
 TTAGTTGAAG TTTTGAAG TGAATATTCA AGGAAAAAAT ATTACTATGT TGCTGGTTAC 1560  
 20 TTGTTTCCTG CCACAGTGGT TGGAGTTTCA GCTGCTATTG ACTATAAGAG CTATGGAACA 1620  
 GAAAAAGCTT GCTGGCTTCA TGTTGATAAC TACTTTATAT GGAGCTTCAT TGGACCTGTT 1680  
 ACCTTCATTA TTCTGCTAAA TATTATCTTC TTGGTGATCA CATTGTGCAA AATGGTGAAG 1740  
 CATTCAAACA CTTTGAAACC AGATTCTAGC AGGTTGGAAA ACATTAAGTC TTGGGTGCTT 1800  
 GCGCCTTTG CTCTTCTGTG TCTTCTTGGC CTCACCTGGT CCTTTGGGT GCTTTTTATT 1860  
 25 AATGAGGAGA CTATTGTGAT GGCATATCTC TTCACTATAT TTAATGCTTT CCAGGGAGTG 1920

TTCATTTTCA TCTTTCAC TGCTCTCCAA AAGAAAGTAC GAAAAGAATA TGGCAAGTGC 1980  
 TTCAGACACT CATACTGCTG TGGAGGCCTC CCAACTGAGA GTCCCCACAG TTCAGTGAAG 2040  
 GCATCAACCA CCAGAACCAG TGCTCGCTAT TCCTCTGGCA CACAGAGTCG TATAAGAAGA 2100  
 ATGTGGAATG ATACTGTGAG AAAACAATCA GAATCTTCTT TTATCTCAGG TGACATCAAT 2160  
 5 AGCACTTCAA CACTTAATCA AGGAATGACT GGCAATTACC TACTAACAAA CCCTCTTCTT 2220  
 CGACCCACAG GCACTAACAA CCCCTATAAC ACATTGCTCG CTGAAACAGT TGTATGTAAT 2280  
 GCCCCTTCAG CTCCTGTATT TAACTCACCA GGACATTCAC TGAACAATGC CAGGGATACA 2340  
 AGTGCCATGG ATACTCTACC GCTAAATGGT AATTTTAACA ACAGCTACTC GCTGCACAAG 2400  
 GGTGACTATA ATGACAGCGT GCAAGTTGTG GACTGTGGAC TAAGTCTGAA TGATACTGCT 2460  
 10 TTTGAGAAAA TGATCATTTT AGAATTAGTG CACAACAAC TACGGGGCAG CAGCAAGACT 2520  
 CACAACCTCG AGCTCAGCT ACCAGTCAAA CCTGTGATTG GAGGTAGCAG CAGTGAAGAT 2580  
 GATGCTATTG TGGCAGATGC TTCATCTTTA ATGCACAGCG ACAACCCAGG GCTGGAGCTC 2640  
 CATCACAAAG AACTCGAGGC ACCACTTATT CCTCAGCGGA CTCACTCCCT TCTGTACCAA 2700  
 CCCCAGAAGA AAGTGAAGTC CGAGGGAAC TACAGCTATG TCTCCCACT GACAGCAGAG 2760  
 15 GCTGAAGATC ACCTACAGTC CCCCAACAGA GACTCTCTTT ATACAAGCAT GCCCAATCTT 2820  
 AGAGACTCTC CCTATCCGGA GAGCAGCCCT GACATGGAAG AAGACCTCTC TCCCTCCAGG 2880  
 AGGAGTGAGA ATGAGGACAT TTACTATAAA AGCATGCCAA ATCTTGAGC TGGCCATCAG 2940  
 CTTCAGATGT GCTACCAGAT CAGCAGGGGC AATAGTGATG GTTATATAAT CCCCATTAAC 3000  
 AAAGAAGGGT GTATTCCAGA AGGAGATGTT AGAGAAGGAC AAATGCAGCT GGTTACAAG 3060  
 20 CTT 3063  
 <210> 5  
 <211> 1474  
 <212> PRT  
 <213> Human  
 25 <400> 5





05744226.012201

	195	200	205	
	Asn Arg Val Asp Gly Thr Gly Phe Val Val Tyr Asp Gly Ala Val Phe			
	210	215	220	
	Tyr Asn Lys Glu Arg Thr Arg Asn Ile Val Lys Tyr Asp Leu Arg Thr			
5	225	230	235	240
	Arg Ile Lys Ser Gly Glu Thr Val Ile Asn Thr Ala Asn Tyr His Asp			
	245	250	255	
	Thr Ser Pro Tyr Arg Trp Gly Gly Lys Thr Asp Ile Asp Leu Ala Val			
	260	265	270	
10	Asp Glu Asn Gly Leu Trp Val Ile Tyr Ala Thr Glu Gly Asn Asn Gly			
	275	280	285	
	Arg Leu Val Val Ser Gln Leu Asn Pro Tyr Thr Leu Arg Phe Glu Gly			
	290	295	300	
	Thr Trp Glu Thr Gly Tyr Asp Lys Arg Ser Ala Ser Asn Ala Phe Met			
15	305	310	315	320
	Val Cys Gly Val Leu Tyr Val Leu Arg Ser Val Tyr Val Asp Asp Asp			
	325	330	335	
	Ser Glu Ala Ala Gly Asn Arg Val Asp Tyr Ala Phe Asn Thr Asn Ala			
	340	345	350	
20	Asn Arg Glu Glu Pro Val Ser Leu Thr Phe Pro Asn Pro Tyr Gln Phe			
	355	360	365	
	Ile Ser Ser Val Asp Tyr Asn Pro Arg Asp Asn Gln Leu Tyr Val Trp			
	370	375	380	
	Asn Asn Tyr Phe Val Val Arg Tyr Ser Leu Glu Phe Gly Pro Pro Asp			
25	385	390	395	400

09744236 01204

Pro Ser Ala Gly Pro Ala Thr Ser Pro Pro Leu Ser Thr Thr Thr Thr

405

410

415

Ala Arg Pro Thr Pro Leu Thr Ser Thr Ala Ser Pro Ala Ala Thr Thr

420

425

430

5 Pro Leu Arg Arg Ala Pro Leu Thr Thr His Pro Val Gly Ala Ile Asn

435

440

445

Gln Leu Gly Pro Asp Leu Pro Pro Ala Thr Ala Pro Val Pro Ser Thr

450

455

460

Arg Arg Pro Pro Ala Pro Asn Leu His Val Ser Pro Glu Leu Phe Cys

10

465

470

475

480

Glu Pro Arg Glu Val Arg Arg Val Gln Trp Pro Ala Thr Gln Gln Gly

485

490

495

Met Leu Val Glu Arg Pro Cys Pro Lys Gly Thr Arg Gly Ile Ala Ser

500

505

510

15

Phe Gln Cys Leu Pro Ala Leu Gly Leu Trp Asn Pro Arg Gly Pro Asp

515

520

525

Leu Ser Asn Cys Thr Ser Pro Trp Val Asn Gln Val Ala Gln Lys Ile

530

535

540

Lys Ser Gly Glu Asn Ala Ala Asn Ile Ala Ser Glu Leu Ala Arg His

20

545

550

555

560

Thr Arg Gly Ser Ile Tyr Ala Gly Asp Val Ser Ser Ser Val Lys Leu

565

570

575

Met Glu Gln Leu Leu Asp Ile Leu Asp Ala Gln Leu Gln Ala Leu Arg

580

585

590

25

Pro Ile Glu Arg Glu Ser Ala Gly Lys Asn Tyr Asn Lys Met His Lys

09744236.012201  
T02210.92244260

	595	600	605	
	Arg Glu Arg Thr Cys Lys Asp Tyr Ile Lys Ala Val Val Glu Thr Val			
	610	615	620	
	Asp Asn Leu Leu Arg Pro Glu Ala Leu Glu Ser Trp Lys Asp Met Asn			
5	625	630	635	640
	Ala Thr Glu Gln Val His Thr Ala Thr Met Leu Leu Asp Val Leu Glu			
	645	650	655	
	Glu Gly Ala Phe Leu Leu Ala Asp Asn Val Arg Glu Pro Ala Arg Phe			
	660	665	670	
10	Leu Ala Ala Lys Glu Asn Val Val Leu Glu Val Thr Val Leu Asn Thr			
	675	680	685	
	Glu Gly Gln Val Gln Glu Leu Val Phe Pro Gln Glu Glu Tyr Pro Arg			
	690	695	700	
	Lys Asn Ser Ile Gln Leu Ser Ala Lys Thr Ile Lys Gln Asn Ser Arg			
15	705	710	715	720
	Asn Gly Val Val Lys Val Val Phe Ile Leu Tyr Asn Asn Leu Gly Leu			
	725	730	735	
	Phe Leu Ser Thr Glu Asn Ala Thr Val Lys Leu Ala Gly Glu Ala Gly			
	740	745	750	
20	Pro Gly Gly Pro Gly Gly Ala Ser Leu Val Val Asn Ser Gln Val Ile			
	755	760	765	
	Ala Ala Ser Ile Asn Lys Glu Ser Ser Arg Val Phe Leu Met Asp Pro			
	770	775	780	
	Val Ile Phe Thr Val Ala His Leu Glu Asp Lys Asn His Phe Asn Ala			
25	785	790	795	800

Asn Cys Ser Phe Trp Asn Tyr Ser Glu Arg Ser Met Leu Gly Tyr Trp

805 810 815

Ser Thr Gln Gly Cys Arg Leu Val Glu Ser Asn Lys Thr His Thr Thr

820 825 830

5 Cys Ala Cys Ser His Leu Thr Asn Phe Ala Val Leu Met Ala His Arg

835 840 845

Glu Ile Tyr Gln Gly Arg Ile Asn Glu Leu Leu Leu Ser Val Ile Thr

850 855 860

Trp Val Gly Ile Val Ile Ser Leu Val Cys Leu Ala Ile Cys Ile Ser

10 865 870 875 880

Thr Phe Cys Phe Leu Arg Gly Leu Gln Thr Asp Arg Asn Thr Ile His

885 890 895

Lys Asn Leu Cys Ile Asn Leu Phe Leu Ala Glu Leu Leu Phe Leu Val

900 905 910

15 Gly Ile Asp Lys Thr Gln Tyr Glu Ile Ala Cys Pro Ile Phe Ala Gly

915 920 925

Leu Leu His Tyr Phe Phe Leu Ala Ala Phe Ser Trp Leu Cys Leu Glu

930 935 940

Gly Val His Leu Tyr Leu Leu Leu Val Glu Val Phe Glu Ser Glu Tyr

20 945 950 955 960

Ser Arg Thr Lys Tyr Tyr Tyr Leu Gly Gly Tyr Cys Phe Pro Ala Leu

965 970 975

Val Val Gly Ile Ala Ala Ala Ile Asp Tyr Arg Ser Tyr Gly Thr Glu

980 985 990

25 Lys Ala Cys Trp Leu Arg Val Asp Asn Tyr Phe Ile Trp Ser Phe Ile

09744265 012001

	995	1000	1005	
	Gly Pro Val Ser Phe Val Ile Val Val Asn Leu Val Phe Leu Met Val			
	1010	1015	1020	
	Thr Leu His Lys Met Ile Arg Ser Ser Ser Val Leu Lys Pro Asp Ser			
5	1025	1030	1035	1040
	Ser Arg Leu Asp Asn Ile Lys Ser Trp Ala Leu Gly Ala Ile Ala Leu			
	1045	1050	1055	
	Leu Phe Leu Leu Gly Leu Thr Trp Ala Phe Gly Leu Leu Phe Ile Asn			
	1060	1065	1070	
10	Lys Glu Ser Val Val Met Ala Tyr Leu Phe Thr Thr Phe Asn Ala Phe			
	1075	1080	1085	
	Gln Gly Val Phe Ile Phe Val Phe His Cys Ala Leu Gln Lys Lys Val			
	1090	1095	1100	
	His Lys Glu Tyr Ser Lys Cys Leu Arg His Ser Tyr Cys Cys Ile Arg			
15	1105	1110	1115	1120
	Ser Pro Pro Gly Gly Thr His Gly Ser Leu Lys Thr Ser Ala Met Arg			
	1125	1130	1135	
	Ser Asn Thr Arg Tyr Tyr Thr Gly Thr Gln Ser Arg Ile Arg Arg Met			
	1140	1145	1150	
20	Trp Asn Asp Thr Val Arg Lys Gln Thr Glu Ser Ser Phe Met Ala Gly			
	1155	1160	1165	
	Asp Ile Asn Ser Thr Pro Thr Leu Asn Arg Gly Thr Met Gly Asn His			
	1170	1175	1180	
	Leu Leu Thr Asn Pro Val Leu Gln Pro Arg Gly Gly Thr Ser Pro Tyr			
25	1185	1190	1195	1200

Asn Thr Leu Ile Ala Glu Ser Val Gly Phe Asn Pro Ser Ser Pro Pro

1205

1210

1215

Val Phe Asn Ser Pro Gly Ser Tyr Arg Glu Pro Lys His Pro Leu Gly

1220

1225

1230

5 Gly Arg Glu Ala Cys Gly Met Asp Thr Leu Pro Leu Asn Gly Asn Phe

1235

1240

1245

Asn Asn Ser Tyr Ser Leu Arg Ser Gly Asp Phe Pro Pro Gly Asp Gly

1250

1255

1260

Gly Pro Glu Pro Pro Arg Gly Arg Asn Leu Ala Asp Ala Ala Ala Phe

10 1265

1270

1275

1280

Glu Lys Met Ile Ile Ser Glu Leu Val His Asn Asn Leu Arg Gly Ser

1285

1290

1295

Ser Ser Ala Ala Lys Gly Pro Pro Pro Pro Glu Pro Pro Val Pro Pro

1300

1305

1310

15 Val Pro Gly Gly Gly Gly Glu Glu Glu Ala Gly Gly Pro Gly Gly Ala

1315

1320

1325

Asp Arg Ala Glu Ile Glu Leu Leu Tyr Lys Ala Leu Glu Glu Pro Leu

1330

1335

1340

Leu Leu Pro Arg Ala Gln Ser Val Leu Tyr Gln Ser Asp Leu Asp Glu

20 1345

1350

1355

1360

Ser Glu Ser Cys Thr Ala Glu Asp Gly Ala Thr Ser Arg Pro Leu Ser

1365

1370

1375

Ser Pro Pro Gly Arg Asp Ser Leu Tyr Ala Ser Gly Ala Asn Leu Arg

1380

1385

1390

25 Asp Ser Pro Ser Tyr Pro Asp Ser Ser Pro Glu Gly Pro Ser Glu Ala

0944236.012301  
"022210" 22244650

	1395	1400	1405	
	Leu Pro Pro Pro Pro Pro Ala Pro Pro Gly Pro Pro Glu Ile Tyr Tyr			
	1410	1415	1420	
	Thr Ser Arg Pro Pro Ala Leu Val Ala Arg Asn Pro Leu Gln Gly Tyr			
5	1425	1430	1435	1440
	Tyr Gln Val Arg Arg Pro Ser His Glu Gly Tyr Leu Ala Ala Pro Gly			
	1445	1450	1455	
	Leu Glu Gly Pro Gly Pro Asp Gly Asp Gly Gln Met Gln Leu Val Thr			
	1460	1465	1470	
10	Ser Leu			
	<210> 6			
	<211> 4422			
	<212> DNA			
	<213> Human			
15	<400> 6			
	ATGGCCCGCC TAGCCGCAGT GCTCTGGAAT CTGTGTGTCA CCGCCGTCCT GGTACCTCG 60			
	GCCACCCAAG GCCTGAGCCG GGCCGGGCTC CCGTTCGGGC TGATGCGCCG GGAGCTGGCG 120			
	TGTGAAGGCT ACCCATCGA GCTGCGGTGC CCCGGCAGCG ACGTCATCAT GGTGGAGAAT 180			
	GCCAACTACG GGCGCACGGA CGACAAGATT TGCGATGCTG ACCCTTTCCA GATGGAGAAT 240			
20	GTGCAGTGCT ACCTGCCGGA CGCCTTCAAG ATCATGTCAC AGAGGTGTAA CAACCGCACC 300			
	CAGTGCGTGG TGGTCGCCGG CTCGGATGCC TTTCTGACC CCTGTCCTGG GACCTACAAG 360			
	TACCTGGAGG TGCAGTACGA CTGTGTCCCC TACAAAGTGG AGCAGAAAGT CTCGTGTGC 420			
	CCAGGGACCC TGCAGAAGGT GCTGGAGCCC ACCTCGACAC ACGAGTCAGA GCACCACTCT 480			
	GGCGCATGGT GCAAGGACCC GCTGCAGGCG GGTGACCGCA TCTACGTGAT GCCCTGGATC 540			
25	CCCTACCGCA CGGACACACT GACTGAGTAT GCCTCGTGGG AGGACTACGT GGCCGCCCCG 600			



CACACCACCA CCTACCGCCT GCCCAACCGC GTGGATGGCA CAGGCTTTGT GGTCTACGAT 660  
 GGTGCCGTCT TCTACAACAA GGAGCGCACG CGCAACATCG TCAAGTATGA CCTACGGACG 720  
 CGCATCAAGA GCGGGGAGAC GGTCAATCAAT ACCGCCAACT ACCATGACAC CTCGCCCTAC 780  
 CGCTGGGGCG GAAAGACCGA CATTGACCTG GCGGTGGACG AGAACGGGCT GTGGGTCATC 840  
 5 TACGCCACTG AGGGCAACAA CGGGCGGCTG GTGGTGAGCC AGCTGAACCC CTACACACTG 900  
 CGCTTTGAGG GCACGTGGGA GACGGGTAC GACAAGCGCT CGGCATCCAA CGCCTTCATG 960  
 GTGTGTGGGG TCCTGTACGT CCTGCGCTCC GTGTACGTGG ATGATGACAG CGAGGCGGCT 1020  
 GGCAACCGCG TGGACTATGC CTTCAACACC AATGCCAACC GCGAGGAGCC TGTACGCCTC 1080  
 ACCTTCCCCA ACCCCTACCA GTTCATCTCC TCCGTTGACT ACAACCCTCG CGACAACCAG 1140  
 10 CTGTACGTCT GGAACAACAA TTTGCTGGTG CGCTACAGCC TGGAGTTTCG GCGCCCGAC 1200  
 CCCAGTGCTG GCCCAGCCAC TTCCCCACCC CTCAGCACGA CCACCACAGC CAGGCCCACG 1260  
 CCCCTCACCA GCACAGCCTC GCGCGCAGCC ACCACCCCGC TCCGCCGGGC ACCCCTCACC 1320  
 ACGCACCCAG TGGGTGCCAT CAACCAGCTG GGACCTGATC TGCCTCCAGC CACAGCCCCA 1380  
 GTCCCCAGCA CCCGGCGGCC CCCAGCCCCG AATCTACAGC TGTCCCCTGA GCTCTTCTGC 1440  
 15 GAGCCCCGAG AGGTACGGCG GGTCCAGTGG CCGGCCACCC AGCAGGGCAT GCTGGTGGAG 1500  
 AGGCCCTGCC CCAAGGGGAC TCGAGGAATT GCCTCCTTCC AGTGTCTACC AGCCTTGGGG 1560  
 CTCTGGAACC CCCGGGGCCC TGACCTCAGC AACTGCACCT CCCCTGGGT CAACCAGGTG 1620  
 GCCCAGAAGA TCAAGAGTGG GGAGAACGCG GCCAACATCG CCAGCGAGCT GGCCCGACAC 1680  
 ACCCGGGGCT CCATCTACGC GGGGGACGTC TCCTCCTCTG TGAAGCTGAT GGAGCAGCTG 1740  
 20 CTGGACATCC TGGATGCCCCA GCTGCAGGCC CTGCGGCCCA TCGAGCGCGA GTCAGCCGGC 1800  
 AAGAACTACA ACAAGATGCA CAAGCGAGAG AGAACTTGTA AGGATTATAT CAAGGCCGTG 1860  
 GTGGAGACAG TGGACAATCT GCTCCGGCCA GAAGCTCTGG AGTCCTGGAA GGACATGAAT 1920  
 GCCACGGAGC AGGTGCACAC GGCCACCATG CTCCTCGACG TCCTGGAGGA GGGCGCCTTC 1980  
 CTGCTGGCCG ACAATGTCAG GGAGCCTGCC CGCTTCCTGG CTGCCAAGGA GAACGTGGTC 2040  
 25 CTGGAGGTCA CAGTCCTGAA CACAGAGGGC CAGGTGCAGG AGCTGGTGTT CCCCAGGAG 2100

GAGTACCCGA GAAAGAACTC CATCCAGCTG TCTGCCAAAA CCATCAAGCA GAACAGCCGC 2160  
AATGGGGTGG TCAAAGTTGT CTTTCATCTC TACAACAACC TGGGCCTCTT CCTGTCCACG 2220  
GAGAATGCCA CAGTGAAGCT GGCCGGCGAA GCAGGCCCGG GTGGCCCTGG GGGCGCCTCT 2280  
CTAGTGGTGA ACTCACAGGT CATCGCAGCA TCCATCAACA AGGAGTCCAG CCGCGTCTTC 2340  
5 CTCATGGACC CTGTCATCTT CACCGTGGCC CACCTGGAGG ACAAGAACCA CTTCAATGCT 2400  
AACTGCTCCT TCTGGAACCT CTCGGAGCGT TCCATGCTGG GCTATTGGTC GACCCAAGGC 2460  
TGCCGCCTGG TGGAGTCCAA CAAGACCCAT ACCACGTGTG CCTGCAGCCA CCTCACCAAC 2520  
TTCGCTGTGC TCATGGCTCA CCGTGAGATC TACCAGGGCC GCATCAACGA GCTGCTGCTG 2580  
TCGGTCATCA CCTGGGTGGG CATTGTGATC TCCCTGGTCT GCTTGGCCAT CTGCATCTCC 2640  
10 ACCTTCTGCT TCCTGCGGGG GCTGCAGACC GACCGCAACA CCATCCACAA GAACCTGTGC 2700  
ATCAACCTCT TCCTGGCTGA GCTGCTCTTC CTGGTCGGGA TCGACAAGAC TCAGTATGAG 2760  
ATTGCCTGCC CCATCTTCGC CGGCCTGCTG CACTATTTCT TCCTGGCTGC CTTCTCCTGG 2820  
CTGTGCCTGG AGGGCGTGCA CCTCTACCTG CTAAGTAGTG AGGTGTTTGA GAGCGAGTAT 2880  
TCCCGCACCA AGTACTACTA CCTGGGTGGC TACTGCTTCC CGGCCCTGGT GGTGGGCATC 2940  
15 GCGGCTGCCA TTGACTACCG CAGCTACGGC ACCGAGAAGG CCTGCTGGCT CCGAGTGGAC 3000  
AATTACTTCA TCTGGAGTTT CATCGGGCCA GTCTCCTTCG TTATCGTGGT CAACCTGGTG 3060  
TTCCTCATGG TGACCCTGCA CAAGATGATC CGAAGCTCAT CTGTGCTCAA GCCCGACTCC 3120  
AGCCGCCTGG ACAACATTAA ATCCTGGGCG CTGGGGGCCA TCGCGCTGCT GTTCCTGCTG 3180  
GGCCTCACCT GGGCTTTTCGG CCTCCTCTTC ATCAACAAGG AGTCGGTGGT CATGGCCTAT 3240  
20 CTCTTCACCA CTTCAACGC CTTCCAGGGG GTCTTCATCT TCGTCTTTCA CTGCGCCTTA 3300  
CAGAAGAAGG TGCACAAGGA GTACAGCAAG TGCCTGCGTC ACTCCTACTG CTGCATCCGC 3360  
TCCCCACCCG GGGGCACTCA CGGATCCCTC AAGACCTCAG CCATGCGAAG CAACACCCGC 3420  
TACTACACAG GGACCCAGAG CCGAATTCGG AGGATGTGGA ATGACACTGT GAGGAAACAG 3480  
ACGGAGTCCT CCTTCATGGC GGGTGACATC AACAGCACCC CCACCCTGAA CCGAGGTACC 3540  
25 ATGGGGAACC ACCTGCTGAC CAACCCCGTG CTGCAGCCCC GTGGGGGCAC CAGTCCCTAC 3600

09744226.012201

5 AACACCCTCA TCGCCGAGTC AGTGGGCTTC AATCCCTCCT CGCCCCCTGT CTTCAACTCC 3660  
CCAGGGAGCT ACCGGGAACC CAAGCACCCC TTGGGAGGCC GGAAGCCTG TGGCATGGAC 3720  
ACCCTGCCCC TGAACGGCAA CTTCAATAAC AGTTACTCCT TCGAAGTGG GGATTTCCCT 3780  
CCCGGGGATG GGGGCCCTGA GCCGCCCGA GGCCGGAACC TAGCCGATGC GGCGGCCTTT 3840  
GAGAAGATGA TCATCTCAGA GCTGGTGAC AACAACTGC GGGGAGCAG CAGCGGGCC 3900  
AAGGGCCCTC CACCGCCTGA GCCCCCTGTG CCACCTGTGC CAGGGGGCGG GGGCGAGGAA 3960  
GAGGCGGGCG GGGCCGGGG TGCTGACCGG GCCGAGATTG AACTTCTCTA TAAGGCCCTG 4020  
GAGGAGCCTC TGCTGCTGCC CCGGGCCCAG TCGGTGCTGT ACCAGAGCGA TCTGGACGAG 4080  
TCGGAGAGCT GCACGGCCGA GGACGGCGCC ACCAGCCGGC CCCTCTCCTC CCCTCCTGGC 4140  
10 CGGGACTCCC TCTATGCCAG CGGGGCCAAC CTGCGGGACT CACCCTCCTA CCCGGACAGC 4200  
AGCCCTGAGG GGCCAGTGA GGCCCTGCCC CCACCCCTC CCGCACCCCC CGGCCCCCCC 4260  
GAAATCTACT ACACCTCGCG CCCGCCAGCC CTGGTGGCCC GGAATCCCCT GCAGGGCTAC 4320  
TACCAGGTGC GGCCTCCTAG CCACGAGGGC TACCTGGCAG CCCAGGCCT TGAGGGGCCA 4380  
GGGCCCCGATG GGGACGGGCA GATGCAGCTG GTCACCAGTC TC 4425

15

Figure 1

1 GCTGAACAGACAAGAAATCACTTGAATGCTGGGGACATCACCTACTCTGTCCGGGCCATG 60  
 1 AlaGluGlnThrArgAsnHisLeuAsnAlaGlyAspIleThrTyrSerValArgAlaMet 20  
 61 GACCAGCTGGTAGGCCTCCTAGATGTACAGCTTCGGAACCTGACCCAGGTGGAAAAGAT 120  
 21 AspGlnLeuValGlyLeuLeuAspValGlnLeuArgAsnLeuThrProGlyGlyLysAsp 40  
 121 AGTGCTGCCCCGAGTTTGAACAAGGCAATGGTCGAGACAGTTAACAACCTCCTTCAGCCA 180  
 41 SerAlaAlaArgSerLeuAsnLysAlaMetValGluThrValAsnAsnLeuLeuGlnPro 60  
 181 CAAGCTTTGAATGCATGGAGAGACCTGACTACGAGTGATCAGCTGCGTGGGCCACCATG 240  
 61 GlnAlaLeuAsnAlaTrpArgAspLeuThrThrSerAspGlnLeuArgAlaAlaThrMet 80  
 241 TTGCTTCATACTGTGGAGGAAAGTGCTTTTGTGCTGGCTGATAACCTTTTGAAGACTGAC 300  
 81 LeuLeuHisThrValGluGluSerAlaPheValLeuAlaAspAsnLeuLeuLysThrAsp 100  
 301 ATTGTCAGGGAGAATACAGACAATATTAAATGGAAGTTGCAAGACTGAGCACAGAAGGA 360  
 101 IleValArgGluAsnThrAspAsnIleLysLeuGluValAlaArgLeuSerThrGluGly 120  
 361 AACTTAGAAGACCTAAAATTTCCAGAAAACATGGGCCATGGAGCACTATCCAGCTGTCT 420  
 121 AsnLeuGluAspLeuLysPheProGluAsnMetGlyHisGlySerThrIleGlnLeuSer 140  
 421 GCAAAATACCTTAAAGCAAAATGGCCGAAATGGAGAGATCAGAGTGGCCTTTGTCTCTGTAT 480  
 141 AlaAsnThrLeuLysGlnAsnGlyArgAsnGlyGluIleArgValAlaPheValLeuTyr 160  
 481 AACAACTTGGGTCCTTATTATCCACGGAGAATGCCAGTATGAAGTTGGGAACGGAAGCT 540  
 161 AsnAsnLeuGlyProTyrLeuSerThrGluAsnAlaSerMetLysLeuGlyThrGluAla 180  
 541 TTGTCACAAAATCATTCGTATTGTCAATTCCCTGTATTACGGCAGCAATAACAAA 600  
 181 LeuSerThrAsnHisSerValIleValAsnSerProValIleThrAlaAlaIleAsnLys 200  
 601 GAGTTCAGTAACAAGGTTTATTGGCTGATCCTGTGGTATTTACTGTTAAACATATCAAG 660  
 201 GluPheSerAsnLysValTyrLeuAlaAspProValValPheThrValLysHisIleLys 220  
 661 CAGTCAGAGGAAAAATTTCAACCTAAGTTCATTTTGGAGCTACTCCAAGCGTACAATG 720  
 221 GlnSerGluGluAsnPheAsnProAsnCysSerPheTrpSerTyrSerLysArgThrMet 240  
 721 ACAGGTTATTGGTCAACACAAGGCTGTGCGCTCCTGACAACAAATAAGACACATACTACA 780  
 241 ThrGlyTyrTrpSerThrGlnGlyCysArgLeuLeuThrThrAsnLysThrHisThrThr 260  
 781 TGCTCTTGTAACCACTTAACAAATTTGCAGTACTGATGGCACATGTGGAAGTTAAGCAC 840  
 261 CysSerCysAsnHisLeuThrAsnPheAlaValLeuMetAlaHisValGluValLysHis 280  
 841 AGTGATGCGGTCCATGACCTCCTCTCGGATGTGATCACGTGGGTGGGAATTTGCTGTCC 900  
 281 SerAspAlaValHisAspLeuLeuLeuAspValIleThrTrpValGlyIleLeuLeuSer 300  
 901 CTTGTTTGTCTCCTGATTTGCATCTTCACATTTTGCTTTTTCCGGGGCTCCAGAGTGAC 960  
 301 LeuValCysLeuLeuIleCysIlePheThrPheCysPhePheArgGlyLeuGlnSerAsp 320  
 961 CGTAACACCATCCACAAGAACCTCTGCATCAGTCTCTTTGTAGCAGAGCTGCTCTTCCTG 1020  
 321 ArgAsnThrIleHisLysAsnLeuCysIleSerLeuPheValAlaGluLeuLeuPheLeu 340  
 1021 ATTGGGATCAACCGAAGTACCAACCAATTGCCTGTGCTGTTTTCCGCTGCCCTGTACAT 1080  
 341 IleGlyIleAsnArgThrAspGlnProIleAlaCysAlaValPheAlaAlaLeuLeuHis 360  
 1081 TTCTTCTCTTGGCTGCCTTCACCTGGATGTTCTGGAGGGGTGCAGCTTTATATCATG 1140  
 361 PhePhePheLeuAlaAlaPheThrTrpMetPheLeuGluGlyValGlnLeuTyrIleMet 380  
 1141 CTGGTGGAGGTTTTGAGAGTGAACATTCACGTAGGAAATACTTTATCTGGTCGGCTAT 1200  
 381 LeuValGluValPheGluSerGluHisSerArgArgLysTyrPheTyrLeuValGlyTyr 400  
 1201 GGGATGCCTGCACCTATTGTGGCTGTGTAGCTGCAGTAGACTACAGGAGTTATGGAACA 1260  
 401 GlyMetProAlaLeuIleValAlaValSerAlaAlaValAspTyrArgSerTyrGlyThr 420  
 1261 GATAAAGTATGTTGGCTCCGACTTGACACCTACTTCATTGGAGTTTTATAGGACCAGCA 1320  
 421 AspLysValCysTrpLeuArgLeuAspThrTyrPheIleTrpSerPheIleGlyProAla 440  
 1321 ACTTTGATAATTATGCTTAATGTAATCTTCCTTGGGATTGCTTTATATAAAATGTTTCAT 1380  
 441 ThrLeuIleIleMetLeuAsnValIlePheLeuGlyIleAlaLeuTyrLysIlePheHis 460  
 1381 CATACTGCTATACTGAAACCTGAATCAGGCTGTCTTGATAACATCAAGTCATGGGTTATA 1440  
 461 HisThrAlaIleLeuLysProGluSerGlyCysLeuAspAsnIleLysSerTrpValIle 480  
 1441 GGTGCAATAGCTCTTCTCTGCTTATTAGGATTGACCTGGGCCTTTGGACTCATGTATATT 1500  
 481 GlyAlaIleAlaLeuLeuCysLeuLeuGlyLeuThrTrpAlaPheGlyLeuMetTyrIle 500


09/744226-012201

Figure 2

1501 AATGAAAGCACAGTCATCATGGCCTATCTCTTACCATTTCATTCCTCTACAGGGAATG 1560  
 501 AsnGluSerThrValIleMetAlaTyrLeuPheThrIlePheAsnSerLeuGlnGlyMet 520  
 1561 TTTATATTTATTTCCATGTGTCTACAGAAGAAGGTACGAAAAGAGTATGGGAAATGC 1620  
 521 PheIlePheIlePheHisCysValLeuGlnLysLysValArgLysGluTyrGlyLysCys 540  
 1621 CTGCGAACACATTGCTGTAGTGGCAAAAGTACAGAGAGTTCATTGGTTCAGGGAACA 1680  
 541 LeuArgIleHisCysCysSerGlyLysSerThrGluSerSerIleGlySerGlyLysThr 560  
 1681 TCTGGTCTCGAACTCCTGGACGCTACTCCACAGGCTCACAGAGCGAATCCGTAGAATG 1740  
 561 SerGlySerArgThrProGlyArgTyrSerThrGlySerGlnSerArgIleArgArgMet 580  
 1741 TGGAAATGACACGGTTCGAAAGCAGTCAGAGTCTTCTTTTACTGGAGACATAAACAGT 1800  
 581 TrpAsnAspThrValArgLysGlnSerGluSerSerPheIleThrGlyAspIleAsnSer 600  
 1801 TCACCGTCACTCAACAGAGAGGGGCTTCTGAACAATGCCAGGGATACAAGTGTCTGGAT 1860  
 601 SerAlaSerLeuAsnArgGluGlyLeuLeuAsnAsnAlaArgAspThrSerValMetAsp 620  
 1861 ACTCTACCACTGAATGGTAACCATGGCAATAGTTACAGCATTGCCAGCGCGAATACCTG 1920  
 621 ThrLeuProLeuAsnGlyAsnHisGlyAsnSerTyrSerIleAlaSerGlyGluTyrLeu 640  
 1921 AGCAACTGTGTGCAAAATCATAGACCGTGGCTATAACCATAAACAGACCGCCCTAGAGAAA 1980  
 641 SerAsnCysValGlnIleIleAspArgGlyTyrAsnHisAsnGluThrAlaLeuGlnLys 660  
 1981 AAGATTCTGAAGGAACCTCACTTCCAACATATCCCTTCTTACCTGAACAACCATGAGCGC 2040  
 661 LysIleLeuLysGluLeuThrSerAsnTyrIleProSerTyrLeuAsnAsnHisGluArg 680  
 2041 TCCAGTGAACAGAACAGGAATCTGATGAACAAGCTGGTGAATAACCTTGGCAGTGGAAAG 2100  
 681 SerSerGluGlnAsnArgAsnLeuMetAsnLysLeuValAsnAsnLeuGlySerGlyArg 700  
 2101 GAAGATGATGCCATTGTCTGGATGATGCCACCTCGTTTAACACAGGAGAGTTTGGGC 2160  
 701 GluAspAspAlaIleValLeuAspAspAlaThrSerPheAsnHisGluGluSerLeuGly 720  
 2161 CTGGAACCTCAITCATGAGGAATCTGATGCTCCTTTGCTGCCCCCAAGAGTATACTCCACC 2220  
 721 LeuGluLeuIleHisGluGluSerAspAlaProLeuLeuProProArgValTyrSerThr 740  
 2221 GAGAACCACACGCCACACCATATACCAGAAGGCGGATCCCCCAAGACCACAGTGAGAGC 2280  
 741 GluAsnHisGlnProHisHisTyrThrArgArgArgIleProGlnAspHisSerGluSer 760  
 2281 TTTTTCCTTTTGCTAACCAACGAGCACACAGAAGATCTCCAGTCACCCCATAGAGACTCT 2340  
 761 PhePheProLeuLeuThrAsnGluHisThrGluAspLeuGlnSerProHisArgAspSer 780  
 2341 CTCTATACCAGCATGCCGACACTGGCTGGTGTGGCCGCCACAGAGAGTGTACCACCAGC 2400  
 781 LeuTyrThrSerMetProThrLeuAlaGlyValAlaAlaThrGluSerValThrThrSer 800  
 2401 ACCCAGACCGAACCCCAACCGGCAATGTGGTGTATGCCGAAGATGTTTACTACAAAAGC 2460  
 801 ThrGlnThrGluProProProAlaLysCysGlyAspAlaGluAspValTyrTyrLysSer 820  
 2461 ATGCCAAACCTAGGCTCCAGAAACCGTCCATCAGCTGCATCTACTACCAGCTAGGT 2520  
 821 MetProAsnLeuGlySerArgAsnHisValHisGlnLeuHisThrTyrTyrGlnLeuGly 840  
 2521 CGCGGCAGCAGTGTATGATTTATAGTTCTCCAAACAAAGATGGGACCCCTCCCGAGGGA 2580  
 841 ArgGlySerSerAspGlyPheIleValProProAsnLysAspGlyThrProProGluGly 860  
 2581 AGTTCAAAGGACCGGCTCATTTGGTCACTAGTCTATAGAAGATGACACAGAAATGGAA 2640  
 861 SerSerLysGlyProAlaHisLeuValThrSerLeu\*\*\* 873  
 2641 CCAACAAAACGTCTAACACCTTGTGACTGTTCTGAGTTGATATAAGCAGTGGTAATAAT 2700  
 873 873  
 2701 GTGTGTACTCCTAAATCTTTATGCTGTCTCTAAAGACAAACACAACTCTCAGACTTTT 2760  
 873 873  
 2761 TTTTTTTTTAATGGGATTTTATAGTTCAGCCAGGGAGAAAGATAACTGCTAAAATCCC 2820  
 873 873  
 2821 CTGTACCCCATCCTTTCTTGTCTTTCCCTTCAGATGGAGACTTCATTATGTTAATGAA 2880  
 873 873  
 2881 CAAGATATGAAGAAAATGGCACTCATTGTGGCCTTGTGAATTATTTGTGTATGTTTAA 2940  
 873 873  
 2941 ACATCTCTGATGCTGTGTACTAAATTTACAAGGACCTGCTTTTTAAAGGCCAGAACAA 3000  
 873 873

09/744226-012201

Figure 3



4/25

Figure 4

1 ----- HK05006  
 1 EGSKGTPPAVSTTKIPPIITNIFPLPERFCEALDSKGKKWPQTQRGMMY HK05490  
  
 1 ----- HK05006  
 51 ERPCPKGTRGTASYLCLMISTGTWNPKGPDLSNCTSHWYNQLAQKIRSGEN HK05490  
  
 1 ----- HK05006  
 101 AASLANELAKHTKGPVFFAGDVSSSVRLMEQLVDILDAQLQELKPSSEKDSA HK05490  
  
 43 ARSLNK ----- AMVETVNNLLQPOALNARDLTTSDDQLRAAT HK05006  
 151 GRSYNNKLOKREKTCRAYLKAIVDTVDNLLRPEALESWKHMNSSEQAH TAT HK05490  
  
 80 MLIHTVEESAFLVADNLLKTDIVRRENTDNILKEVARLSTEGNLEDLKFP E HK05006  
 201 MLLDTLEEAGAFVLADNLLLEPTRVSMPTENIVLEVAVLESTEGQIQDFKFP L HK05490  
  
 130 NM-CHGSTIQLSANTLKKQNGRNGEIRVAFVLYNNLGPY LSTENASMKLG T HK05006  
 251 GIKGAGSSIQLSANTVKQNSRNGLAKLVFIIRSLGQFLSTENATIKLGA HK05490  
  
 179 EALSTNHSVIVNSPVIITAAINKEFSENKVVYLAADPVVFTVKHHIKQS EENFN P HK05006  
 301 DFIGRNS TIAVNSHVIVSVSINKEE-SSRVYLTDPVLFETLPHI-DP DNNYFNA HK05490  
  
 229 NCSFWSSYSKRRTMTGYWNSTQGCRLTLTNKTHTTTCSCHLNTNFALMAHVEY HK05006  
 349 NCSFNNYSERTMMGYWNSTQGCCKLVDTNKTRTTTCACSHLNTNFALMAHREI HK05490  
  
 279 KHSDAVHDL LLDVITWVGILLSLVCLLICI FTFCFFRGLQSDRNTIHKNL HK05006  
 399 AYKKG VHE LLLT VITWVGIVISLVCLAICIFTFCFFRGLQSDRNTIHKNL HK05490  
  
 329 CISLFVAELLFLIGIINRTDQPIACAVFALLLHFFFLA AFTW MFL EGVQLY HK05006  
 449 CINLEI AEFIFLIGIGIDKTKYAIACPIFAGLLHFFFLA AFAWMLCEGVQLY HK05490  
  
 379 IMLVEVFESSEHSRRKKYFYLVGYGMPALIVAVSAAVDYRSYGTDKVCWLR L HK05006  
 499 LMLVEVFESSEYSRRKKYFYVAGYLFPA TVVGVSA AIDYKSYGT EKA CNLHV HK05490

5/25

Figure 5

429 DTYFIWSEFIGPATLIIMLNVIFLGLIAYKMFHHTAILKPESGCLDNIKSW HK05006  
 549 DNYFIWSEFIGPVTFIILLNIIFLVIITLCKMVKHSNTLKPDS SRL ENIKSW HK05490  
  
 479 VIGAIALLCLLGLLTWAFGLMYINESTVIIMAYLFTIFNSLQGMFIFI FHC V HK05006  
 599 VLGAFALLCLLGLLTWAFGLMYINESTVIIMAYLFTIFNSLQGMFIFI FHC A HK05490  
  
 529 LQKKVRKEYGKCLH-THCCSGKSTESSIGSGKTSGSRTPPGRYSTGSSQSRI HK05006  
 649 LQKKVRKEYGKCFRHSYCCGGGLPTESPHSSVKASTTRTSARYSSGTQSRI HK05490  
  
 578 RRMWNDDTVRKQSESSFIITGDINSSASLNREG L----- HK05006  
 699 RRMWNDDTVRKQSESSFISGDINSTSTLN-QGM TGN YLLLTNP L LRRPHGTNN HK05490  
  
 610 ----- LNNARDTSVMDTLP L NGNHGNYSYS HK05006  
 748 PYN TLLAETVVCNAPSAPVFNSPGHSLNNARDTSAMD TLP L NGNFNNSYS HK05490  
  
 534 IASCEYLSNCVQIIDRGYNHNETALEKKILKELTSNYIFSYLNNHERSSIE HK05006  
 798 LHKGDY-NDSSVQVYDCGLSLNDTAFKKMIISEL-----VHNNLRGSS HK05490  
  
 684 CNRNLMNKL VNN--LGS GREDDAIVLD DATSFNHEESLGLELIHEESDAP HK05006  
 839 KTHNLELTI PVKPVIGGSSSEDDAIVADASSLMHSDNPPGLELHHKELEAP HK05490  
  
 732 LLPPRVYS TENHQPHHYTRRRRIPODHSSEFFP LLTNETHEDLQSPH RDS L HK05006  
 889 LIIPORTHSLI-YQPO--KKVKSEGTDSYVSQLTAEAEEDHLOSPNRD S L HK05490  
  
 782 YTSMP TLAGVAATESVT TSTQTEPPPAKCGDAEDVYKSSMPNLGS RNH V H HK05006  
 934 YTSMPNL RDSPY PESS-SPDMEEEDLSPSRRENEED IY YKSSMPNLGA---GH HK05490  
  
 832 QLHTY YQLGRGSSDGGFIVPPNKKDGT PPPEGSSK-GPAHLV TSL HK05006  
 980 QLQNCYQISRGNSDGYIIPINKEGCIPEGDVRE GQMQLV TSL HK05490



6/25

Figure 6




Figure 7

1 GAAGGAAGCAAGGGACAAACCACCTCCAGCAGTTTCTACCAACCAAAATTCACCTATA 60  
 1 GluGlySerLysGlyThrLysProProAlaValSerThrThrLysIleProProIle 20  
 61 ACAATATTTTCCCTGCCAGAGAGATTCTGTGAAGCAITTAGACTCCCAAGGGGATAAAG 120  
 21 ThrAsnIlePheProLeuProGluArgPheCysGluAlaLeuAspSerLysGlyIleLys 40  
 121 TGGCCTCAGACACAAGGGGAATGATGTTGAACGACCATGCCCTAAGGGAACAAGAGGA 180  
 41 TrpProGlnThrGlnArgGlyMetMetValGluArgProCysProLysGlyThrArgGly 60  
 181 ACTGCCTCATATCTCTGCATGATTTCCACTGGAACATGGAACCCCTAAGGGCCCCGATCTT 240  
 61 ThrAlaSerTyrLeuCysMetIleSerThrGlyThrTrpAsnProLysGlyProAspLeu 80  
 241 AGCAACTGTACCTCACA CTGGTGATTCACCTGCTCAGAGATCAGAAGCGGAGAAAAT 300  
 81 SerAsnCysThrSerHisTrpValasnGlnLeuAlaGlnLysIleArgSerGlyGluAsn 100  
 301 GCTGCTAGTCTGCCANTGAACTGGCTAAACATACCAGGGCCAGTGTGCTGGGGAT 360  
 101 AlaAlaSerLeuAlaAsnGluLeuAlaLysHisThrLysGlyProValPheAlaGlyAsp 120  
 361 GTAAGTTCITTCAGTGAGATTGATGGAGCAGTTGGTGGACATCCTTGATGCCACAGCTGCAG 420  
 121 ValSerSerValArgLeuMetGluGlnLeuValAspIleLeuAspAlaGlnLeuGln 140  
 421 GAACCTGAACCTAGTGAAAAGATTTCAGCTGGACGGAGTTATTAACAAGCTCCAAAACGA 480  
 141 GluLeuLysProSerGluLysAspSerAlaGlyArgSerTyrAsnLysLeuGlnLysArg 160

Figure 8

481 GAGAGACATGCGGGCTTACCTTAAGGCAATGTTGACACAGTGGACACCTTCTCAGA 540  
 161 GluLysThrCysArgAlaTyrLeuLysAlaIleValAspThrValAspAsnLeuLeuArg 180  
  
 541 CCTGAAGCTTTGGAATCATGGAACATATGAAATCTTCTGAACAAGCACATAGTCACAA 600  
 181 ProGluAlaLeuGluSerThrLysHisMetAsnSerSerGluGlnAlaHisThrAlaThr 200  
  
 601 ATGTTACTCGATACATTTGGAAGAGAGAGCTTTTGCTCTAGCTGACAAATCTTTAGAACCA 660  
 201 MetLeuLeuAspThrLeuGluGluGlyAlaPheValLeuAlaAspAsnLeuLeuGluPro 220  
  
 661 ACAAGGGTCTCAATGCCACAGAAATATTTCTCTGGAGTTGCCGTACTCAGTACAGAA 720  
 221 ThrArgValSerMetProThrGluAsnIleValLeuGluValAlaValLeuSerThrGlu 240  
  
 721 GGACAGATCCAAGACTTTAATTTCTCTGGCATCAAGGAGCAGGAGCTCAATCCAA 780  
 241 GlyGlnIleGlnAspPheLysPheProLeuGlyIleLysGlyAlaGlySerSerIleGln 260  
  
 781 CTGTCCGCAATACCGTCAACAGACAGAGGAATGGCTTGCAAGTTGGTGTTCATC 840  
 261 LeuSerAlaAsnThrValLysGlnAsnSerArgAsnGlyLeuAlaLysLeuValPheIle 280  
  
 841 ATTATCCGGAGCTGGACAGTTCCTTAGTACAGAAATGCCAACCATTAAACTGGGTCT 900  
 281 IleTyrArgSerLeuGlyGlnPheLeuSerThrGluAsnAlaThrIleLysLeuGlyAla 300  
  
 901 GATTATTTGGTCTAATAGCACCATTCAGTGAACCTCTCAGTCATTTTCAGTTTCATC 960  
 301 AspPheIleGlyArgAsnSerThrIleAlaValAsnSerHisValIleSerValSerIle 320  
  
 961 AATAAGAGTCCAGCCGAGTATACCTGACTGATCTCTGTGCTTTTACCCCTGCCACACAT 1020

Figure 9

321 AsnLysGluSerSerArgValTyrLeuThrAspProValLeuPheThrLeuProHisIle 340  
 1021 GATCCTGACAATTATTTCAATGCAAACTGCTCCTTCGGAACCTACTCAGAGAGAACTATG 1080  
 341 AspProAspAsnTyrPheAsnAlaAsnCysSerPheTrpAsnTyrSerGluArgThrMet 360  
 1081 ATGGGATATTGCTCTACCCAGGGCTGCAAGCTGGTGTGACACTAATAAACTCGAACCAACG 1140  
 361 MetGlyTyrTrpSerThrGlnGlyCysLysLeuValAspThrAsnLysThrArgThrThr 380  
 1141 TGTGCATGCAGCCACCTAACCAATTTTGCAATTCATGGCCACAGGGAATTCATAT 1200  
 381 CysAlaCysSerHisLeuThrAsnPheAlaIleLeuMetAlaHisArgGluIleAlaTyr 400  
 1201 AAAGATGGGTTTCATGAATTACTTCTTACAGTCATCACCTGGGGTGGCAATGTCAATTCC 1260  
 401 LysAspGlyValHisGluLeuLeuLeuThrValIleThrTrpValGlyIleValIleSer 420  
 1261 CTTGTTTCCCTGGCTATCTGCATCTTCACCTTCGCTTTTCGGTGGCTACAGAGTGAC 1320  
 421 LeuValCysLeuAlaIleCysIlePheThrPheCysPhePheArgGlyLeuGlnSerAsp 440  
 1321 CGAAATACCTATTCACAAGAACCCTTTGTATCAACCTTTTTCATTCGCTGAATTTATTTCTTA 1380  
 441 ArgAsnThrIleHisLysAsnLeuCysIleAsnLeuPheIleAlaGluPheIlePheLeu 460  
 1381 ATAGGCATTGATAAGACAAATATGCGATTGATGCCCAATATTTGCAGGACITCTACAC 1440  
 461 IleGlyIleAspLysThrLysTyrAlaIleAlaCysProIlePheAlaGlyLeuLeuHis 480

09/744226

10/25

Figure 10

1441 TTTTCTTTTGGCAGCTTTTGCTGGATGTGCCTAGAAGGTGTGCAGCTCTACCTAATG 1500  
481 PhePhePheLeuAlaAlaPheAlaTrpMetCysLeuGluGlyValGlnLeuTyrLeuMet 500

1501 TTAGTTGAAGTTTGTGAAAGTGAATATTCAAGGAAAAATATTACTATGTTGCTGGTTAC 1560  
501 LeuValGluValPheGluSerGluTyrSerArgLysLysTyrTyrTyrValAlaGlyTyr 520

1561 TTGTTTCTGCCCACAGTGGTTGGAGTTTCAGCTGCTATTGACTATAAGAGCTATGGAACA 1620  
521 LeuPheProAlaThrValValGlyValSerAlaAlaIleAspTyrLysSerTyrGlyThr 540

1621 GAAAAAGCTTCTGGCTTCATGTTGATAACTACTTTATATGGAGCTTCATTGGACCTGTT 1680  
541 GluLysAlaCysTrpLeuHisValAspAsnTyrPheIleTrpSerPheIleGlyProVal 560

1681 ACCTTCATTATTCTGCTAAATATTATCTTCTTGGTGATCACATTGTGCAAAATGGTGAAG 1740  
561 ThrPheIleIleLeuLeuAsnIleIlePheLeuValIleThrLeuCysLysMetValLys 580

1741 CATTCAAACACTTTGAAACCAGATTCTAGCAGGTGGAAAACATTAACTCTTGGGTGCTT 1800  
581 HisSerAsnThrLeuLysProAspSerSerArgLeuGluAsnIleLysSerTrpValLeu 600

1801 GGCCTTTCTGCTCTTCTGTGTCTTCTTGGCCTCACCTGGTCCTTTGGGTTCCTTTTATT 1860  
601 GlyAlaPheAlaLeuLeuCysLeuLeuGlyLeuThrTrpSerPheGlyLeuLeuPheIle 620

1861 AATGAGGAGACTATTGTGATGGCATATCTCTCACTATATTTAATGCTTTCAGGGAGTG 1920  
621 AsnGluGluThrIleValMetAlaTyrLeuPheThrIlePheAsnAlaPheGlnGlyVal 640

1921 TTCATTTTCATCTTTCAGTGTGCTCTCCAAAAGAAAGTACGAAAAGATATGGCAAGTGC 1980  
641 PheIlePheIlePheHisCysAlaLeuGlnLysLysValArgLysGluTyrGlyLysCys 660

09/744226.012301

Figure 11

1981	TTCA	CAC	ACT	CAT	ACT	GCT	GCT	GAG	GCC	TCC	CA	ACT	GAG	TCC	CA	CA	CT	CAG	TGA	AAG	2040								
661	Phe	Arg	His	Ser	Tyr	Cys	Gly	Leu	Pro	Thr	Thr	Glu	Ser	Pro	His	Ser	Ser	Val	Lys	680									
2041	GCAT	CA	ACC	ACC	AG	AC	CG	TC	CT	CG	CT	AT	TCT	CT	GG	CA	CAC	AG	TC	GTA	PA	GA	AAG	2100					
681	Ala	Ser	Thr	Thr	Arg	Thr	Ser	Ala	Arg	Tyr	Ser	Ser	Gly	Thr	Gln	Ser	Arg	Glu	Leu	Arg	Arg		700						
2101	ATG	TGA	AT	GAT	ACT	GT	GAG	AAA	CA	AT	CAG	AT	CT	CT	TTT	TAT	CT	CAG	TC	GAT	CA	TCA	AT	2160					
701	Met	Trp	Asn	Asp	Thr	Val	Arg	Lys	Gln	Ser	Glu	Ser	Ser	Phe	Ile	Ser	Gly	Asp	Ile	Leu	Asn		720						
2161	AGCA	CTT	CA	CA	CT	TA	AT	CA	AG	GA	TG	ACT	TG	GC	CA	ATT	TAC	CT	TA	CA	CA	AA	CC	CT	CT	CT	TT	2220	
721	Ser	Thr	Ser	Thr	Leu	Asn	Gln	Gly	Met	Thr	Gly	Asn	Tyr	Leu	Leu	Thr	Asn	Pro	Leu	Leu				740					
2221	CGAC	CCC	CA	CGG	CA	CTA	ACA	CC	CC	TAT	TA	CA	CA	ATT	TG	CG	CG	CA	AG	TGT	AT	GTA	AT	2280					
741	Arg	Pro	His	Gly	Thr	Asn	Asn	Pro	Tyr	Asn	Thr	Leu	Leu	Ala	Glu	Thr	Val	Val	Cys	Asn				760					
2281	GCCC	CTT	CAG	CT	CC	TGT	TAT	TTA	ACT	CA	CC	AG	GA	CA	TT	CA	CT	GA	CA	AT	GC	CA	GG	AT	2340				
761	Ala	Pro	Ser	Ala	Pro	Val	Phe	Asn	Ser	Pro	Gly	His	Ser	Leu	Asn	Asn	Ala	Arg	Asp	Thr				780					
2341	AGT	GC	AT	GG	AT	ACT	CT	AC	CG	CT	TA	AT	TGG	TA	AT	TTT	TA	CA	CA	AG	CT	ACT	CG	CT	GC	CA	CA	AAG	2400
781	Ser	Ala	Met	Asp	Thr	Leu	Pro	Leu	Asn	Gly	Asn	Phe	Asn	Ser	Tyr	Ser	Leu	His	Lys					800					
2401	GGT	GAC	TAT	AAT	GAC	AG	CG	TC	CA	AG	TGT	TG	GAC	TGT	GG	ACT	TA	AG	TC	TGA	AT	GAT	ACT	GCT	2460				
801	Gly	Asp	Tyr	Asn	Asp	Ser	Val	Gln	Val	Val	Ala	Sp	Cys	Gly	Leu	Ser	Leu	Asn	Asp	Thr	Ala			820					

Figure 12

2461	TTTGAGAAATGATCATTTCAGAAATTAGTCACAACAACCTTACGGGGCAGCAGCAAGACT	2520
821	PheGluLysMetIleIleSerGluLeuValHisAsnAsnLeuArgGlySerSerLysThr	840
2521	CACAACCTCGAGCTCAGCTACCGTACCAGTCAACCTGTGATGGAGGTAGCAGCAGTGAAGAT	2580
841	HisAsnLeuGluLeuThrLeuProValLysProValIleGlyGlySerSerSerGluAsp	860
2581	GATGCTATTGTGGCAGATGCTTCATCTTTAATGCACACGACAACCCAGGGCTCGAGCTC	2640
861	AspAlaIleValAlaAspAlaSerSerLeuMetHisSerAspAsnProGlyLeuGluLeu	880
2641	CATCACAAGAACTCGAGGGCACCACTTATTCCTCAGCGGACTCACTCCCTTCGTACCAA	2700
881	HisHisLysGluLeuGluAlaProLeuIleProGlnArgThrHisSerLeuLeuTyrGln	900
2701	CCCCAGAGAAAGTGAAGTCCGAGGGAACTGACAGCTATGTCTCCCACTGACAGCAGAG	2760
901	ProGlnLysLysValLysSerGluGlyThrAspSerTyrValSerGlnLeuThrAlaGlu	920
2761	GCTGAAGATCACCCTACAGTCCCCCAACAGAGACTCTCTTTATACAGCATGCCCAATCTT	2820
921	AlaGluAspHisLeuGlnSerProAsnArgAspSerLeuTyrThrSerMetProAsnLeu	940
2821	AGAGACTCTCCCTATCCGGAGAGCAGCCCTGACATGGAAGAAGACCTCTCTCCCTCCAGG	2880
941	ArgAspSerProTyrProGluSerSerProAspMetGluGluAspLeuSerProSerArg	960
2881	AGGAGTCAGAAATGAGGACATTACTATAAAGCATGCCAAATCTTGAGCTGGCCATCAG	2940
961	ArgSerGluAsnGluAspIleTyrTyrLysSerMetProAsnLeuGlyAlaGlyHisGln	980

Figure 13

2941 CTTTCAGATGTGCTACCATCAGATCAGCAGGGGCAATAGTGTATATATATCCCCATTAAAC 3000  
981 LeuGlnMetCysTyrGlnIleSerArgGlyAsnSerAspGlyTyrIleIleProIleAsn 1000

3001 AAAGAAGGGTGTATTCCAGAAGGAGATGTTAGAGAAGGACAATGCAGCTGGTTACAAGT 3060  
1001 LysGluGlyCysIleProGluGlyAspValArgGluGlyGlnMetGlnLeuValThrSer 1020

3061 CTTTAAATCATACAGCTAAGGAATTCGAAGGCCACATGCCGAGTATTAAATAAATAAAGACA 3120  
1021 Leu\*\*\* 1022

3121 CCATTGGCCTGAAGCAGCTCCCTCAAACCTCTGCTTGAAGAGATGACTCTTGACCTGTGGT 3180  
1022 1022

3181 TCTCTGGTGTAATAAAGATGACAGACCTTGCAGTCTCTGGAATTTTATAAAACATACA 3240  
1022 1022

3241 AAAACITTTGTATATACACAGAGTATACATAAAGTGAATTTTGTACAAAGAAAGAGAT 3300  
1022 1022

3301 GCCAGCCAGGTATTTTAAGATTCCTGCTGTTTGTAGAGAAATGTGAACAAGCAAAACA 3360  
1022 1022

3361 AAACTTCCAGCCATTTTACTGCAGCAGTCTGTGAACATAATTTGTAATATGGCTGCAC 3420  
1022 1022



Figure 14

3471 CATTTTGTAGGCCCTGCTGTATATATATACAGACGTAGGCCTTAAATCCCTGTGGAC 3480  
1022

3481 AAATTTACTGTACCTTACTATTCCTGACAAGACCTTGGAAAGCAGAGAGATATTCGCA 3540  
1022

3541 TCAGTTTGCAGTTTCACTGCAATCTTTTACATTATAGGCAAGATTGAAACATGCTTAAC 3600  
1022

3601 CACTAGCAATCAAGCCACAGGCCCTTATTTTCATATGTTTCCCACTGTACAATGAACCTAT 3660  
1022

3661 TCTCATGAAATGGCTAAGAAATATATTTTGTCTATTTGCTAGGGTAAATTAATAC 3720  
1022

3721 ATTGTGTCCAACTGAATATATATTTGTCAATTAATTAATTTTAAAGAGTGAAGAAATAT 3780  
1022

3781 TGTGAAAGCTCTGTGGTGCACATGTTATGAATGTTTTTCTTACACCTTGTCTATGGTA 3840  
1022

3841 AGTTCTACTCAATTTCACTTCTTTTCCACTGTATACAGTGTCTGTCTTGTGACAAGTTAG 3900  
1022

3901 TCCTTATTACTTACATTTAAATTTCTTATTGCCAAAGAACGTGTTTATGGGAGAAAC 3960

Figure 15

1022		1022
3961	AAACTCITTTGAAGCCAGTTTATGTCATGCCCTTGCACAAAGTGATGAATCTAGAAAAGAT	4020
1022		1022
4021	TGTGTGTCACCCCGTGTTTATTCITGAAACAGAGGGCAAGAGGGCCTGGGCACITCTCAC	4080
1022		1022
4081	AACTTTCTAGTGAACAAAAGGTGCTATCTTTTTTAAAAAATAAATAAACATATAA	4140
1022		1022
4141	TATTACTCTCCATATTCCTTCCTGCTATATTTAGTAATTAATTTTATGATAAAGT	4200
1022		1022
4201	TCTAATGAANTGTAAATGTTCAGCAAAATTCIGCTTTTTTTCATCCCTTTGTATAAA	4260
1022		1022
4261	CCGTGTTAATAATGAGCCCATCCTAATAATCCAGTGTAAAGTTTAAACACGGTTTGACAGTA	4320
1022		1022
4321	AATAAATGTGAATTTTTTCAAGT	4343
1022		1022

16/25

Figure 16

	1				50
HK05006					
HK05490					
HH02631	MARLA AVLWN	LCVTAVLVTS	ATQGLSRAGL	PFGLMRRELA	CEGYPIELRC
	51				100
HK05006					
HK05490					
HH02631	PGSDVIMVEN	ANYGRDDKI	CDADPFQMEN	VQCYLPDAFK	IMSQRNNRT
	101				150
HK05006					
HK05490					
HH02631	QCVVVAGSDA	FPDPCPGTYK	YLEVQYDCVP	YKVEQKVFVC	PGTLQKVLEP
	151				200
HK05006					
HK05490					
HH02631	TSTHESEHQS	GAWCKDPLQA	GDRIYVMPWI	PYRTDTLTEY	ASWEDYVAAR
	201				250
HK05006					
HK05490					
HH02631	HTTTYRLPNR	VDGTGFVVD	GAVFYNKERT	RNIVKYDLRT	RIKSGETVIN
	251				300
HK05006					
HK05490					
HH02631	TANYHDTSPY	RWGGKTDIDL	AVDENGLWVI	YATEGNNGRL	VVSQLNPYTL
	301				350
HK05006					
HK05490					
HH02631	RFEGTWETGY	DKRSASNAFM	VCGVLYVLRS	VYVDDSEAA	GNRVDAFNT

09/744226.01201

Figure 17

	351				400
HK05006					
HK05490					
HH02631	NANREEPVSL	TFPNPYQFIS	SVDYNPRDNQ	LYVWNNYFVV	RYSLEFGPPD
	401				450
HK05006					
HK05490					E
HH02631	PSAGPATSP	LSTTTTARPT	PLTSTASPAA	TTPLRRAPLT	THPVGAINQL
	451				500
HK05006					
HK05490	GSKGTKPPPA	VSTTKIPPIT	NIFPLPERFC	EALDSKGIKW	PQTQRGMMVE
HH02631	GPDLPATAP	VPSTRRPPAP	NLHVSPFLFC	EPREVRVQW	PATQQGMLVE
	501				550
HK05006					
HK05490	RPCPKGTRGT	ASYLCMISTG	TWNPKGPDLS	NCTSHWVNQL	AQKIRSGENA
HH02631	RPCPKGTRGI	ASFQCLPALG	LWNPRGPDLS	NCTSPWVNQV	AQKIKSGENA
	551				600
HK05006	AEQ	TRNHLNAGDI	TYSVRAMDQL	VGLLDVQLRN	LTPGGKDSAA
HK05490	ASLANELAKH	TKGPVFAGDV	SSSVRLMEQL	VDILDAQLQE	LKPSEKDSAG
HH02631	ANIASELARH	TRGSIYAGDV	SSSVKLMEQL	LDILDAQLQA	LRPIERESAG
	601				650
HK05006	RSLN.....	KAM	VETVNNLLQP	QALNAWRDLT	TSDQLRAATM
HK05490	RSYNKLQKRE	KTCRAYLKAI	VDTVNDLLRP	EALSWKHMN	SSEQAHTATM
HH02631	KNYNKMHKRE	RTCKDYIKAV	VETVDNLLRP	EALSWKDMN	ATEQVHTATM
	651				700
HK05006	LLHTVEESAF	VLADNLLKTD	IVRENTDNIK	LEVARLSTEG	NLEDLKFP.E
HK05490	LLDTLEEGAF	VLADNLLIPT	RYSMPTENIV	LEVAVLSTEG	QIQDFKFPLG
HH02631	LLDVLEEGAF	LLADNVREPA	RFLAAKENVV	LEVTVLNTEG	QVQELVFPQE

09/744226

18/25

Figure 18

	701		750
HK05006	NMGHGSTIQL SANTLKQNGR NGEIRYAFVL YNNLGPYLST ENASMKLGTE		
HK05490	IKGAGSSIQL SANTVKQNSR NGLAKLVFII YRSLGQFLST ENATIKLGAD		
HH02631	EYPRKNSIQL SAKTIKQNSR NGVVKVVFIL YNNLGLFLST ENATVKLAGE		
	751		800
HK05006	A...LSTNHS VIVNSPVITA AINKEFSNKV YLADPVVFTV KHIKQSEENF		
HK05490	F...IGRNST IAVNSHVISV SINKE. SSRV YLTDPVLFTL PHI. DPDNYF		
HH02631	AGPGGPGGAS LVVNSQVIAA SINKE. SSRV FLMDPVIFTV AHL. EDKNHF		
	801		850
HK05006	NPNCSEWSYS KRTMTGYWST QGCRLTTNK THHTCSCNHL TNFAVLMAHV		
HK05490	NANCSFWNYS ERTMMGYWST QGCKLVDTNK TRTTCACSHL TNFAILMAHR		
HH02631	NANCSFWNYS ERSMLGYWST QGCRLVESNK THHTCACSHL TNFAVLMAHR		
	851		900
HK05006	EVKHSDAVHD LLLDVITWVG ILLSLVCLLI CIFTFCFFRG LQSDRNTIHK		
HK05490	EIAYKDGVE LLLTVITWVG IVISLVCLAI CIFTFCFFRG LQSDRNTIHK		
HH02631	EI. YQGRINE LLLSVITWVG IVISLVCLAI CISTFCFLRG LQTDNRNTIHK		
	901		950
HK05006	NLCISLFVAE LLFLIGINRT DQPIACAVFA ALLHFFFLAA FTWMFLEGVQ		
HK05490	NLCINLFIAE FIFLIGIDKT KYAIACPIFA GLLHFFFLAA FAWMCLEGVQ		
HH02631	NLCINLFLAE LLFLVGIDKT QEYIACPIFA GLLHYFFLAA FSWLCLEGVH		
	951		1000
HK05006	LYIMLVEVFE SEHSRRKYFY LVGYGMPALI VAVSAAVDYR SYGTDKVCWL		
HK05490	LYLMLVEVFE SEYSRKKYYY VAGYLFPATV VGVSAAIDYK SYGTEKACWL		
HH02631	LYLLLVEVFE SEYSRTKYYY LGGYCFPALV VGIAAAIDYR SYGTEKACWL		
	1001		1050
HK05006	RLDTYFIWSF IGPATLIIML NVIFLGIALY KMFHHTAILK PESGCLDNIK		
HK05490	HVDNYFIWSF IGPVTFIILL NIIFLVITLC KMKHSNTLK PDSSRLNIK		
HH02631	RVDNYFIWSF IGPVSFVIVV NLVFLMVT LH KMIRSSSVLK PDSSRLDNIK		

09/744226 01201

19/25

Figure 19

	1051		1100
HK05006	SWVIGAIALL CLLGLTWAFG LMYINESTVI MAYLFTIFNS LQGMFIFIFH		
HK05490	SWVLGAFALL CLLGLTWSFG LLFINEETIV MAYLFTIFNA FQGVFIFIFH		
HH02631	SWALGAIALL FLLGLTWAFG LLFINKESVV MAYLFTTFNA FQGVFIFVFH		
	1101		1150
HK05006	CVLQKKVRKE YGKCLR. THC CSGKSTESSI GSGKTSGSRT PGRYSTGSQS		
HK05490	CALQKKVRKE YGKCFRHSYC CGGLPTESPH SSVKASTTRT SARYSSGTQS		
HH02631	CALQKKVHKE YSKCLRHSYC CIRSPPGGTH GSKTSAMRS NTRYTGTQS		
	1151		1200
HK05006	RIRRMWNDIV RKQSESSFIT GDINSSASLN REGLLN. ....		
HK05490	RIRRMWNDIV RKQSESSFIS GDINSTSTLN QGMTGNYLLT NPLLRPHGTH		
HH02631	RIRRMWNDIV RKQTESSFMA GDINSTPTLN RGTMGNHLLT NPVLQPRGGT		
	1201		1250
HK05006	..... NARDTS VMDTLPLNGN		
HK05490	NPYNTLLAET VVCNAPSAPV FNSPGHSLN. .... NARDTS AMDTLPLNGN		
HH02631	SPYNTLIAES VGFNPSSPPV FNSPGSYREP KHPLGGREAC GMDTLPLNGN		
	1251		1300
HK05006	HGNSYSIASG EYLSN. CVQI IDRGYNHNE. TALEKKILKE LTSNYIPSYL		
HK05490	FNNSYSLHKG DY. . NDSVQV VDCGLSLND. TAFEKMIISE LVHN. . . NL		
HH02631	FNNSYSLRSG DFPPGDDGPE PPRGRNLADA AAFEKMIISE LVHN. . . NL		
	1301		1350
HK05006	NNHERSSEQN RNLMNKLNN LGSGREDDAI VLDDATSFNH EESLGLELIH		
HK05490	RGSSKTHN. . LETLPVKPV IGGSSSEDDA IVADASSLMH SDNPGLELHH		
HH02631	RGSSSAAGP PPPEPPVPPV PGGGGEE. . . . EAGGPGG ADRAEIELLY		
	1351		1400
HK05006	EESDAPLLPP RVYSTENHQP HHYTRRRIPQ DHSSEFFPLL TNEHTDLQS		
HK05490	KELEAPLIPQ RTHSL. .... LYQPQKKVKS EGTDSYVSQ L TAEADHLQS		
HH02631	KALEEPLLLP RAQSV. .... LYQSD. . . L DESECTAED GATSRPLSSP		

09/744226-012201

Figure 20

1401 1450  
HK05006 PHRDSLYTSM PTLAGVAATE SVTTSTQTE. .. PPPAKCGD AEDVYYKSM.  
HK05490 PNRDSLYTSM PNLRDSP. YP ESSPDMEEDL ... SPSRRSE NEDIYYKSM.  
HH02631 PGRDSLYASG ANLRDSPSYP DSSPEGPSEA LPPPPPAPPG PPEIYYTSRP

1451 1500  
HK05006 PNLGSRNHVH QLHTYYQLGR GSSDGFIVPP NKDGTPEGS . SKGPAHLVT  
HK05490 PNLGAG...H QLQMCYQISR GNSDGYIPI NKEGCIPEGD VREGQMLVT  
HH02631 PALVAR...N PLQGYQVRR PSHEGYLAAP GLEGPGPDGD ... GQMQLVT

1501  
HK05006 SL  
HK05490 SL  
HH02631 SL

Figure 21

TTTTTTTTTTTTTTTTCTAATTTTTGGTCGGCGGCGGTGCTGGGCCAG 50  
 GGAAGGAAGGGACACGGAGGCCGCCCTCGTCCCGCCACCTCCTACCCGC 100  
 TTCCCCCAGCCCCGGCTCCGGGAGATGTGCCGGGCGGGGGGCCCGGGT 150  
 CGCCGAGCCGAGGAGACACGCTGGGCCGACCCAGAGAGGCGCTGGA 200  
 CAGGCTGGTGGTCCAGGCCGTGGTGCCTGCCAGGTGATGTGGGGCAAAGC 250  
 CCCCCGCACAGGCCACTGAGAGCTCCGGACACGCACCCGGCTGCCACCAT 300  
 GGCCCGCCTAGCCGCAGTGTCTGGAATCTGTGTGTACCCGCCGTCTTG 350  
 TCACCTCGGCCACCCAAGGCCTGAGCCGGGCGGGCTCCCGTTCGGGCTG 400  
 ATGCCCGGGAGCTGGCGTGTGAAGGCTACCCCATCGAGCTGCGGTGCC 450  
 CGGCAGCGACGTCATCATGGTGGAGAATGCCAACTACGGGCGCACGGACG 500  
 ACAAGATTTGCGATGCTGACCCTTTCCAGATGGAGAATGTGCAGTGCTAC 550  
 CTGCCGGACGCCTTCAAGATCATGTACAGAGGTGTAACAACCGCACCCA 600  
 GTGCGTGGTGGTCCCGGCTCGGATGCCTTTCCTGACCCTGTCTTGGA 650  
 CCTACAAGTACCTGGAGGTGCAGTACGACTGTGTCCCCTACAAAGTGGAG 700  
 CAGAAAGTCTTCGTGTGCCAGGGACCCTGCAGAAGGTGCTGGAGCCAC 750  
 CTCGACACACGAGTCAGAGCACCAAGTCTGGCGCATGGTGCAAGGACCCGC 800  
 TGCAGGCGGGTGACCGCATCTACGTGATGCCCTGGATCCCCTACCGCACG 850  
 GACACACTGACTGAGTATGCCTCGTGGGAGGACTACGTGGCCGCCCGCCA 900  
 CACCACCACCTACCGCCTGCCCAACCGCGTGGATGGCACAGGCTTTGTGG 950  
 TCTACGATGGTGCCGTCTTCTACAACAAGGAGCGCACGCGCAACATCGTC 1000  
 AAGTATGACCTACGGACGCGCATCAAGAGCGGGGAGACGGTCATCAATAC 1050  
 CGCCAACTACCATGACACCTCGCCCTACCGCTGGGGCGGAAAGACCGACA 1100  
 TTGACCTGGCGGTGGACGAGAACGGGCTGTGGGTGATCTACGCCACTGAG 1150  
 GGCAACAACGGGCGGCTGGTGGTGAGCCAGCTGAACCCCTACACACTGCG 1200  
 CTTTGAGGGCACGTGGGAGACGGGTACGACAAGCGCTCGGCATCCAACG 1250  
 CCTTCATGGTGTGTGGGGTCTGTACGTCTGCGCTCCGTGTACGTGGAT 1300  
 GATGACAGCGAGGCGGCTGGCAACCGCGTGGACTATGCCTTCAACACCAA 1350  
 TGCCAACCGCGAGGAGCCTGTACGCCTCACCTTCCCAACCCCTACCAGT 1400  
 TCATCTCCTCCGTTGACTACAACCCTCGCGACAACCAGCTGTACGTCTGG 1450  
 AACAACATTTTCGTGGTGGCTACAGCCTGGAGTTCGGGCGGCCCGACCC 1500  
 CAGTGCTGGGCCAGCCACTTCCCCACCCCTCAGCACGACCACCACAGCCA 1550  
 GGCCACGCCCCCTCACCAGCACAGCCTCGCCCGCAGCCACCACCCCGCTC 1600  
 CGCCGGGCACCCCTCACCACGCACCCAGTGGGTGCCATCAACCAGCTGGG 1650  
 ACCTGATCTGCCTCCAGCCACAGCCCCAGTCCCCAGCACCCGGCGGGCCC 1700  
 CAGCCCCGAATCTACACGTGTCCCTGAGCTCTTCTGCGAGCCCCGAGAG 1750



Figure 22

GTACGGCGGGTCCAGTGGCCGGCCACCCAGCAGGGCATGCTGGTGGAGAG 1800  
 GCCCTGCCCCAAGGGGACTCGAGGAATTGCCTCCTTCCAGTGTCTACCAG 1850  
 CCTTGGGGCTCTGGAACCCCCGGGGCCCTGACCTCAGCAACTGCACCTCC 1900  
 CCCTGGGTCAACCAGGTGGCCCAGAAGATCAAGAGTGGGGAGAACGCGGC 1950  
 CAACATCGCCAGCGAGCTGGCCCGACACACCCGGGGCTCCATCTACGCGG 2000  
 GGGACGTCTCCTCCTCTGTGAAGCTGATGGAGCAGCTGCTGGACATCCTG 2050  
 GATGCCCAGCTGCAGGCCCTGCGGCCCATCGAGCGCGAGTCAGCCGGCAA 2100  
 GAACTACAACAAGATGCACAAGCGAGAGAGAACTTGTAAGGATTATATCA 2150  
 AGGCCGTGGTGGAGACAGTGGACAATCTGCTCCGGCCAGAAGCTCTGGAG 2200  
 TCCTGGAAGGACATGAATGCCACGGAGCAGGTGCACACGGCCACCATGCT 2250  
 CCTCGACGTCCTGGAGGAGGGCGCCTTCCTGCTGGCCGACAATGTCAGGG 2300  
 AGCCTGCCCCGCTTCCTGGCTGCCAAGGAGAACGTGGTCCTGGAGGTCACA 2350  
 GTCCTGAACACAGAGGGCCAGGTGCAGGAGCTGGTGTTCCTCCAGGAGGA 2400  
 GTACCCGAGAAAGAACTCCATCCAGCTGTCTGCCAAAACCATCAAGCAGA 2450  
 ACAGCCGCAATGGGGTGGTCAAAGTTGTCTTCATCCTCTACAACAACCTG 2500  
 GGCCTCTTCCTGTCCACGGAGAATGCCACAGTGAAGCTGGCCGGCGAAGC 2550  
 AGGCCCGGGTGGCCCTGGGGGCGCCTCTCTAGTGGTGAAGTCACAGGTCA 2600  
 TCGCAGCATCCATCAACAAGGAGTCCAGCCGCGTCTTCCTCATGGACCT 2650  
 GTCATCTTCACCGTGGCCACCTGGAGGACAAGAACCACTTCAATGCTAA 2700  
 CTGCTCCTTCTGGAATACTCGGAGCGTTCCATGCTGGGCTATTGGTCGA 2750  
 CCCAAGGCTGCCGCTGGTGGAGTCCAACAAGACCCATACCACGTGTGCC 2800  
 TGCAGCCACCTACCAACTTCGCTGTGCTCATGGCTCACCGTGAGATCTA 2850  
 CCAGGGCCGCATCAACGAGCTGCTGCTGTGCGTCATCACCTGGGTGGGCA 2900  
 TTGTGATCTCCCTGGTCTGCTTGGCCATCTGCATCTCCACCTTCTGCTTC 2950  
 CTGCGGGGGCTGCAGACCGACCGCAACACCATCCACAAGAACCTGTGCAT 3000  
 CAACCTCTTCCTGGCTGAGCTGCTCTTCCTGGTCGGGATCGACAAGACTC 3050  
 AGTATGAGATTGCCTGCCCCATCTTCGCCGGCCTGCTGCACTATTTCTTC 3100  
 CTGGCTGCCTTCTCCTGGCTGTGCCTGGAGGGCGTGACCTCTACCTGCT 3150  
 ACTAGTGGAGGTGTTTGAGAGCGAGTATTCGCCGACCAAGTACTACTACC 3200  
 TGGGTGGCTACTGCTTCCCGGCCCTGGTGGTGGGCATCGCGGCTGCCATT 3250  
 GACTACCGCAGCTACGGCACCGAGAAGGCCTGCTGGCTCCGAGTGGACAA 3300  
 TTAATTCATCTGGAGTTTCATCGGGCCAGTCTCCTTCGTTATCGTGGTCA 3350  
 ACCTGGTGTTCCTCATGGTGACCCTGCACAAGATGATCCGAAGCTCATQT 3400  
 GTGCTCAAGCCCGACTCCAGCCGCCTGGACAACATTAAATCCTGGGCGCT 3450  
 GGGGGCCATCGCGCTGCTGTTCTGCTGGGCCTCACCTGGGCTTTCCGGCC 3500

09/744226


Figure 23

TCCTCTTCATCAACAAGGAGTCGGTGGTCATGGCCTATCTCTTCACCACC 3550  
TTCAACGCCTTCCAGGGGTCTTCATCTTCGTCTTTCCTGCGCCTTACA 3600  
GAAGAAGGTGCACAAGGAGTACAGCAAGTGCCTGCGTCACTCCTACTGCT 3650  
GCATCCGCTCCCCACCCGGGGGCACTCACGGATCCCTCAAGACCTCAGCC 3700  
ATGCGAAGCAACACCCGCTACTACACAGGGACCCAGAGCCGAATTCGGAG 3750  
GATGTGGAATGACACTGTGAGGAAACAGACGGAGTCCTCCTTCATGGCGG 3800  
GTGACATCAACAGCACCCCCACCCTGAACCGAGGTACCATGGGGAACCAC 3850  
CTGCTGACCAACCCCGTGCTGCAGCCCCGTGGGGGCACCAGTCCCTACAA 3900  
CACCCCTCATCGCCGAGTCAGTGGGCTTCAATCCCTCCTCGCCCCCTGTCT 3950  
TCAACTCCCCAGGGAGCTACCGGGAACCCAAGCACCCCTTGGGAGGCCGG 4000  
GAAGCCTGTGGCATGGACACCCTGCCCCCTGAACGGCAACTTCAATAACAG 4050  
TTACTCCTTGCGAAGTGGGGATTTCCCTCCCGGGGATGGGGGCCCTGAGC 4100  
CGCCCCGAGGCCGGAACCTAGCCGATGCGGGCGGCCTTTGAGAAGATGATC 4150  
ATCTCAGAGCTGGTGCACAACAACCTGCGGGGGAGCAGCAGCGCGGCCAA 4200  
GGGCCCTCCACCGCCTGAGCCCCCTGTGCCACCTGTGCCAGGGGGCGGGG 4250  
GCGAGGAAGAGCGGGCGGGCCCCGGGGGTGCTGACCGGGCCGAGATTGAA 4300  
CTTCTCTATAAGGCCCTGGAGGAGCCTCTGCTGCTGCCCCGGGCCAGTC 4350  
GGTGTGTACAGAGCGATCTGGACGAGTCGGAGAGCTGCACGGCCGAGG 4400  
ACGGCGCCACCAGCGGCCCTCTCCTCCCCTCCTGGCCGGGACTCCCTC 4450  
TATGCCAGCGGGGCCAACCTGCGGGACTCACCTCCTACCCGGACAGCAG 4500  
CCCTGAGGGGCCAGTGAGGCCCTGCCCCACCCCTCCCGCACCCCCCG 4550  
GCCCCCCCCGAAATCTACTACACCTCGCGCCCGCCAGCCCTGGTGGCCCG 4600  
AATCCCTGCAGGGCTACTACCAGGTGCGGCGTCCTAGCCACGAGGGCTA 4650  
CCTGGCAGCCCCAGGCCTTGAGGGGCCAGGGCCCGATGGGGACGGGCAGA 4700  
TGCAGCTGGTCACCAGTCTCTGAGGGCACCTCATGGACCAGGGGCTGGTG 4750  
GCCCAGGCCAGGGAGGGAACCTGGGCAGGGCTCTGGTGGGAGAGGGAGA 4800  
CAGATGGAGGCAGTGGCTGGTGGGCCACTCTCTCCAGGTGCCCCCTCAGCC 4850  
ATGGGGCCCTACAGTCCCCTCAGGGGACTCTAACCTGGGGGCCTGAGGTGC 4900  
CAGGGTTCACAGACAGGGTTTCCCACCAGCCACACGCACCAGCTCTATTT 4950  
GGGGGAAGTGTAGTGAGGAGGAGCCCAGAGGACCCAGGGGAGTGAGGAG 5000  
GGAGAACTTGGAAGGGTGCAGCCCACTTCCAGACTCTCCCCTCTCCCACC 5050  
CTTCTACCTGTGAAGGGAAATGAGGGCTTTAGTTTCCTGGGCAGGGAGG 5100  
GGCAGCTTCTGAGGTTGCCAAAGGCCCCCACTGGATGGAACCTGTTAGCT 5150  
GCTCCTCTCCGCAGCCAGAAATGCTGCCGGCTGCACCCAGAGGGAGCAGT 5200  
GAGGCAGGACAGATGGACAGGTTCTCCTGCGCTGTAATTCCTGCTCCC 5250

Figure 24

TGGAGACTGGGAAAAGGCCGCAGGGCAGGGGGACTGGGCGGTGGTGGCTG	5300
GTGGTTTAAAGGTTGAACCTTCTCTGAAGCTCCTTTCCCCTTGCTCTTGG	5350
TCCCTGCCCCGCAAGCAAACCTGCCCCCTCTGCCTCCCAGTGCACCCAAT	5400
GACCCCCTCCCTTGGGGCGACTCCTGATGAAGCACAACCTCCCCGCAGGGC	5450
CCCCAGCCCACAGGGGTGGCCATATTTGGGCAGTCCCAGTCCTGTGGGC	5500
TCGGCTATCTGGGGAGCAGATTTTGGGTCTGGATCTCCCTGGGGAGTGGG	5550
TCCTGGGCTTGGATCTTTCCCTAGGGGGCCCTCTTACTCCTTCCTCTCTC	5600
CTCCTCCTTCCCCATTGCTGTAAATATTTCAACGAAATGGAAAAGAAAAA	5650
AAAAAAGAC	5659

Figure 25



09/744226

J002 Rec'd PCT/PTO 22 JAN 2001  
Docket No.2534USOP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Osamu OHARA et al.  
Serial No. :  
Filed on :  
Group Art Unit :  
Examiner :  
Title : Novel G Protein Coupled Receptor Protein and Its DNA

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

**STATEMENT IN SUPPORT OF FILING  
AND SUBMISSIONS IN ACCORDANCE WITH 37 CFR § § 1.821-1.825**

In accordance with 37 CFR § 1.821(f), I hereby state that the content of the paper and computer-readable copies of the sequence listing submitted in accordance with 37 CFR § § 1.821-1.825, respectively, are the same.

Date: January 12, 2001

Respectfully submitted,



Philippe Y. Riesen, Reg. No. 35,657  
Attorney for Applicants  
Customer No. 23,115

09/744226

## SEQUENCE LISTING

<110> Ohara, Osamu  
 <110> Nagase, Takahiro  
 <110> Nomura, Nobuo  
 <110> Hinuma, Shuji  
 <110> Fujii, Ryo  
 <110> Kitahara, Osamu  
 <110> Mogi, Shinichi  
 <120> Novel G Protein Coupled Receptor Protein and Its Use  
 <130> 2534USOP  
 <140>  
 <141>  
 <150> PCT/JP99/03909  
 <151> 1998-07-22  
 <150> JP 10-207579  
 <151> 1998-07-23  
 <150> JP 10-225060  
 <151> 1998-08-07  
 <150> JP 10-284328  
 <151> 1998-10-06  
 <160> 6  
 <170>

<210> 1  
 <211> 872  
 <212> PRT  
 <213> Human  
 <400> 1

Ala	Glu	Gln	Thr	Arg	Asn	His	Leu	Asn	Ala	Gly	Asp	Ile	Thr	Tyr	Ser
1				5					10					15	
Val	Arg	Ala	Met	Asp	Gln	Leu	Val	Gly	Leu	Leu	Asp	Val	Gln	Leu	Arg
		20						25				30			
Asn	Leu	Thr	Pro	Gly	Gly	Lys	Asp	Ser	Ala	Ala	Arg	Ser	Leu	Asn	Lys
		35				40					45				
Ala	Met	Val	Glu	Thr	Val	Asn	Asn	Leu	Leu	Gln	Pro	Gln	Ala	Leu	Asn
	50					55				60					
Ala	Trp	Arg	Asp	Leu	Thr	Thr	Ser	Asp	Gln	Leu	Arg	Ala	Ala	Thr	Met
	65				70				75					80	
Leu	Leu	His	Thr	Val	Glu	Glu	Ser	Ala	Phe	Val	Leu	Ala	Asp	Asn	Leu
		85							90					95	
Leu	Lys	Thr	Asp	Ile	Val	Arg	Glu	Asn	Thr	Asp	Asn	Ile	Lys	Leu	Glu
		100						105					110		
Val	Ala	Arg	Leu	Ser	Thr	Glu	Gly	Asn	Leu	Glu	Asp	Leu	Lys	Phe	Pro
		115					120					125			
Glu	Asn	Met	Gly	His	Gly	Ser	Thr	Ile	Gln	Leu	Ser	Ala	Asn	Thr	Leu
	130				135						140				
Lys	Gln	Asn	Gly	Arg	Asn	Gly	Glu	Ile	Arg	Val	Ala	Phe	Val	Leu	Tyr
	145				150				155					160	
Asn	Asn	Leu	Gly	Pro	Tyr	Leu	Ser	Thr	Glu	Asn	Ala	Ser	Met	Lys	Leu
			165					170						175	
Gly	Thr	Glu	Ala	Leu	Ser	Thr	Asn	His	Ser	Val	Ile	Val	Asn	Ser	Pro
		180					185						190		
Val	Ile	Thr	Ala	Ala	Ile	Asn	Lys	Glu	Phe	Ser	Asn	Lys	Val	Tyr	Leu
	195					200						205			
Ala	Asp	Pro	Val	Val	Phe	Thr	Val	Lys	His	Ile	Lys	Gln	Ser	Glu	Glu
	210				215						220				
Asn	Phe	Asn	Pro	Asn	Cys	Ser	Phe	Trp	Ser	Tyr	Ser	Lys	Arg	Thr	Met
	225			230					235					240	
Thr	Gly	Tyr	Trp	Ser	Thr	Gln	Gly	Cys	Arg	Leu	Leu	Thr	Thr	Asn	Lys
			245				250							255	
Thr	His	Thr	Thr	Cys	Ser	Cys	Asn	His	Leu	Thr	Asn	Phe	Ala	Val	Leu
		260					265						270		
Met	Ala	His	Val	Glu	Val	Lys	His	Ser	Asp	Ala	Val	His	Asp	Leu	Leu
		275				280						285			
Leu	Asp	Val	Ile	Thr	Trp	Val	Gly	Ile	Leu	Leu	Ser	Leu	Val	Cys	Leu

290	Leu	Ile	Cys	Ile	Phe	Thr	Phe	Cys	Phe	Phe	Arg	Gly	Leu	Gln	Ser	Asp
305	Arg	Asn	Thr	Ile	His	Lys	Asn	Leu	Cys	Ile	Ser	Leu	Phe	Val	Ala	Glu
				325						330					335	
	Leu	Leu	Phe	Leu	Ile	Gly	Ile	Asn	Arg	Thr	Asp	Gln	Pro	Ile	Ala	Cys
				340					345					350		
	Ala	Val	Phe	Ala	Ala	Leu	Leu	His	Phe	Phe	Phe	Leu	Ala	Ala	Phe	Thr
			355					360					365			
	Trp	Met	Phe	Leu	Glu	Gly	Val	Gln	Leu	Tyr	Ile	Met	Leu	Val	Glu	Val
			370				375				380					
	Phe	Glu	Ser	Glu	His	Ser	Arg	Arg	Lys	Tyr	Phe	Tyr	Leu	Val	Gly	Tyr
			385				390				395					400
	Gly	Met	Pro	Ala	Leu	Ile	Val	Ala	Val	Ser	Ala	Ala	Val	Asp	Tyr	Arg
				405						410					415	
	Ser	Tyr	Gly	Thr	Asp	Lys	Val	Cys	Trp	Leu	Arg	Leu	Asp	Thr	Tyr	Phe
				420					425					430		
	Ile	Trp	Ser	Phe	Ile	Gly	Pro	Ala	Thr	Leu	Ile	Ile	Met	Leu	Asn	Val
			435					440					445			
	Ile	Phe	Leu	Gly	Ile	Ala	Leu	Tyr	Lys	Met	Phe	His	His	Thr	Ala	Ile
			450				455					460				
	Leu	Lys	Pro	Glu	Ser	Gly	Cys	Leu	Asp	Asn	Ile	Lys	Ser	Trp	Val	Ile
			465				470				475					480
	Gly	Ala	Ile	Ala	Leu	Leu	Cys	Leu	Leu	Gly	Leu	Thr	Trp	Ala	Phe	Gly
				485						490					495	
	Leu	Met	Tyr	Ile	Asn	Glu	Ser	Thr	Val	Ile	Met	Ala	Tyr	Leu	Phe	Thr
				500					505					510		
	Ile	Phe	Asn	Ser	Leu	Gln	Gly	Met	Phe	Ile	Phe	Ile	Phe	His	Cys	Val
			515					520					525			
	Leu	Gln	Lys	Lys	Val	Arg	Lys	Glu	Tyr	Gly	Lys	Cys	Leu	Arg	Thr	His
			530				535					540				
	Cys	Cys	Ser	Gly	Lys	Ser	Thr	Glu	Ser	Ser	Ile	Gly	Ser	Gly	Lys	Thr
			545				550				555					560
	Ser	Gly	Ser	Arg	Thr	Pro	Gly	Arg	Tyr	Ser	Thr	Gly	Ser	Gln	Ser	Arg
				565						570					575	
	Ile	Arg	Arg	Met	Trp	Asn	Asp	Thr	Val	Arg	Lys	Gln	Ser	Glu	Ser	Ser
				580					585					590		
	Phe	Ile	Thr	Gly	Asp	Ile	Asn	Ser	Ser	Ala	Ser	Leu	Asn	Arg	Glu	Gly
			595					600					605			
	Leu	Leu	Asn	Asn	Ala	Arg	Asp	Thr	Ser	Val	Met	Asp	Thr	Leu	Pro	Leu
							615					620				
	Asn	Gly	Asn	His	Gly	Asn	Ser	Tyr	Ser	Ile	Ala	Ser	Gly	Glu	Tyr	Leu
			625				630				635					640
	Ser	Asn	Cys	Val	Gln	Ile	Ile	Asp	Arg	Gly	Tyr	Asn	His	Asn	Glu	Thr
				645						650					655	
	Ala	Leu	Glu	Lys	Lys	Ile	Leu	Lys	Glu	Leu	Thr	Ser	Asn	Tyr	Ile	Pro
				660					665					670		
	Ser	Tyr	Leu	Asn	Asn	His	Glu	Arg	Ser	Ser	Glu	Gln	Asn	Arg	Asn	Leu
				675				680					685			
	Met	Asn	Lys	Leu	Val	Asn	Asn	Leu	Gly	Ser	Gly	Arg	Glu	Asp	Asp	Ala
				690			695					700				
	Ile	Val	Leu	Asp	Asp	Ala	Thr	Ser	Phe	Asn	His	Glu	Glu	Ser	Leu	Gly
			705				710				715					720
	Leu	Glu	Leu	Ile	His	Glu	Glu	Ser	Asp	Ala	Pro	Leu	Leu	Pro	Pro	Arg
				725						730					735	
	Val	Tyr	Ser	Thr	Glu	Asn	His	Gln	Pro	His	His	Tyr	Thr	Arg	Arg	Arg
				740					745					750		
	Ile	Pro	Gln	Asp	His	Ser	Glu	Ser	Phe	Phe	Pro	Leu	Leu	Thr	Asn	Glu
			755					760					765			
	His	Thr	Glu	Asp	Leu	Gln	Ser	Pro	His	Arg	Asp	Ser	Leu	Tyr	Thr	Ser
			770				775					780				
	Met	Pro	Thr	Leu	Ala	Gly	Val	Ala	Ala	Thr	Glu	Ser	Val	Thr	Thr	Ser
			785				790				795					800
	Thr	Gln	Thr	Glu	Pro	Pro	Pro	Ala	Lys	Cys	Gly	Asp	Ala	Glu	Asp	Val
				805					810						815	
	Tyr	Tyr	Lys	Ser	Met	Pro	Asn	Leu	Gly	Ser	Arg	Asn	His	Val	His	Gln
				820					825					830		

Leu His Thr Tyr Tyr Gln Leu Gly Arg Gly Ser Ser Asp Gly Phe Ile  
 835 840 845  
 Val Pro Pro Asn Lys Asp Gly Thr Pro Pro Glu Gly Ser Ser Lys Gly  
 850 855 860  
 Pro Ala His Leu Val Thr Ser Leu  
 865 870

<210> 2  
 <211> 2616  
 <212> DNA  
 <213> Human  
 <400> 2

GCTGAACAGA CAAGAAATCA CTTGAATGCT GGGGACATCA CCTACTCTGT CCGGGCCATG 60  
 GACCAGCTGG TAGGCCCTCT AGATGTACAG CTTCGGAAC TGAACCCAGG TGGAAAAGAT 120  
 AGTGCTGCCG GGAGTTTGAA CAAGGCAATG GTCGAGACAG TTAACAACCT CCTTCAGCCA 180  
 CAAGCTTTGA ATGCATGGAG AGACCTGACT ACGAGTGATC AGCTGCGTGC GGCCACCATG 240  
 TTGCTTCATA CTGTGGAGGA AAGTGCCTTT GTGCTGGCTG ATAACCTTTT GAAGACTGAC 300  
 ATTGTCAGGG AGAATACAGA CAATATTAAA TTGGAAGTTG CAAGACTGAG CACAGAAGGA 360  
 AACTTAGAAG ACCTAAAAT TCCAGAAAAC ATGGGGCCATG GAAGCACTAT CCAGCTGTCT 420  
 GCAAAATACCT TAAAGCAAAA TGGCCGAAAT GGAGAGATCA GAGTGGCCTT TGTCTGTAT 480  
 AACAACTTGG GTCCTTATTT ATCCACGGAG AATGCCAGTA TGAAGTTGGG AACGGAAGCT 540  
 TTGTCCACAA ATCATTTCTGT TATTGTCAAT TCCCCTGTTA TTACGGCAGC AATAAACAAA 600  
 GAGTTTCACT ACAAGGTTTA TTTGGCTGAT CCTGTGGTAT TTACTGTTAA ACATATCAAG 660  
 CAGTCAGAGG AAAATTTTCAA CCCTAATCTGT TCATTTTGGG GCTACTCCAA GCGTACAATG 720  
 ACAGGTTATT GGTCAACACA AGGCTGTCGG CTCCTGACAA CAAATAAGAC ACATACTACA 780  
 TGCTCTTGTA ACCACCTAAC AAATTTTGGCA CACATGTGGG AGTTAAGCAC 840  
 AGTGATGCGG TCCATGACCT CCTTCTGGAT GTGATCACGT GGGTTGGAAT TTTGCTGTCC 900  
 CTGTGTTGTC TCCTGATTTG CATCTTCACA TTTTGCTTTT TCCGCGGGCT CCAGAGTGAC 960  
 CGTAACACCA TCCACAAGAA CCTCTGCATC AGTCTCTTTG TAGCAGAGCT GCTCTTCCTG 1020  
 ATTGGGATCA ACCGAACCTGA CCAACCAATT GCCTGTGCTG TTTTCGCTGC CCTGTTTTCT 1080  
 TCTTCTTGGC TGCCTTCACC TGGATGTTCC TGGAGGGGGT GCAGCTTTAT ATACATCATG 1140  
 CTGGTGGAGG TTTTGGAGAG TGAACATTCA CGTAGGAAAT ACTTTTATCT GGTCCGCTAT 1200  
 GGGATGCCCTG CACTCATTTG GGCTGTGTCA GCTGCAGTAG ACTACAGGAG TTATGGAACA 1260  
 GATAAAGTAT GTTGGCTCCG ACTTGACACC TACTTCATTT GGAGTTTAT AGGACCAGCA 1320  
 ACTTTGATAA TTTATGCTTAA TGTAACTTTC CTGGGATTG CTTTATATAA AATGTTTCAT 1380  
 CATACTGCTA TACTGAAACC TGAATCAGGC TGTCTTGATA ACATCAAGTC ATGGGTTATA 1440  
 GGTGCAATAG CTCTTCTCTG CCTATTAGGA TTGACCTGGG CCTTTGGACT CATGTATATT 1500  
 AATGAAAGCA CAGTCATCAT GGCCTATCTC TTCACCATTT TCAATTCTCT ACAGGGAATG 1560  
 TTTATATTTA TTTTCCATTG TGTCTACAG AAGAAGGTAC GAAAAGAGTA TGGGAAATGC 1620  
 CTGCGAACAC ATTGCTGTAG TGGCAAAAGT ACAGAGAGTT CCATTGGTTC AGGGAAAACA 1680  
 TCTGGTTCTC GAACTCCTGG ACGCTACTCC ACAGGCTCAC AGAGCCGAAT CCGTAGAATG 1740  
 TGAATGACA CGGTTGCAAA GCAGTCAGAG TCTTCCTTTA TTACTGGAGA CATAAACAGT 1800  
 TCAGCGTCCAC TCAACAGAGA GGGGCTTCTG AACAAATGCC GGGATACAAG TGTATGGAT 1860  
 ACTCTACCAC TGAATGGTAA CCATGGCAAT AGTTACAGCA TTGCCAGCGG CGAATACCTG 1920  
 AGCAACTGTG TGCAAAATCAT AGACCGTGGC TATAACCATA ACGAGACCGC CCTAGAGAAA 1980  
 AAGATTCTGA AGGAACTCAC TTCCAATAT ATCCTTCTT ACCTGAACAA CCATGAGCGC 2040  
 TCCAGTGAAC AGAACAGGAA TCTGATGAAC AAGCTGGTGA ATAACCTTGG CAGTGAAGG 2100  
 GAAGATGATG CCATTGTCCT GGATGATGCC ACCTCGTTTA ACCACGAGGA GAGTTTGGGC 2160  
 CTGGAACCTA TTCATGAGGA ATCTGATGCT CCTTTGCTGC CCCCAGAGT ATACTCCACC 2220  
 GAGAACCACC AGCCACACCA TTATACCAGA AGGCGGATCC CCCCAGACCA CAGTGAGAGC 2280  
 TTTTTCCTTT TGCTAACCAA CGAGCACACA GAAGATCTCC AGTCACCCCA TAGAGACTCT 2340  
 CTCTATACCA GCATGCCGAC ACTGGCTGGT GTGGCCGCCA CAGAGAGTGT TACCACCAGC 2400  
 ACCCAGACCG AACCCCAACC GGCCAAATGT GGTGATGCCG AAGATGTTTA CTACAAAAGC 2460  
 ATGCCAAACC TAGGCTCCAG AAACCACGTC CATCAGCTGC ATACTTACTA CCAGCTAGGT 2520  
 CGCGGCAGCA GTGATGGATT TATAGTTCCT CCAAACAAAG ATGGGACCCC TCCCGAGGGA 2580  
 AGTTCAAAAG GACCGGCTCA TTTGGTCACT AGTCTA 2616

<210> 3  
 <211> 1021  
 <212> PRT  
 <213> Human  
 <400> 3

Glu Gly Ser Lys Gly Thr Lys Pro Pro Pro Ala Val Ser Thr Thr Lys  
 1 5 10 15  
 Ile Pro Pro Ile Thr Asn Ile Phe Pro Leu Pro Glu Arg Phe Cys Glu



				20				25					30		
Ala	Leu	Asp	Ser	Lys	Gly	Ile	Lys	Trp	Pro	Gln	Thr	Gln	Arg	Gly	Met
		35					40					45			
Met	Val	Glu	Arg	Pro	Cys	Pro	Lys	Gly	Thr	Arg	Gly	Thr	Ala	Ser	Tyr
	50					55					60				
Leu	Cys	Met	Ile	Ser	Thr	Gly	Thr	Trp	Asn	Pro	Lys	Gly	Pro	Asp	Leu
	65				70					75					80
Ser	Asn	Cys	Thr	Ser	His	Trp	Val	Asn	Gln	Leu	Ala	Gln	Lys	Ile	Arg
				85					90					95	
Ser	Gly	Glu	Asn	Ala	Ala	Ser	Leu	Ala	Asn	Glu	Leu	Ala	Lys	His	Thr
			100					105					110		
Lys	Gly	Pro	Val	Phe	Ala	Gly	Asp	Val	Ser	Ser	Ser	Val	Arg	Leu	Met
		115					120					125			
Glu	Gln	Leu	Val	Asp	Ile	Leu	Asp	Ala	Gln	Leu	Gln	Glu	Leu	Lys	Pro
	130					135					140				
Ser	Glu	Lys	Asp	Ser	Ala	Gly	Arg	Ser	Tyr	Asn	Lys	Leu	Gln	Lys	Arg
145					150					155					160
Glu	Lys	Thr	Cys	Arg	Ala	Tyr	Leu	Lys	Ala	Ile	Val	Asp	Thr	Val	Asp
				165					170					175	
Asn	Leu	Leu	Arg	Pro	Glu	Ala	Leu	Glu	Ser	Trp	Lys	His	Met	Asn	Ser
			180					185					190		
Ser	Glu	Gln	Ala	His	Thr	Ala	Thr	Met	Leu	Leu	Asp	Thr	Leu	Glu	Glu
		195					200					205			
Gly	Ala	Phe	Val	Leu	Ala	Asp	Asn	Leu	Leu	Glu	Pro	Thr	Arg	Val	Ser
	210				215						220				
Met	Pro	Thr	Glu	Asn	Ile	Val	Leu	Glu	Val	Ala	Val	Leu	Ser	Thr	Glu
225					230					235					240
Gly	Gln	Ile	Gln	Asp	Phe	Lys	Phe	Pro	Leu	Gly	Ile	Lys	Gly	Ala	Gly
				245					250					255	
Ser	Ser	Ile	Gln	Leu	Ser	Ala	Asn	Thr	Val	Lys	Gln	Asn	Ser	Arg	Asn
			260					265					270		
Gly	Leu	Ala	Lys	Leu	Val	Phe	Ile	Ile	Tyr	Arg	Ser	Leu	Gly	Gln	Phe
		275					280					285			
Leu	Ser	Thr	Glu	Asn	Ala	Thr	Ile	Lys	Leu	Gly	Ala	Asp	Phe	Ile	Gly
	290					295					300				
Arg	Asn	Ser	Thr	Ile	Ala	Val	Asn	Ser	His	Val	Ile	Ser	Val	Ser	Ile
305					310					315					320
Asn	Lys	Glu	Ser	Ser	Arg	Val	Tyr	Leu	Thr	Asp	Pro	Val	Leu	Phe	Thr
				325					330					335	
Leu	Pro	His	Ile	Asp	Pro	Asp	Asn	Tyr	Phe	Asn	Ala	Asn	Cys	Ser	Phe
			340					345					350		
Trp	Asn	Tyr	Ser	Glu	Arg	Thr	Met	Met	Gly	Tyr	Trp	Ser	Thr	Gln	Gly
		355					360					365			
Cys	Lys	Leu	Val	Asp	Thr	Asn	Lys	Thr	Arg	Thr	Thr	Cys	Ala	Cys	Ser
	370														

Thr Phe Ile Ile Leu Leu Asn Ile Ile Phe Leu Val Ile Thr Leu Cys  
 565 570 575  
 Lys Met Val Lys His Ser Asn Thr Leu Lys Pro Asp Ser Ser Arg Leu  
 580 585 590  
 Glu Asn Ile Lys Ser Trp Val Leu Gly Ala Phe Ala Leu Leu Cys Leu  
 595 600 605  
 Leu Gly Leu Thr Trp Ser Phe Gly Leu Leu Phe Ile Asn Glu Glu Thr  
 610 615 620  
 Ile Val Met Ala Tyr Leu Phe Thr Ile Phe Asn Ala Phe Gln Gly Val  
 625 630 635 640  
 Phe Ile Phe Ile Phe His Cys Ala Leu Gln Lys Lys Val Arg Lys Glu  
 645 650 655  
 Tyr Gly Lys Cys Phe Arg His Ser Tyr Cys Cys Gly Gly Leu Pro Thr  
 660 665 670  
 Glu Ser Pro His Ser Ser Val Lys Ala Ser Thr Thr Arg Thr Ser Ala  
 675 680 685  
 Arg Tyr Ser Ser Gly Thr Gln Ser Arg Ile Arg Arg Met Trp Asn Asp  
 690 695 700  
 Thr Val Arg Lys Gln Ser Glu Ser Ser Phe Ile Ser Gly Asp Ile Asn  
 705 710 715 720  
 Ser Thr Ser Thr Leu Asn Gln Gly Met Thr Gly Asn Tyr Leu Leu Thr  
 725 730 735  
 Asn Pro Leu Leu Arg Pro His Gly Thr Asn Asn Pro Tyr Asn Thr Leu  
 740 745 750  
 Leu Ala Glu Thr Val Val Cys Asn Ala Pro Ser Ala Pro Val Phe Asn  
 755 760 765  
 Ser Pro Gly His Ser Leu Asn Asn Ala Arg Asp Thr Ser Ala Met Asp  
 770 775 780  
 Thr Leu Pro Leu Asn Gly Asn Phe Asn Asn Ser Tyr Ser Leu His Lys  
 785 790 795 800  
 Gly Asp Tyr Asn Asp Ser Val Gln Val Val Asp Cys Gly Leu Ser Leu  
 805 810 815  
 Asn Asp Thr Ala Phe Glu Lys Met Ile Ile Ser Glu Leu Val His Asn  
 820 825 830  
 Asn Leu Arg Gly Ser Ser Lys Thr His Asn Leu Glu Leu Thr Leu Pro  
 835 840 845  
 Val Lys Pro Val Ile Gly Gly Ser Ser Ser Glu Asp Asp Ala Ile Val  
 850 855 860  
 Ala Asp Ala Ser Ser Leu Met His Ser Asp Asn Pro Gly Leu Glu Leu  
 865 870 875 880  
 His His Lys Glu Leu Glu Ala Pro Leu Ile Pro Gln Arg Thr His Ser  
 885 890 895  
 Leu Leu Tyr Gln Pro Gln Lys Lys Val Lys Ser Glu Gly Thr Asp Ser  
 900 905 910  
 Tyr Val Ser Gln Leu Thr Ala Glu Ala Glu Asp His Leu Gln Ser Pro  
 915 920 925  
 Asn Arg Asp Ser Leu Tyr Thr Ser Met Pro Asn Leu Arg Asp Ser Pro  
 930 935 940  
 Tyr Pro Glu Ser Ser Pro Asp Met Glu Glu Asp Leu Ser Pro Ser Arg  
 945 950 955 960  
 Arg Ser Glu Asn Glu Asp Ile Tyr Tyr Lys Ser Met Pro Asn Leu Gly  
 965 970 975  
 Ala Gly His Gln Leu Gln Met Cys Tyr Gln Ile Ser Arg Gly Asn Ser  
 980 985 990  
 Asp Gly Tyr Ile Ile Pro Ile Asn Lys Glu Gly Cys Ile Pro Glu Gly  
 995 1000 1005  
 Asp Val Arg Glu Gly Gln Met Gln Leu Val Thr Ser Leu  
 1010 1015 1020

<210> 4

<211> 3063

<212> DNA

<213> Human

<400> 4

GAAGGAAGCA AAGGGACAAA ACCACCTCCA GCAGTTTCTA CAACCAAAAT TCCACCTATA 60  
 ACAAATATTT TTCCCCTGCC AGAGAGATTC TGTGAAGCAT TAGACTCCAA GGGGATAAAG 120

TGGCCTCAGA	CACAAAGGGG	AATGATGGTT	GAACGACCAT	GCCCTAAGGG	AACAAGAGGA	180
ACTGCCTCAT	ATCTCTGCAT	GATTTCCACT	GGAACATGGA	ACCCTAAGGG	CCCCGATCTT	240
AGCAACTGTA	CCTCACACTG	GGTGAATCAG	CTGGCTCAGA	AGATCAGAAG	CGGAGAAAAT	300
GCTGCTAGTC	TTGCCAATGA	ACTGGCTAAA	CATACCAAAG	GGCCAGTGTT	TGCTGGGGAT	360
GTAAGTTCTT	CAGTGAGATT	GATGGAGCAG	TTGGTGGACA	TCCTTGATGC	ACAGCTGCAG	420
GAAC TGAAAC	CTAGTGAAAA	AGATT CAGCT	GGACGGAGTT	ATAACAAGCT	CCAAAAACGA	480
GAGAAGACAT	GCAGGGCTTA	CCTTAAGGCA	ATTGTTGACA	CAGTGGACAA	CCTTCTGAGA	540
CCTGAAGCTT	TGGAATCATG	GAAACATATG	AATTCTTCTG	AACAAGCACA	TACTGCAACA	600
ATGTTACTCG	ATACATTGGA	AGAAGGAGCT	TTTGTCTTAG	CTGACAATCT	TTTAGAACCA	660
ACAAGGGTCT	CAATGCCAC	AGAAAATATT	GTCCTGGAAG	TTGCCGTACT	CAGTACAGAA	720
GGACAGATCC	AAGACTTTAA	ATTTCTCTCTG	GGCATCAAAG	GAGCAGGCAG	CTCAATCCAA	780
CTGTCCGCAA	ATACCGTCAA	ACAGAACAGC	AGGAATGGGC	TTGCAAAGTT	GGTGTTCATC	840
ATTTTACCGGA	GCCTGGGACA	GTTCCTTAGT	ACAGAAAATG	CAACCATTAA	ACTGGGTGCT	900
GATTTTATTG	GTCGTAATAG	CACCATTGCA	GTGAACTCTC	ACGTCATTTT	AGTTTCAATC	960
AATAAAGAGT	CCAGCCGAGT	ATACCTGACT	GATCCTGTGC	TTTTTTACCCT	GCCACACATT	1020
GATCCTGACA	ATTATTTCAA	TGCAAAC TGC	TCCTTCTGGA	ACTACTCAGA	GAGAACTATG	1080
ATGGGATATT	GGTCTACCCA	GGGCTGCAAG	CTGGTTGACA	CTAATAAAAC	TCGAACAACG	1140
TGTGCATGCA	GCCACCTAAC	CAATTTTGCA	ATTCTCATGG	CCCACAGGGA	AATTGCATAT	1200
AAAGATGGCG	TTCATGAATT	ACTTCTTACA	GTCATCACCT	GGGTGGGAAT	TGTCATTTTCC	1260
CTTGTTTGCC	TGGCTATCTG	CATCTTCACC	TTCTGCTTTT	TCCGTGGCCT	ACAGAGTGAC	1320
CGAAATACTA	TTCACAAGAA	CCTTTGTATC	AACCTTTTCA	TTGCTGAATT	TATTTTCCFA	1380
ATAGGCATTG	ATAAGACAAA	ATATGCGATT	GCATGCCCAA	TATTTGCAGG	ACTTCTACAC	1440
TTTTTCTTTT	TGGCAGCTTT	TGCTTGGATG	TGCTTAGAAG	GTGTGCAGCT	CTACCTAATG	1500
TTAGTTGAAG	TTTTTGAAG	TGAATATTCA	AGGAAAAAAT	ATTACTATGT	TGCTGGTTAC	1560
TTGTTTCTCTG	CCACAGTGGT	TGGAGTTTCA	GCTGCTATTG	ACTATAAGAG	CTATGGAACA	1620
GAAAAAGCTT	GCTGGCTTCA	TGTTGATAAC	TACTTTATAT	GGAGCTTCAT	TGGACCTGTT	1680
ACCTTCATTA	TTCTGCTAAA	TATTATCTTC	TTGGTGATCA	CATTGTGCAA	AATGGTGAAG	1740
CATTCAAACA	CTTTGAAACC	AGATTCTAGC	AGGTTGGAAA	ACATTAAGTC	TTGGGTGCTT	1800
GGCGCTTTCTG	CTCTTCTGTG	TCTTCTTGGC	CTCACCTGGT	CCTTTGGGTT	GCTTTTTTATT	1860
AATGAGGAGA	CTATTGTGAT	GGCATATCTC	TTCACTATAT	TTAATGCTTT	CCAGGGAGTG	1920
TTCATTTTCA	TCTTTCACTG	TGCTCTCCAA	AAGAAAGTAC	GAAAAGAATA	TGGCAAGTGC	1980
TTCAGACACT	CATACTGCTG	TGGAGGCCTC	CCAACTGAGA	GTCCCCACAG	TTCAGTGAAG	2040
GCATCAACCA	CCAGAACCAG	TGCTCGCTAT	TCCTCTGGCA	CACAGAGTCG	TATAAGAAGA	2100
ATGTGGAATG	ATACTGTGAG	AAAACAATCA	GAATCTTCTT	TTATCTCAGG	TGACATCAAT	2160
AGCACTTCAA	CACCTTAATCA	AGGAATGACT	GGCAATTACC	TACTAACAAA	CCCTCTTCTT	2220
CGACCCACAG	GCACTAACAA	CCCCATAAAC	ACATTGCTCG	CTGAAACAGT	TGTATGTAAT	2280
GCCCCCTCAG	CTCCTGTATT	TAAC TCACCA	GGACATTAC	TGAACAATGC	CAGGGATACA	2340
AGTGCCATGG	ATACTCTACC	GCTAAATGGT	AATTTTAAACA	ACAGCTACTC	GCTGCACAAG	2400
GGTGACTATA	ATGACAGCGT	GCAAGTTGTG	GACTGTGGAC	TAAGTCTGAA	TGATACTGCT	2460
TTTGAGAAAA	TGATCATTTT	AGAATTAGTG	CACAACAAC	TACGGGGCAG	CAGCAAGACT	2520
CACAACCTCG	AGCTCACGCT	ACCAGTCAAA	CCTGTGATTG	GAGGTAGCAG	CAGTGAAGAT	2580
GATGCTATTG	TGGCAGATGC	TTCATCTTTA	ATGCACAGCG	ACAACCCAGG	GCTGGAGCTC	2640
CATCACAAAG	AACTCGAGGC	ACCACTTATT	CCTCAGCGGA	CTCACTCCCT	TCTGTACCAA	2700
CCCCAGAAGA	AAGTGAAGTC	CGAGGGAAT	GACAGCTATG	TCTCCCAACT	GACAGCAGAG	2760
GCTGAAGATC	ACCTACAGTC	CCCCAACAGA	GACTCTCTTT	ATACAAGCAT	GCCCAATCTT	2820
AGAGACTCTC	CCTATCCGGA	GAGCAGCCCT	GACATGGAAG	AAGACCTCTC	TCCCTCCAGG	2880
AGGAGTGAGA	ATGAGGACAT	TTACTATAAA	AGCATGCCAA	ATCTTGGAGC	TGGCCATCAG	2940
CTTCAGATGT	GCTACCAGAT	CAGCAGGGGC	AATAGTGATG	GTTATATAAT	CCCCATTAAC	3000
AAAGAAGGGT	GTATTCCAGA	AGGAGATGTT	AGAGAAGGAC	AAATGCAGCT	GGTTACAAG	3060
CTT						3063

<210> 5  
 <211> 1474  
 <212> PRT  
 <213> Human  
 <400> 5

Met	Ala	Arg	Leu	Ala	Ala	Val	Leu	Trp	Asn	Leu	Cys	Val	Thr	Ala	Val
			5						10					15	
Leu	Val	Thr	Ser	Ala	Thr	Gln	Gly	Leu	Ser	Arg	Ala	Gly	Leu	Pro	Phe
			20						25					30	
Gly	Leu	Met	Arg	Arg	Glu	Leu	Ala	Cys	Glu	Gly	Tyr	Pro	Ile	Glu	Leu
			35				40					45			
Arg	Cys	Pro	Gly	Ser	Asp	Val	Ile	Met	Val	Glu	Asn	Ala	Asn	Tyr	Gly
			50			55					60				
Arg	Thr	Asp	Asp	Lys	Ile	Cys	Asp	Ala	Asp	Pro	Phe	Gln	Met	Glu	Asn
			65			70				75					80

Val	Gln	Cys	Tyr	Leu	Pro	Asp	Ala	Phe	Lys	Ile	Met	Ser	Gln	Arg	Cys
				85					90					95	
Asn	Asn	Arg	Thr	Gln	Cys	Val	Val	Val	Ala	Gly	Ser	Asp	Ala	Phe	Pro
			100					105					110		
Asp	Pro	Cys	Pro	Gly	Thr	Tyr	Lys	Tyr	Leu	Glu	Val	Gln	Tyr	Asp	Cys
		115					120					125			
Val	Pro	Tyr	Lys	Val	Glu	Gln	Lys	Val	Phe	Val	Cys	Pro	Gly	Thr	Leu
	130					135					140				
Gln	Lys	Val	Leu	Glu	Pro	Thr	Ser	Thr	His	Glu	Ser	Glu	His	Gln	Ser
145					150					155					160
Gly	Ala	Trp	Cys	Lys	Asp	Pro	Leu	Gln	Ala	Gly	Asp	Arg	Ile	Tyr	Val
				165					170					175	
Met	Pro	Trp	Ile	Pro	Tyr	Arg	Thr	Asp	Thr	Leu	Thr	Glu	Tyr	Ala	Ser
			180					185					190		
Trp	Glu	Asp	Tyr	Val	Ala	Ala	Arg	His	Thr	Thr	Thr	Tyr	Arg	Leu	Pro
		195					200					205			
Asn	Arg	Val	Asp	Gly	Thr	Gly	Phe	Val	Val	Tyr	Asp	Gly	Ala	Val	Phe
	210					215					220				
Tyr	Asn	Lys	Glu	Arg	Thr	Arg	Asn	Ile	Val	Lys	Tyr	Asp	Leu	Arg	Thr
225					230					235					240
Arg	Ile	Lys	Ser	Gly	Glu	Thr	Val	Ile	Asn	Thr	Ala	Asn	Tyr	His	Asp
				245					250					255	
Thr	Ser	Pro	Tyr	Arg	Trp	Gly	Gly	Lys	Thr	Asp	Ile	Asp	Leu	Ala	Val
		260						265					270		
Asp	Glu	Asn	Gly	Leu	Trp	Val	Ile	Tyr	Ala	Thr	Glu	Gly	Asn	Asn	Gly
		275					280					285			
Arg	Leu	Val	Val	Ser	Gln	Leu	Asn	Pro	Tyr	Thr	Leu	Arg	Phe	Glu	Gly
	290					295					300				
Thr	Trp	Glu	Thr	Gly	Tyr	Asp	Lys	Arg	Ser	Ala	Ser	Asn	Ala	Phe	Met
305					310					315					320
Val	Cys	Gly	Val	Leu	Tyr	Val	Leu	Arg	Ser	Val	Tyr	Val	Asp	Asp	Asp
				325					330				335		
Ser	Glu	Ala	Ala	Gly	Asn	Arg	Val	Asp	Tyr	Ala	Phe	Asn	Thr	Asn	Ala
		340						345					350		
Asn	Arg	Glu	Pro	Val	Ser	Leu	Thr	Phe	Pro	Asn	Pro	Tyr	Gln	Phe	
		355				360					365				
Ile	Ser	Ser	Val	Asp	Tyr	Asn	Pro	Arg	Asp	Asn	Gln	Leu	Tyr	Val	Trp
	370					375					380				
Asn	Asn	Tyr	Phe	Val	Val	Arg	Tyr	Ser	Leu	Glu	Phe	Gly	Pro	Pro	Asp
385					390					395					400
Pro	Ser	Ala	Gly	Pro	Ala	Thr	Ser	Pro	Pro	Leu	Ser	Thr	Thr	Thr	Thr
				405					410					415	
Ala	Arg	Pro	Thr	Pro	Leu	Thr	Ser	Thr	Ala	Ser	Pro	Ala	Ala	Thr	Thr
		420						425					430		
Pro	Leu	Arg	Arg	Ala	Pro	Leu	Thr	Thr	His	Pro	Val	Gly	Ala	Ile	Asn
		435					440					445			
Gln	Leu	Gly	Pro	Asp	Leu	Pro	Pro	Ala	Thr	Ala	Pro	Val	Pro	Ser	Thr
	450					455					460				
Arg	Arg	Pro	Pro	Ala	Pro	Asn	Leu	His	Val	Ser	Pro	Glu	Leu	Phe	Cys
465					470				475						480
Glu	Pro	Arg	Glu	Val	Arg	Arg	Val	Gln	Trp	Pro	Ala	Thr	Gln	Gln	Gly
				485					490					495	
Met	Leu	Val	Glu	Arg	Pro	Cys	Pro	Lys	Gly	Thr	Arg	Gly	Ile	Ala	Ser
		500						505					510		
Phe	Gln	Cys	Leu	Pro	Ala	Leu	Gly	Leu	Trp	Asn	Pro	Arg	Gly	Pro	Asp
		515					520					525			
Leu	Ser	Asn	Cys	Thr	Ser	Pro	Trp	Val	Asn	Gln	Val	Ala	Gln	Lys	Ile
	530					535					540				
Lys	Ser	Gly	Glu	Asn	Ala	Ala	Asn	Ile	Ala	Ser	Glu	Leu	Ala	Arg	His
545					550				555						560
Thr	Arg	Gly	Ser	Ile	Tyr	Ala	Gly	Asp	Val	Ser	Ser	Ser	Val	Lys	Leu
				565					570					575	
Met	Glu	Gln	Leu	Leu	Asp	Ile	Leu	Asp	Ala	Gln	Leu	Gln	Ala	Leu	Arg
		580						585					590		
Pro	Ile	Glu	Arg	Glu	Ser	Ala	Gly	Lys	Asn	Tyr	Asn	Lys	Met	His	Lys
		595					600					605			
Arg	Glu	Arg	Thr	Cys	Lys	Asp	Tyr	Ile	Lys	Ala	Val	Val	Glu	Thr	Val

610	615	620
Asp Asn Leu Leu Arg Pro Glu Ala Leu Glu Ser Trp Lys Asp Met Asn		
625	630	635
Ala Thr Glu Gln Val His Thr Ala Thr Met Leu Leu Asp Val Leu Glu		
645	650	655
Glu Gly Ala Phe Leu Leu Ala Asp Asn Val Arg Glu Pro Ala Arg Phe		
660	665	670
Leu Ala Ala Lys Glu Asn Val Val Leu Glu Val Thr Val Leu Asn Thr		
675	680	685
Glu Gly Gln Val Gln Glu Leu Val Phe Pro Gln Glu Glu Tyr Pro Arg		
690	695	700
Lys Asn Ser Ile Gln Leu Ser Ala Lys Thr Ile Lys Gln Asn Ser Arg		
705	710	715
Asn Gly Val Val Lys Val Val Phe Ile Leu Tyr Asn Asn Leu Gly Leu		
725	730	735
Phe Leu Ser Thr Glu Asn Ala Thr Val Lys Leu Ala Gly Glu Ala Gly		
740	745	750
Pro Gly Gly Pro Gly Gly Ala Ser Leu Val Val Asn Ser Gln Val Ile		
755	760	765
Ala Ala Ser Ile Asn Lys Glu Ser Ser Arg Val Phe Leu Met Asp Pro		
770	775	780
Val Ile Phe Thr Val Ala His Leu Glu Asp Lys Asn His Phe Asn Ala		
785	790	795
Asn Cys Ser Phe Trp Asn Tyr Ser Glu Arg Ser Met Leu Gly Tyr Trp		
805	810	815
Ser Thr Gln Gly Cys Arg Leu Val Glu Ser Asn Lys Thr His Thr Thr		
820	825	830
Cys Ala Cys Ser His Leu Thr Asn Phe Ala Val Leu Met Ala His Arg		
835	840	845
Glu Ile Tyr Gln Gly Arg Ile Asn Glu Leu Leu Leu Ser Val Ile Thr		
850	855	860
Trp Val Gly Ile Val Ile Ser Leu Val Cys Leu Ala Ile Cys Ile Ser		
865	870	875
Thr Phe Cys Phe Leu Arg Gly Leu Gln Thr Asp Arg Asn Thr Ile His		
885	890	895
Lys Asn Leu Cys Ile Asn Leu Phe Leu Ala Glu Leu Leu Phe Leu Val		
900	905	910
Gly Ile Asp Lys Thr Gln Tyr Glu Ile Ala Cys Pro Ile Phe Ala Gly		
915	920	925
Leu Leu His Tyr Phe Phe Leu Ala Ala Phe Ser Trp Leu Cys Leu Glu		
930	935	940
Gly Val His Leu Tyr Leu Leu Leu Val Glu Val Phe Glu Ser Glu Tyr		
945	950	955
Ser Arg Thr Lys Tyr Tyr Leu Gly Gly Tyr Cys Phe Pro Ala Leu		
965	970	975
Val Val Gly Ile Ala Ala Ala Ile Asp Tyr Arg Ser Tyr Gly Thr Glu		
980	985	990
Lys Ala Cys Trp Leu Arg Val Asp Asn Tyr Phe Ile Trp Ser Phe Ile		
995	1000	1005
Gly Pro Val Ser Phe Val Ile Val Val Asn Leu Val Phe Leu Met Val		
1010	1015	1020
Thr Leu His Lys Met Ile Arg Ser Ser Ser Val Leu Lys Pro Asp Ser		
1025	1030	1035
Ser Arg Leu Asp Asn Ile Lys Ser Trp Ala Leu Gly Ala Ile Ala Leu		
1045	1050	1055
Leu Phe Leu Leu Gly Leu Thr Trp Ala Phe Gly Leu Leu Phe Ile Asn		
1060	1065	1070
Lys Glu Ser Val Val Met Ala Tyr Leu Phe Thr Thr Phe Asn Ala Phe		
1075	1080	1085
Gln Gly Val Phe Ile Phe Val Phe His Cys Ala Leu Gln Lys Lys Val		
1090	1095	1100
His Lys Glu Tyr Ser Lys Cys Leu Arg His Ser Tyr Cys Cys Ile Arg		
1105	1110	1115
Ser Pro Pro Gly Gly Thr His Gly Ser Leu Lys Thr Ser Ala Met Arg		
1125	1130	1135
Ser Asn Thr Arg Tyr Tyr Thr Gly Thr Gln Ser Arg Ile Arg Arg Met		
1140	1145	1150

Trp Asn Asp Thr Val Arg Lys Gln Thr Glu Ser Ser Phe Met Ala Gly  
 1155 1160 1165  
 Asp Ile Asn Ser Thr Pro Thr Leu Asn Arg Gly Thr Met Gly Asn His  
 1170 1175 1180  
 Leu Leu Thr Asn Pro Val Leu Gln Pro Arg Gly Gly Thr Ser Pro Tyr  
 1185 1190 1195 1200  
 Asn Thr Leu Ile Ala Glu Ser Val Gly Phe Asn Pro Ser Ser Pro Pro  
 1205 1210 1215  
 Val Phe Asn Ser Pro Gly Ser Tyr Arg Glu Pro Lys His Pro Leu Gly  
 1220 1225 1230  
 Gly Arg Glu Ala Cys Gly Met Asp Thr Leu Pro Leu Asn Gly Asn Phe  
 1235 1240 1245  
 Asn Asn Ser Tyr Ser Leu Arg Ser Gly Asp Phe Pro Pro Gly Asp Gly  
 1250 1255 1260  
 Gly Pro Glu Pro Pro Arg Gly Arg Asn Leu Ala Asp Ala Ala Phe  
 1265 1270 1275 1280  
 Glu Lys Met Ile Ile Ser Glu Leu Val His Asn Asn Leu Arg Gly Ser  
 1285 1290 1295  
 Ser Ser Ala Ala Lys Gly Pro Pro Pro Pro Glu Pro Pro Val Pro Pro  
 1300 1305 1310  
 Val Pro Gly Gly Gly Gly Glu Glu Ala Gly Gly Pro Gly Gly Ala  
 1315 1320 1325  
 Asp Arg Ala Glu Ile Glu Leu Leu Tyr Lys Ala Leu Glu Pro Leu  
 1330 1335 1340  
 Leu Leu Pro Arg Ala Gln Ser Val Leu Tyr Gln Ser Asp Leu Asp Glu  
 1345 1350 1355 1360  
 Ser Glu Ser Cys Thr Ala Glu Asp Gly Ala Thr Ser Arg Pro Leu Ser  
 1365 1370 1375  
 Ser Pro Pro Gly Arg Asp Ser Leu Tyr Ala Ser Gly Ala Asn Leu Arg  
 1380 1385 1390  
 Asp Ser Pro Ser Tyr Pro Asp Ser Ser Pro Glu Gly Pro Ser Glu Ala  
 1395 1400 1405  
 Leu Pro Pro Pro Pro Pro Ala Pro Pro Gly Pro Pro Glu Ile Tyr Tyr  
 1410 1415 1420  
 Thr Ser Arg Pro Pro Ala Leu Val Ala Arg Asn Pro Leu Gln Gly Tyr  
 1425 1430 1435 1440  
 Tyr Gln Val Arg Arg Pro Ser His Glu Gly Tyr Leu Ala Ala Pro Gly  
 1445 1450 1455  
 Leu Glu Gly Pro Gly Pro Asp Gly Asp Gly Gln Met Gln Leu Val Thr  
 1460 1465 1470  
 Ser Leu

<210> 6  
 <211> 4422  
 <212> DNA  
 <213> Human  
 <400> 6

ATGGCCCGCC TAGCCGCAGT GCTCTGGAAT CTGTGTGTCA CCGCCGTCCT GGTCACCTCG 60  
 GCCACCCAAG GCCTGAGCCG GGCCGGGCTC CCGTTCGGGC TGATGCGCCG GGAGCTGGCG 120  
 TGTGAAGGCT ACCCCATCGA GCTGCGGTGC CCCGGCAGCG ACCTCATCAT GGTGGAGAAT 180  
 GCCAACTACG GCGGCACGGA CGACAAGATT TCGGATGCTG ACCCTTTCCA GATGGAGAAT 240  
 GTGCAGTGCT ACCTGCCGGA CGCCTTCAAG ATCATGTAC AGAGGTGTAA CAACCGCACC 300  
 CAGTGCCTGG TGGTCGCCGG CTCGGATGCC TTTCTGACC CCGTCTCTGG GACCTACAAG 360  
 TACCTGGAGG TGCAGTACGA CTGTGTCCCC TACAAAGTGG AGCAGAAAGT CTTCGTGTGC 420  
 CCAGGGACCC TGCAGAAGGT GCTGGAGCCC ACCTCGACAC ACAGTACAGA GCACCACTCT 480  
 GGCGCATGGT GCAAGGACCC GCTGCAGGCG GGTGACCGCA TCTACGTGAT GCCCTGGATC 540  
 CCCTACCGCA CGGACACACT GACTGAGTAT GCCTCGTGGG AGGACTACGT GGCCGCCCCG 600  
 CACACCACCA CCTACCGCCT GCCCAACCGC GTGGATGGCA CAGGCTTTGT GGTCTACGAT 660  
 GGTGCCGTCT TCTACAACAA GGAGCGCACG CGCAACATCG TCAAGTATGA CCTACGGACG 720  
 CGCATCAAGA GCGGGGAGAC GGTTCATCAAT ACCGCCAAT ACCATGACAC CTCGCCCTAC 780  
 CGCTGGGGCG GAAAGACCGA CATTGACCTG GCGGTGGACG AGAACGGGCT GTGGGTATC 840  
 TACGCCACTG AGGGCAACAA CGGGCGGCTG GTGGTGAGCC AGCTGAACCC CTACACACTG 900  
 CGCTTTGAGG GCACGTGGGA GACGGGTAC GACAAGCGCT CGGCATCCAA CGCCTTCATG 960  
 GTGTGTGGGG TCCTGTACGT CCTGCGCTCC GTGTACGTGG ATGATGACAG CGAGCGGGCT 1020  
 GGCAACCGCG TGGACTATGC CTTCAACACC AATGCCAACC GCGAGGAGCC GTTCAGCCTC 1080  
 ACCTTCCCCA ACCCTACCA GTTCATCTCC TCCGTTGACT ACAACCCTCG CGACAACCAG 1140

CTGTACGTCT	GGAACAACATA	TTTCGTGGTG	CGCTACAGCC	TGGAGTTCGG	GCCGCCCCGAC	1200
CCCAGTGCTG	GCCCAGCCAC	TTCCCCACCC	CTCAGCACGA	CCACCACAGC	CAGGCCCCACG	1260
CCCCTCACCA	GCACAGCCTC	GCCCGCAGCC	ACCACCCCGC	TCCGCCGGGC	ACCCCTCACC	1320
ACGCACCCAG	TGGGTGCCAT	CAACCAGCTG	GGACCTGATC	TGCCTCCAGC	CACAGCCCCA	1380
GTCCCCAGCA	CCCGGCGGCC	CCCAGCCCCG	AATCTACACG	TGTCCCCTGA	GCTCTTCTGC	1440
GAGCCCCGAG	AGGTACGGCG	GGTCCAGTGG	CCGGCCACCC	AGCAGGGCAT	GCTGGTGGAG	1500
AGGCCCTGCC	CCAAGGGGAC	TCGAGGAATT	GCCTCCTTCC	AGTGTCTACC	AGCCTTGGGG	1560
CTCTGGAACC	CCCGGGGCCC	TGACCTCAGC	AATGTCACCT	CCCCCTGGGT	CAACCAGGTG	1620
GCCCCAGAAG	TCAAGAGTGG	GGAGAACGCG	GCCAACATCG	CCAGCGAGCT	GGCCCCGACAC	1680
ACCCGGGGCT	CCATCTACGC	GGGGGACGTC	TCCTCCTCTG	TGAAGCTGAT	GGAGCAGCTG	1740
CTGGACATCC	TGGATGCCCA	GCTGCAGGCC	CTGCGGCCCA	TCGAGCGCGA	GTCAGCCGGC	1800
AAGAACTACA	ACAAGATGCA	CAAGCGAGAG	AGAACTTGTA	AGGATTATAT	CAAGGCCCGTG	1860
GTGGAGACAG	TGGACAATCT	GCTCCGGCCA	GAAGCTCTGG	AGTCCTGGAA	GGACATGAAT	1920
GCCACGGAGC	AGGTGCACAC	GGCCACCATG	CTCCTCGACG	TCCTGGAGGA	GGGCGCCTTC	1980
CTGCTGGCCG	ACAATGTGAG	GGAGCCTGCC	CGCTTCCTGG	CTGCCAAGGA	GAACGTGGTC	2040
CTGGAGGTCA	CAGTCCTGAA	CACAGAGGGC	CAGGTGCAGG	AGCTGGTGTT	CCCCCAGGAG	2100
GAGTACCCGA	GAAAGAACTC	CATCCAGCTG	TCTGCCAAA	CCATCAAGCA	GAACAGCCCG	2160
AATGGGGTGG	TCAAAGTTGT	CTTCATCCTC	TACAACAACC	TGGGCCCTCTT	CCTGTCCACG	2220
GAGAATGCCA	CAGTGAAGCT	GGCCGGCGAA	GCAGGCCCGG	GTGGCCCTGG	GGGCGCCTCT	2280
CTAGTGGTGA	ACTCACAGGT	CATCGCAGCA	TCCAACAACA	AGGAGTCCAG	CCGCGTCTTC	2340
CTCATGGACC	CTGTCACTTT	CACCGTGGCC	CACCTGGAGG	ACAAGAACCA	CTTCAATGCT	2400
AACTGCTCCT	TCTGGAACATA	CTCGGAGCGT	TCCATGCTGG	GCTATTGGTC	GACCCAAGGC	2460
TGCCGCCTGG	TGGAGTCCAA	CAAGACCCAT	ACCACGTGTG	CCTGCAGCCA	CCTCACCAAC	2520
TTCGCTGTGC	TCATGGCTCA	CCGTGAGATC	TACCAGGGCC	GCATCAACGA	GCTGCTGCTG	2580
TCGGTCAATCA	CCTGGGTGGG	CATTGTGATC	TCCCTGGTCT	GCTTGGCCAT	CTGCATCTCC	2640
ACCTTCTGCT	TCCTGCGGGG	GCTGCAGACC	GACCGCAACA	CCATCCACAA	GAACCTGTGC	2700
ATCAACCTCT	TCCTGGCTGA	GCTGCTCTTC	CTGGTTCGGG	TCGACAAGAC	TCAGTATGAG	2760
ATTGCCTGCC	CCATCTTCGC	CGGCCTGCTG	CACFATTTCT	TCCTGGCTGC	CTTCTCCTGG	2820
CTGTGCCTGG	AGGGCGTGCA	CCTCTACCTG	CTACTAGTGG	AGGTGTTTGA	GAGCGAGTAT	2880
TCCCGCACC	AGTACTACTA	CCTGGGTGGC	TACTGCTTCC	CGGCCCTGGT	GGTGGGCATC	2940
GCGGCTGCCA	TTGACTACCG	CAGCTACGGC	ACCAGAAAGG	CCTGCTGGCT	CCGAGTGGAC	3000
AATTACTTCA	TCTGGAGTTT	CATCGGGCCA	GTCTCCTTCG	TTATCGTGGT	CAACCTGGTG	3060
TTCTCTATGG	TGACCCTGCA	CAAGATGATC	CGAAGCTCAT	CTGTGCTCAA	CCCCGACTCC	3120
AGCCGCCTGG	ACAACATTAA	ATCCTGGGCG	CTGGGGGCCA	TCGCGCTGCT	GTTCCTGCTG	3180
GGCCTCACCT	GGGCTTTTCG	CCTCCTCTTC	ATCAACAAGG	AGTCGGTGGT	CATGGCCTAT	3240
CTCTTCACCA	CCTTCAACGC	CTTCCAGGGG	GTCTTCATCT	TCGTCTTTCA	CTGCGCCTTA	3300
CAGAAGAAAG	TGCACAAGGA	GTACAGCAAG	TGCCTGCGTC	ACTCCTACTG	CTGCATCCGC	3360
TCCCCACCCG	GGGGCACTCA	CGGATCCCTC	AAGACCTCAG	CCATGCGAAG	CAACACCCGC	3420
TACTACACAG	GGACCCAGAG	CCGAATTTCG	AGGATGTGGA	ATGACACTGT	GAGGAAACAG	3480
ACGGAGTCC	CCTTCATGGC	GGGTGACATC	AACAGCACCC	CCACCCTGAA	CCGAGGTACC	3540
ATGGGGAACC	ACCTGCTGAC	CAACCCCGTG	CTGCAGCCCC	GTGGGGGCAC	CAGTCCCTAC	3600
AACACCTCA	TCGCCGAGTC	AGTGGGCTTC	AATCCCTCCT	CGCCCCCTGT	CTTCAACTCC	3660
CCAGGGAGCT	ACCGGGAACC	CAAGCACCCC	TTGGGAGGCC	GGGAAGCCTG	TGGCATGGAC	3720
ACCCTGCCCC	TGAACGGCAA	CTTCAATAAC	AGTTACTCCT	TGCGAAGTGG	GGATTTCCCT	3780
CCCGGGGATG	GGGGCCCTGA	GCCGCCCCGA	GGCCGGAACC	TAGCCGATGC	GGCGGCCCTT	3840
GAGAAGATGA	TCATCTCAGA	GCTGGTGCAC	AACAACCTGC	GGGGGAGCAG	CAGCGCGGCC	3900
AAGGGCCCTC	CACCGCCTGA	GCCCCCTGTG	CCACCTGTGC	CAGGGGGCGG	GGGCGAGGAA	3960
GAGGCGGGCG	GGCCCGGGGG	TGCTGACCCG	GCCGAGATTG	AACTTCTCTA	TAAGGCCCTG	4020
GAGGAGCCTC	TGCTGCTGCC	CCGGGCCAG	TCGGTGTCTG	ACCAGAGCGA	TCTGGACGAG	4080
TCGGAGAGCT	GCACGGCCGA	GGACGGCGCC	ACCAGCCGGC	CCCTCTCCTC	CCCTCCTGGC	4140
CGGGACTCCC	TCTATGCCAG	CGGGGCCAAC	CTGCGGGACT	CACCCCTCCTA	CCCGGACAGC	4200
AGCCCTGAGG	GGCCCACTGA	GGCCCTGCCC	CCACCCCTTC	CCGCACCCCC	CGGCCCCCCC	4260
GAAATCTACT	ACACCTCGCG	CCCGCCAGCC	CTGGTGGCCC	GGAATCCCTC	GCAGGGCTAC	4320
TACCAGGTGC	GGCGTCCTAG	CCACGAGGGC	TACCTGGCAG	CCCCAGGCCT	TGAGGGGCCA	4380
GGGCCCCGATG	GGGACGGGCA	GATGCAGCTG	GTCACCACTC	TC		4425

## Japanese Language Declaration (日本語宣言書)

私は、ここに、以下に記載した外国での特許出願または発明者証の出願、或いは米国以外の少なくとも一国を指定している米国法典第35編第365条(a)によるPCT国際出願について、同第119条(a)-(d)項又は第365条(b)項に基づいて優先権を主張するとともに、優先権を主張する本出願の出願日より前の出願日を有する外国での特許出願または発明者証の出願、或いはPCT国際出願については、いかなる出願も、下記の枠内をチェックすることにより示した。

I hereby claim foreign priority under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application for which priority is claimed

Prior Foreign Application(s)

Priority Not Claimed

優先権主張なし

外国での先行出願

10-207579

Japan

23/07/1998

(Number)  
(番号)(Country)  
(国名)(Day/Month/Year Filed)  
(出願日/月/年)

10-225060

Japan

07/08/1998

(Number)  
(番号)(Country)  
(国名)(Day/Month/Year Filed)  
(出願日/月/年)

10-284328

Japan

06/10/1998

私は、ここに、下記のいかなる米国仮特許出願についても、その米国法典第35編第119条(e)項の利益を主張する。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.)  
(出願番号)(Filing Date)  
(出願日)(Application No.)  
(出願番号)(Filing Date)  
(出願日)

私は、ここに、下記のいかなる米国出願についても、その米国法典第35編第120条に基づく利益を主張し、又米国を指定するいかなるPCT国際出願についても、その同第365条(c)に基づく利益を主張する。また、本出願の各特許請求の範囲の主題が、米国法典第35編第112条第1段に規定された態様で、先行する米国出願又はPCT国際出願に開示されていない場合においては、その先行出願の出願日と本国内出願日またはPCT国際出願日との間の期間中に入手された情報で、連邦規則法典第37編規則1.56に定義された特許性に関わる重要な情報について開示義務があることを承認する。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.)  
(出願番号)(Filing Date)  
(出願日)(Status: Patented, Pending, Abandoned)  
(現況: 特許許可、係属中、放棄)(Application No.)  
(出願番号)(Filing Date)  
(出願日)(Status: Patented, Pending, Abandoned)  
(現況: 特許許可、係属中、放棄)

私は、ここに表明された私自身の知識に係わる陳述が真実であり、且つ情報と信ずることに基づく陳述が、真実であると信じられることを宣言し、さらに、故意に虚偽の陳述などを行った場合は、米国法典第18編第1001条に基づき、罰金または拘禁、若しくはその両方により処罰され、またそのような故意による虚偽の陳述は、本出願またはそれに対して発行されるいかなる特許も、その有効性に問題が生ずることを理解した上で陳述が行われたことを、ここに宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



## Declaration and Power of Attorney for Patent Application

### 特許出願宣言書及び委任状

#### Japanese Language Declaration

#### 日本語宣言書

私は、以下に記名された発明者として、ここに下記の通り宣言する：

As a below named inventor, I hereby declare that:

私の住所、郵便の宛先そして国籍は、私の氏名の後に記載された通りである。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明について、特許請求範囲に記載され、且つ特許が求められている発明主題に関して、私は、最初、最先且つ唯一の発明者である（唯一の氏名が記載されている場合）か、或いは最初、最先且つ共同発明者である（複数の氏名が記載されている場合）と信じている。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Novel G Protein Coupled Receptor Protein and  
Its DNA

上記発明の明細書はここに添付されているが、下記の欄がチェックされている場合は、この限りでない：

the specification of which is attached hereto unless the following box is checked:

☐ \_\_\_\_\_ の日に出版され、  
この出版の米国出版番号またはPCT国際出版番号は、  
\_\_\_\_\_ であり、且つ  
\_\_\_\_\_ の日に補正された出版（該当する場合）

☒ was filed on July 22, 1999  
as United States Application Number or  
PCT International Application Number  
PCT/JP99/03909 and was amended on  
\_\_\_\_\_ (if applicable)

私は、上記の補正書によって補正された、特許請求範囲を含む上記明細書を検討し、且つ内容を理解していることをここに表明する。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編規則1.56に定義されている、特許性について重要な情報を開示する義務があることを認める。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56

## Japanese Language Declaration (日本語宣言書)

委任状: 私は本出願を審査する手続を行い、且つ米国特許商標庁との全ての業務を遂行するために、記名された発明者として、下記の弁護士及び/または弁理士を任命する。(氏名及び登録番号を記載すること)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number)  
 Philippe Y. RIESEN (Reg. No. 35,657), Mark CHAO (Reg. No. 37,293)

書類送付先

Send Correspondence to:

Customer No. 23,115

直通電話連絡先: (氏名及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Mark CHAO  
 Takeda Pharmaceuticals America, Inc.  
 Phone:(847)383-3372 Fax:(847)383-3481

唯一または第一発明者氏名

Full name of sole or first inventor

Osamu OHARA

発明者の署名

日付

Inventor's signature

Date

Osamu Ohara

November 22, 2000

住所

Residence

20-25, Josai 2-chome, Kisarazu-shi, CHIBA 292-0801 JAPAN

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

Kazusa DNA Research Institute  
 1532-3, Yana, Kisarazu-shi, CHIBA 292-0812 JAPAN

第二共同発明者がある場合、その氏名

Full name of second joint inventor, if any

Takahiro NAGASE

第二共同発明者の署名

日付

Second inventor's signature

Date

Takahiro Nagase

Nov. 24, 2000

住所

Residence

1-26, Kiyomidai-minami 5-chome, Kisarazu-shi, CHIBA 292-0042

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

Kazusa DNA Research Institute  
 1532-3, Yana, Kisarazu-shi, CHIBA 292-0812 JAPAN

(第三以下の共同発明者についても同様に記載し、署名をすること)

(Supply similar information and signature for third and subsequent joint inventors.)

## Attached Sheet to the Declaration

第三共同発明者		Full name of third joint inventor, if any	
		<u>Nobuo NOMURA</u>	
発明者の署名	日付	Third inventor's signature	date
	3/10	<u>Nobuo Nomura</u>	November 24, 2000
住所		Residence	
5-2-11, Hachimandai 5-chome, Kisarazu-shi, CHIBA 292-0804 JAPAN		JF+	
国籍		Citizenship	
		Japan	
郵便の宛先		Post Office Address	
Kazusa DNA Research Institute, 1532-3, Yana, Kisarazu-shi, CHIBA 292-0812 JAPAN			
第四共同発明者		Full name of fourth joint inventor, if any	
		<u>Shuji HINUMA</u>	
発明者の署名	日付	Fourth inventor's signature	date
	4/10	<u>Shuji Hinuma</u>	November 17, 2000
住所		Residence	
7-9-1402, Kasuga 1-chome, Tsukuba, IBARAKI 305-0821 JAPAN		JF+	
国籍		Citizenship	
		Japan	
郵便の宛先		Post Office Address	
Takeda Chemical Industries, Ltd. (IPD), 17-85, Jusohonmachi 2-chome, Yodogawa-ku, OSAKA 532-8686 JAPAN			
第五共同発明者		Full name of fifth joint inventor, if any	
		<u>Ryo FUJII</u>	
発明者の署名	日付	Fifth inventor's signature	date
	5/10	<u>Ryo Fujii</u>	November 30, 2000
住所		Residence	
7-9-303, Kasuga 1-chome, Tsukuba, IBARAKI 305-0821 JAPAN		JF+	
国籍		Citizenship	
		Japan	
郵便の宛先		Post Office Address	
Takeda Chemical Industries, Ltd. (IPD), 17-85, Jusohonmachi 2-chome, Yodogawa-ku, OSAKA 532-8686 JAPAN			
第六共同発明者		Full name of sixth joint inventor, if any	
		<u>Osamu KITAHARA</u>	
発明者の署名	日付	Sixth inventor's signature	date
	6/10	<u>Osamu Kitahara</u>	December 9, 2000
住所		Residence	
36-3-402, Kasuga 2-chome, Tsukuba, IBARAKI 305-0821 JAPAN		JF+	
国籍		Citizenship	
		Japan	
郵便の宛先		Post Office Address	
Takeda Chemical Industries, Ltd. (IPD), 17-85, Jusohonmachi 2-chome, Yodogawa-ku, OSAKA 532-8686 JAPAN			
第七共同発明者		Full name of seventh joint inventor, if any	
		<u>Shinichi MOGI</u>	
発明者の署名	日付	Seventh inventor's signature	date
	7/10	<u>Shin-ichi Mogi</u>	November 17, 2000
住所		Residence	
17-16, Mizukino 1-chome, Moriya-machi, Kitasoma-gun IBARAKI 302-0121 JAPAN		JF+	
国籍		Citizenship	
		Japan	
郵便の宛先		Post Office Address	
Takeda Chemical Industries, Ltd. (IPD), 17-85, Jusohonmachi 2-chome, Yodogawa-ku, OSAKA 532-8686 JAPAN			

T02210"92244250